Advertisement

COVID-19

Continuous Coverage of COVID-19

The staff of The ASCO Post recognizes the steady flow of news on the novel coronavirus, or COVID-19. Here, we've compiled a list of links to articles and resources on the COVID-19 pandemic. If you have a report you'd like to share, please e-mail it to us at editor@ascopost.com.

Direct From ASCO:...

Prostate Cancer

Gallium-68 PSMA PET/CT Prior to Surgery or Radiotherapy in High-Risk Prostate Cancer

In an Australian phase III trial (proPSMA) reported in The Lancet, Michael S. Hofman, MBBS, and colleagues found that gallium-68 prostate-specific membrane antigen-11 positron-emission tomography/computed tomography (PSMA PET/CT) provided greater accuracy in identifying nodal and distant metastases ...

Issues in Oncology
COVID-19

Harvard Medical Student’s Innovation: Disinfection You Can See

In 2014, three undergrads at Columbia University had a crazy idea for a hackathon challenge: colorize bleach so health-care workers could spot missed areas on the surfaces and personal protective equipment they are trying to disinfect. Five years later, the result is a product called Highlight®,...

COVID-19

Cancer Care in the Time of COVID-19: Statement From Fox Chase Cancer Center

In an article published by Kutikov et al in Annals of Internal Medicine, practitioners from Fox Chase Cancer Center reviewed the challenges faced in cancer care during the COVID-19 crisis and suggested measures that may help to maintain standards of care while reducing risk of transmission as well...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Trastuzumab Beyond Disease Progression in HER2‑Positive Advanced Gastric/Gastroesophageal Junction Cancer

In the Japanese phase II T-ACT study reported in the Journal of Clinical Oncology, Makiyama et al found no benefit of continued trastuzumab combined with paclitaxel after disease progression on first-line trastuzumab plus fluoropyrimidine/platinum chemotherapy in patients with HER2-positive...

Issues in Oncology

Apixaban for Cancer-Associated Venous Thromboembolism

For patients with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low–molecular-weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), with no excess in major bleeding events. These findings from the phase III Caravaggio study were...

Breast Cancer
Bladder Cancer
Lymphoma
Immunotherapy

FDA Pipeline: Approval of New Dosing for Biosimilar, Plus Two Fast Track Designations

The U.S. Food and Drug Administration (FDA) recently approved a new dose for a biosimilar referencing trastuzumab and granted Fast Track designations to agents for patients with urothelial cancer and follicular lymphoma.

Approval of Multidose Vial of Trastuzumab Biosimilar

The FDA approved a...

Hepatobiliary Cancer
Immunotherapy

Camrelizumab for Previously Treated Advanced Hepatocellular Carcinoma

In a Chinese phase II study reported in The Lancet Oncology, Qin et al found that the programmed cell death protein 1 (PD-1) inhibitor camrelizumab showed activity in patients with previously treated advanced hepatocellular carcinoma.

Study Details

In the open-label multicenter trial, 217 evaluable ...

COVID-19

Oncologists on the Front Lines of the COVID-19 Pandemic: A Conversation With Miriam A. Knoll, MD

During the coronavirus disease 2019 (COVID-19) pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Miriam A. Knoll, MD, a radiation oncologist at the John Theurer Cancer Center, Hackensack University Medical Center, ...

Neuroendocrine Tumors
Immunotherapy

Pembrolizumab in Previously Treated Metastatic High-Grade Neuroendocrine Neoplasms

As reported in the British Journal of Cancer by Namrata Vijayvergia, MD, and colleagues, a pooled analysis of two phase II studies found that pembrolizumab monotherapy showed little activity in patients with previously treated metastatic high-grade neuroendocrine neoplasms.

Study Details

In the...

Survivorship

Factors Associated With Small Adult Height in Childhood Cancer Survivors

In an analysis from the French Childhood Cancer Survivors (CCS) Study reported in the Journal of Clinical Oncology, Demoor-Goldschmidt et al found that receipt of pituitary irradiation, busulfan, and higher doses of lomustine were risk factors for small adult height in survivors of childhood...

Hematologic Malignancies
COVID-19

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

On April 1, the ASH Research Collaborative's (ASH RC) Data Hub launched the ASH RC Data Hub COVID-19 Registry for Hematologic Malignancy, a global registry with clinical data exclusively on people with COVID-19 and a current or past diagnosis of a hematologic malignancy. The registry is intended to ...

COVID-19

Maintaining Blood Donations During the COVID-19 Pandemic

A major casualty of the coronavirus disease 2019 (COVID-19) pandemic is the dramatic decrease in the number of blood donations across the United States. As more people are urged to shelter-in-place and avoid social contact, the number of cancellations in blood drives has been dramatic. According to ...

COVID-19

COVID-19 and Pediatric Patients With Cancer

In a correspondence published in The Lancet Oncology, Rishi S. Kotecha, MB, ChB, of the Government of Western Australia Department of Health, identified challenges in protecting children with cancer from COVID-19 infection and stressed that some measures proposed to protect adults with...

Sarcoma

Does Ivosidenib Show Activity in Patients With Advanced IDH1-Mutated Chondrosarcoma?

In a phase I study reported in the Journal of Clinical Oncology, William D. Tap, MD, and colleagues found that the selective mutant-IDH1 inhibitor ivosidenib produced no objective responses but resulted in durable disease control in a cohort of patients with advanced chondrosarcoma.

As noted by...

Prostate Cancer

Effect of Familial and Hereditary Cancer Syndromes on Risk of Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Jennifer L. Beebe-Dimmer, MPH, PhD, and colleagues found that risk of prostate cancer varied according to cancer family history, with the strongest association being observed between family history and early-onset prostate cancer.

Study...

Issues in Oncology
Lung Cancer

Disparities in Receipt of Chemotherapy Among Patients With pN1 Lung Cancer

In patients with non–small cell lung cancer (NSCLC) where the cancer has spread to one or more lymph nodes close to the lungs—a condition known as pathologic N1 (pN1) disease—current guidelines recommend a two-part protocol: surgical resection, followed by chemotherapy.

However, a retrospective...

Issues in Oncology
Gynecologic Cancers
Global Cancer Care

Gynecologic Cancer Screening After a Natural Disaster

Cervical cancer screening rates were significantly affected in the years following the Great East Japan Earthquake of 2011, according to a report published by Miki et al in PLOS ONE.

“Conflicts and disasters, and the social isolation that often follows, have a major impact on health care and lead...

Solid Tumors

Selumetinib for Inoperable Plexiform Neurofibromas in Children With Neurofibromatosis Type 1

In a phase II trial reported in The New England Journal of Medicine, Gross et al found that the oral MEK inhibitor selumetinib produced a high response rate and durable responses in children with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas.

Study Details

The study,...

Gastroesophageal Cancer
Immunotherapy

Bemarituzumab for FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma

In a phase I trial reported in the Journal of Clinical Oncology, Daniel V.T. Catenacci, MD, PhD, and colleagues found that the first-in-class anti–fibroblast growth factor receptor 2b (FGFR2b) antibody bemarituzumab showed activity in patients with high FGFR2b-overexpressing, advanced-stage...

Breast Cancer

Quality of Life After Adjuvant Radiotherapy With vs Without Tumor Bed Boost for Patients With Non–Low-Risk DCIS

In a health-related quality-of-life study reported in The Lancet Oncology, King et al found that adjuvant radiotherapy with a tumor bed boost was associated with poorer cosmetic status and arm and shoulder functional status than radiotherapy with no boost among women with non–low-risk ductal...

Hematologic Malignancies
Immunotherapy

Bispecific Antibodies: Successes and Challenges

Bispecific T-cell engager (BiTE) antibodies, such blinatumomab, may be the most appealing type of bispecific antibodies, a class of manufactured constructs that is expected to expand into the solid tumor space, according to Hermann Einsele, MD, Professor of Medicine at the University of Würzburg,...

Immunotherapy
Lung Cancer

FDA Approves Durvalumab as Part of a First-Line Combination Regimen for Extensive-Stage SCLC

On March 27, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (SCLC).

CASPIAN Trial

Efficacy of this combination in patients...

COVID-19

French Guidelines on Patients With Cancer and SARS-CoV-2 Infection

As reported by You et al in The Lancet Oncology, a representative group of French medical and radiation oncologists formulated guidelines to protect patients with cancer against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Guideline development was overseen by the French...

Lung Cancer

Imaging-Based Radiotherapy Target Volume Reduction in Locally Advanced NSCLC

In a European trial (PET-Plan) reported in The Lancet Oncology, Nestle et al found that the use of reduced radiotherapy target volumes determined by 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) alone may achieve improved local control vs conventional target planning with...

Issues in Oncology
Cost of Care

Evidence-Based Anticancer Drug Use in Physician Offices vs Hospital Outpatient Facilities

In a study reported in JCO Oncology Practice, Fishman et al found no significant difference in the use of optimal evidence-based anticancer drug regimens in physician offices vs hospital-based outpatient departments. However, the investigators found significantly higher costs of treatment in the...

Solid Tumors
Immunotherapy

Does Pembrolizumab Show Activity in Some Rare Cancers?

A study published by Naing et al in the Journal for ImmunoTherapy of Cancer found that treatment with pembrolizumab demonstrated acceptable toxicity and antitumor activity in patients with four types of advanced, hard-to-treat rare cancers.

“Our findings that pembrolizumab has a favorable toxicity...

Issues in Oncology
Geriatric Oncology

Polypharmacy and Inpatient Hospitalization Rates in Older Patients With Cancer

In a study published by Grace Lu-Yao, PhD, and colleagues in the Journal of Geriatric Oncology, researchers found hospitalization rates can increase by as much as 114% in patients with breast, prostate, and lung cancers when those patients have taken 15 or more medications prior to chemotherapy...

Breast Cancer
Immunotherapy

End-of-Study Results From CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

As reported in The Lancet Oncology by Sandra M. Swain, MD, and colleagues, long-term follow-up of the phase III CLEOPATRA trial has shown maintained overall survival benefit with the addition of pertuzumab to trastuzumab plus docetaxel in patients with previously untreated HER2-positive metastatic...

COVID-19

The Blind Leading the Blind: COVID-19, Cancer, and the Need for More Data

In the novel Blindness, Portuguese author José Saramago describes an epidemic that quickly and inexorably causes nearly all inhabitants of an unnamed city to lose their sight. The Nobel Laureate writes in long uninterrupted sentences, making the reader experience the fears and anxieties of the...

Solid Tumors
Genomics/Genetics

First-in-Human Study of RAF Family Kinase Inhibitor Lifirafenib in Solid Tumors

In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Desai et al found that the RAF family kinase inhibitor lifirafenib produced responses in several solid tumor types in patients with BRAF or KRAS/NRAS mutations.

Study Details

The study, conducted in Australia and New...

COVID-19

American College of Surgeons Issues COVID-19 Guidelines for Triage of Patients Undergoing Cancer Surgery

This week, the American College of Surgeons issued guidelines on triage of patients undergoing elective cancer surgery during the COVID-19 pandemic.

During the current COVID-19 pandemic, hospital leadership and individual providers are facing increasingly difficult decisions about how to conserve...

Hepatobiliary Cancer
Global Cancer Care

Trends in Global Rates of Liver Cancer From 1990 to 2017

New research published by Liu et al in the journal Cancer has revealed rising rates of liver cancer around the world, despite advances aimed at preventing the disease; however, some steps towards alleviation have been made due to control of hepatitis.

Methods

To obtain trends and estimates of liver ...

Hepatobiliary Cancer

Pemigatinib for Previously Treated Advanced Cholangiocarcinoma

In the phase II FIGHT-202 study reported in The Lancet Oncology, Ghassan K. Abou-Alfa, MD, and colleagues found that the fibroblast growth factor receptor 1 (FGFR1), FGFR2, and FGFR3 inhibitor pemigatinib was active in patients with previously treated locally advanced or metastatic...

COVID-19

Practicing Oncology in the Era of COVID-19

The coronavirus-related pandemic has affected nearly every corner of the globe. What originated in one country is on course to likely affect every country in the world. In a few countries, the disease has peaked and is on the downward trend. In some, including the United States, the disease is on...

Colorectal Cancer

Prognostic Impact of Tumor Deposits in Patients Receiving Adjuvant Therapy for Stage III Colon Cancer

In a post hoc analysis of the phase III IDEA France trial reported in the Journal of Clinical Oncology, Delattre et al found that the presence of tumor deposits was associated with poorer prognosis in patients with stage III colon cancer receiving 3 or 6 months of adjuvant FOLFOX (fluorouracil,...

COVID-19

Association for Clinical Oncology: More Testing, Personal Protective Equipment, Practice Support Needed During COVID-19 Crisis

The Association for Clinical Oncology, ASCO's affiliated 501(c)(6) organization, is urging the White House and leaders in Congress to swiftly work together to meet the needs of patients and health-care professionals in response to the COVID-19 crisis.

In a letter to the President, Vice President,...

Issues in Oncology
Global Cancer Care
Genomics/Genetics

International Uptake of Molecular Testing Across Tumor Types: Analysis of Eight Countries

In a study reported in JCO Oncology Practice, Chambers et al found that use of molecular testing across tumor types often varied widely in several countries, sometimes reflecting regional differences in the incidence of cancer types.

Study Details

The study involved the use of aggregated results of ...

Gynecologic Cancers
Immunotherapy

Predicting Which Patients With Ovarian Cancer May Respond to Combination PARP and PD-1 Inhibition

In some patients with advanced ovarian cancer, the combination of programmed cell death protein 1 (PD-1) and poly (ADP-ribose) polymerase (PARP) inhibitors can produce responses, but up until now, investigators have been unable to predict which patients would not benefit from the treatment and...

COVID-19

Oncologists on the Front Lines of COVID‑19

Coronavirus disease 2019 (COVID-19) is dramatically affecting health-care systems. This is the first in a series of interviews The ASCO Post will conduct with oncologists, to learn what they and their cancer centers are doing to deal with the crisis. In this article, we talk with John Cole, MD, a...

Gynecologic Cancers
Immunotherapy

Lenvatinib/Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer

As reported in the Journal of Clinical Oncology by Vicky Makker, MD, and colleagues, findings from a phase Ib/II trial indicate that the combination of lenvatinib and pembrolizumab is active in patients with previously treated advanced endometrial carcinoma.

Study Details

The report is the primary ...

COVID-19

A Message From the FDA OCE for Patients With Cancer and Health-Care Providers on COVID-19

On March 23, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) issued the following statement:

The FDA OCE recognizes that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease (COVID-19). While everyone’s daily lives...

Solid Tumors
Lymphoma
Immunotherapy

Nivolumab for Children and Young Adults With Relapsed or Refractory Solid Tumors or Lymphoma

In the phase I/II ADVL1412 study reported in The Lancet Oncology, Davis et al identified the phase II dosage of nivolumab monotherapy in children and young adults with relapsed or refractory solid tumors or lymphoma. Objective responses were observed in patients with lymphoma, but not in those with ...

Issues in Oncology
Prostate Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer

Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation

People with a history of cancer have an over twofold risk of developing atrial fibrillation, the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology’s Annual Scientific Session (Abstract 1216-235). In...

Skin Cancer

Clinical and Dermoscopic Features of Uncommon Melanoma Variants: Systematic Review

In a literature review published by Pampena et al in JAMA Dermatology, researchers provided detailed and extensive information about the features of several different kinds of rare cutaneous melanomas.

According to the researchers, the analysis was performed to “…provide a comprehensive overview of ...

Lung Cancer
Immunotherapy

Updated Analysis From KEYNOTE-189: Adding Pembrolizumab to Pemetrexed/Platinum for Nonsquamous NSCLC

An updated analysis from the phase III KEYNOTE-189 trial, reported by Shirish Gadgeel, MB, BS, and colleagues in the Journal of Clinical Oncology, indicated that the addition of pembrolizumab to pemetrexed/platinum chemotherapy continues to be associated with progression-free and overall survival...

COVID-19

Managing Cancer Care During the COVID-19 Pandemic

A special feature in JNCCN–Journal of the National Comprehensive Cancer Network by Ueda et al highlighted the unique circumstances and challenges of providing treatment to patients with cancer during the global COVID-19 pandemic.

Physicians from the Seattle Cancer Care Alliance, Fred Hutchinson...

Breast Cancer
Genomics/Genetics

Association of Germline Variant Status and Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer

In a study of the GeparOcto trial population reported in JAMA Oncology, Pohl-Rescigno et al found that presence of germline BRCA1/2 variants was associated with increased rates of complete pathologic response (pCR) to neoadjuvant chemotherapy in women with high-risk early breast cancer, and that a...

Skin Cancer

Trends in Deaths From Cutaneous Melanoma in the United States

Recent treatment advances in metastatic melanoma resulted in reductions in population-level mortality from the disease, according to a study published by Polsky et al in the American Journal of Public Health.

Methods

Researchers analyzed new cases and deaths from melanoma from nine U.S....

Colorectal Cancer
Immunotherapy

Reintroduction of FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

In the Italian phase III TRIBE2 trial reported in The Lancet Oncology, Cremolini et al found that reintroduction of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab after progression on upfront treatment with the regimen was associated with improved...

COVID-19

COVID-19 May Remain Stable for Hours to Days in Aerosols and on Surfaces

The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study published as a research letter in The New England Journal of Medicine.

A team of researchers from the National Institutes of Health (NIH); the Centers ...

Hepatobiliary Cancer

Does Aspirin Use Lower the Risk of Hepatocellular Carcinoma and Liver-Related Mortality in Patients With Chronic Viral Hepatitis?

In a study reported in The New England of Medicine, Tracey G. Simon, MD, MPH, and colleagues found that low-dose aspirin use was associated with a reduced risk of hepatocellular carcinoma and liver-related mortality among patients with chronic hepatitis B or C infection.

Study Details

The study...

Survivorship

Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors

An analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology by Yan et al found that adherence to Children’s Oncology Group (COG) recommended surveillance for second malignant neoplasms and cardiac dysfunction in high-risk childhood cancer survivors is ...

Breast Cancer

Digital Breast Tomosynthesis vs Digital Mammography Outcomes: Comparison Over 5 Years

A new study published by Conant et al in the journal Radiology found that the advantages of digital breast tomosynthesis over digital mammography, including increased cancer detection and fewer false-positive findings, are maintained over multiple years and rounds of screening. In addition,...

COVID-19

COVID-19 Infection in Patients With Cancer in China

In a study of the COVID-19 crisis in China reported in The Lancet Oncology, Liang et al found that patients with cancer may be at a higher risk of COVID-19 respiratory disease requiring admission to hospital than individuals without cancer, and that those with cancer who contract the virus have a...

Kidney Cancer

Addition of Vincristine/Irinotecan to Established Chemotherapy Regimen in Patients With Diffuse Anaplastic Wilms Tumor

In a Children’s Oncology Group study (AREN0321) reported in the Journal of Clinical Oncology, Daw et al found that the addition of vincristine/irinotecan to a regimen used in the National Wilms Tumor Study 5 (NWTS-5; vincristine, doxorubicin, cyclophosphamide, carboplatin, and etoposide plus...

Gastroesophageal Cancer

Proton Beam Therapy vs Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer

In a single-institution phase IIb trial reported in the Journal of Clinical Oncology, Steven H. Lin, MD, PhD, and colleagues found that proton beam therapy was associated with less toxicity and similar progression-free survival vs intensity-modulated radiation therapy in patients with locally...

Issues in Oncology

Spring 2020 ABIM Maintenance of Certification Exams Canceled

The American Board of Internal Medicine (ABIM) has announced that all spring 2020 maintenance of certification (MOC) assessment administrations are canceled in light of the COVID-19 pandemic. They issued the following communication:

As frontline health-care professionals, many board-certified...

Issues in Oncology
Survivorship

Cancer Incidence and Survivorship in Transgender Patients

The first-ever population-based study of cancer prevalence in transgender people was recently published by Boehmer et al in the journal Cancer. The authors of the report estimate that 62,530 of the nearly 17 million cancer survivors in the United States are transgender.

Methods

The researchers used ...

COVID-19

Mitigating the Spread of COVID-19 and Its Impact on Cancer

On March 11, the World Health Organization (WHO) took the step it had been avoiding for weeks and declared that the spread of the coronavirus disease 2019 (COVID-19), and the virus that causes it, now identified as SARS-CoV-2, had reached global pandemic levels, the first pandemic sparked by a...

COVID-19

How COVID-19 Is Affecting the Oncology Community

Over the past month, medical societies worldwide have been monitoring the escalating outbreak of the novel coronavirus and its effect on international and domestic travel and making difficult decisions to cancel or postpone their scientific conferences or make them available digitally.

On March...

COVID-19

Strategies for Protecting Patients and Health-Care Providers Against COVID-19

For Patients

Patients undergoing active treatment for cancer and cancer survivors may be at increased risk of becoming infected with the coronavirus because of their compromised immune system and their susceptibility to other illnesses. ASCO has developed information on Cancer.Net on how patients...

Breast Cancer

Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide for Patients With HER2-Negative Breast Cancer and a BRCA Mutation

In a phase II trial (INFORM; Translational Breast Cancer Research Consortium [TBCRC] 031) reported in the Journal of Clinical Oncology, Nadine Tung, MD, and colleagues found that neoadjuvant cisplatin did not improve pathologic complete response rate or residual cancer burden vs...

Solid Tumors

Adjuvant Etoposide/Cisplatin for Pathologic Stage II Nonseminomatous Germ Cell Tumors

In a single-center retrospective analysis reported by McHugh et al in the Journal of Clinical Oncology, two cycles of adjuvant etoposide plus cisplatin proved highly effective in patients with pathologic stage II nonseminomatous germ cell tumors. The combination also had acceptable toxicity and...

Gynecologic Cancers

Risk of Cervical Cancer With Different Types of Intrauterine Devices

Patients who used copper intrauterine devices (IUDs) were found to have a lower risk of high-grade cervical neoplasms vs users of the levonorgestrel-releasing intrauterine system, according to a study published by Spotnitz et al in the journal Obstetrics & Gynecology.

The study notes that more...

Issues in Oncology
Survivorship

Are Younger Cancer Survivors More Susceptible to Financial and Food-Related Anxieties?

New research from the American Cancer Society published by Zheng et al in JNCCN–Journal of the National Comprehensive Cancer Network found that younger cancer survivors are more likely to experience significant financial strain for daily living necessities—such as food, housing, and monthly...

Prostate Cancer

Conventionally Fractionated vs Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer: Long-Term Update

As reported in the Journal of Clinical Oncology by Avkshtol et al, the 10-year update of a single-center trial has confirmed the primary analysis of the study, showing no superiority in 5-year biochemical and/or clinical disease failure rate with moderate hypofractionated intensity-modulated...

Leukemia

Addition of Venetoclax to Cytarabine in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

In a phase I trial reported in The Lancet Oncology, Karol et al found that the combination of the BCL2 inhibitor venetoclax and the chemotherapeutic agent cytarabine with or without idarubicin produced responses in pediatric patients with relapsed or refractory acute myeloid leukemia.

As noted by...

Breast Cancer
Genomics/Genetics

Evaluation of Genetic Testing in NCCN Criteria for Women With Breast Cancer

In a single-institution study reported in the Journal of Clinical Oncology, Yadav et al found that many women with breast cancer with germline pathogenic genetic variants do not qualify for genetic testing on current National Comprehensive Cancer Network® (NCCN®) hereditary testing criteria....

Colorectal Cancer

Colorectal Cancer Statistics 2020 Published

The burden of colorectal cancer is shifting to younger individuals as incidence increases in young adults and declines in older age groups, according to Colorectal Cancer Statistics 2020. The median age of diagnosis dropped from 72 in 2001–2002 to 66 in 2015–2016. This finding and other data were...

Lung Cancer
Gynecologic Cancers
Neuroendocrine Tumors
Breast Cancer

FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More

Over the past week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a bispecific antibody for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations; granted approval to a test for human...

Breast Cancer

Preoperative Letrozole for Postmenopausal Patients With Estrogen Receptor–Positive DCIS

In the phase II CALGB 40903/Alliance trial reported in the Journal of Clinical Oncology, E. Shelley Hwang MD, MPH, and colleagues found that preoperative letrozole was associated with beneficial imaging and biomarker changes in postmenopausal women with estrogen receptor­ (ER)-positive ductal...

Hematologic Malignancies

Bendamustine/Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis

In a phase II trial reported in the Journal of Clinical Oncology, Suzanne Lentzsch, MD, PhD, and colleagues found that the combination of bendamustine and dexamethasone showed activity in patients with relapsed/refractory systemic light-chain amyloidosis. As stated by the investigators, there...

Pancreatic Cancer

Survival in Patients With Pancreatic Cancer Receiving Molecularly Matched Therapies

In a retrospective study reported in The Lancet Oncology, Michael J. Pishvaian, MD, and colleagues found that overall survival was better in patients with pancreatic cancer with actionable molecular alterations who received matched therapies compared with those who received only unmatched therapies ...

Issues in Oncology

Annual Report to the Nation on the Status of Cancer Released

The Annual Report to the Nation on the Status of Cancer has found that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined. The report was published by Hensley et al in the journal Cancer.

The annual report is a collaborative effort among the ...

Head and Neck Cancer
Immunotherapy

Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer

The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...

Head and Neck Cancer
Immunotherapy

Expert Point of View: Sue Sun Yom, MD, PhD

Sue Sun Yom, MD, PhD, Professor of Radiation Oncology & Otolaryngology–Head and Neck Surgery at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, said there is “reasonableness to further investigation” of the combination of programmed cell death...

Pancreatic Cancer

Preoperative Chemoradiotherapy vs Immediate Surgery for Pancreatic Cancer

In the Dutch phase III PREOPANC trial reported in the Journal of Clinical Oncology, Versteijne et al found that preoperative chemoradiotherapy did not improve overall survival vs immediate surgery in patients with resectable and borderline resectable pancreatic cancer. Benefits of preoperative...

Neuroendocrine Tumors

Ho-166 Radioembolization After Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor Liver Metastases

In a single-center Dutch phase II trial reported in The Lancet Oncology, Braat et al found that holmium Ho-166 radioembolization produced responses in patients with neuroendocrine tumor liver metastases who had received peptide receptor radionuclide therapy with lutetium Lu-177 dotatate.

Study...

Prostate Cancer

Association of Genomic Prostate Score With Adverse Pathology at Radical Prostatectomy After Initial Active Surveillance

In a study reported in the Journal of Clinical Oncology, Daniel W. Lin, MD, and colleagues found that the 17-gene Oncotype DX Genomic Prostate Score was not associated with the finding of adverse pathology among men with prostate cancer undergoing radical prostatectomy after initial active...

Breast Cancer

Receipt of Adjuvant vs Neoadjuvant Chemotherapy and Start of Treatment in Patients With Breast Cancer

Research published by Melchior et al in Cancer Medicine has indicated that starting chemotherapy before surgery does not expedite the start or completion of treatment for breast cancer vs performing surgery first.

“Increasingly, patients are given [neoadjuvant] chemotherapy…This is done for breast ...

Survivorship

Five-Year Survival for Cancers in Adolescents and Young Adults: 4-Decade Analysis

The 5-year survival rate for adolescents and young adults with cancer has significantly improved from 1975 to 2005 in the United States overall, but this was not the case for all types of cancer, according to a report published by Anderson et al in the Journal of the National Cancer Institute.

“We ...

Hepatobiliary Cancer
Immunotherapy

FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma

On March 10, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with hepatocellular carcinoma who have been previously treated with sorafenib.

CheckMate 040

Efficacy of the combination was...

Leukemia
Immunotherapy

First-Line Cladribine With Concurrent or Delayed Rituximab for Hairy Cell Leukemia

In a phase II study reported in the Journal of Clinical Oncology, Robert J. Kreitman, MD, and colleagues found that achievement of minimal residual disease–free complete remission for patients with hairy cell leukemia was enhanced by adding concurrent rituximab to first-line cladribine; a lesser...

Prostate Cancer

Evaluation of Different Methods of Biopsy for the Diagnosis of Prostate Cancer

In a study reported in The New England Journal of Medicine, Ahdoot et al found that combined use of magnetic resonance imaging (MRI)-targeted biopsy and 12-core systematic prostate biopsy led to enhanced detection of prostate cancers vs either approach alone in men with MRI-visible prostate...

Solid Tumors

Prognostic Value of Teratoma in Metastatic Nonseminomatous Germ Cell Tumor

In a single-institution retrospective study reported in the Journal of Clinical Oncology, Taza et al found that the presence of teratoma in primary tumor and postchemotherapy retroperitoneal lymph node dissection specimens was not a prognostic factor in patients with metastatic testicular germ cell ...

Colorectal Cancer
Issues in Oncology

Study Examines Survival Rates in Pediatric and Young Adult Patients With Colon Cancer

According to research published by Andrea Hayes-Jordan, MD, FACS, and colleagues in the Journal of the American College of Surgeons, children and young adults with colon cancer are more likely to have shorter overall survival and recurrence-free survival than middle-aged adults. In a...

Bladder Cancer

Adjuvant Gemcitabine/Platinum-Based Chemotherapy vs Surveillance for Upper Tract Urothelial Carcinoma: POUT Trial

In the phase III POUT trial, reported in The Lancet, Alison Birtle, MD, and colleagues found that adjuvant gemcitabine/platinum chemotherapy was associated with improved disease-free survival vs surveillance in patients with locally advanced urothelial carcinoma of the upper urinary tract.

As...

Hematologic Malignancies

Can Diversity of Intestinal Microbiota Help Predict Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation?

In a study reported in The New England Journal of Medicine, Peled et al found that intestinal microbiota from patients undergoing allogeneic hematopoietic cell transplantation at four centers showed patterns of disruption characterized by loss of diversity and domination by a single taxon. Lower...

Breast Cancer
Issues in Oncology
Cost of Care

Young Women Diagnosed With Breast Cancer May Face Employment Disruption and Financial Hardship

A study evaluating the economic impact of the cancer in young women has found that the diagnosis can result in employment disruption and financial decline. The findings—published by Tangka et al in Cancer Epidemiology, Biomarkers & Preventionindicate the need for obtaining and maintaining...

Lymphoma
Solid Tumors
Hepatobiliary Cancer

FDA Pipeline: Priority Review in DLBCL, Fast Track Designations in T-Cell Lymphoma and Adenoid Cystic Carcinoma

Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a combination therapy in diffuse large B-cell lymphoma (DLBCL); gave Fast Track designations for treatments in T-cell lymphoma and adenoid cystic carcinoma; granted Orphan Drug designation to an agent for the ...

COVID-19

NCCN Postpones 2020 Annual Conference, Citing Precautions Against Potential Patient Exposure to COVID-19

The National Comprehensive Cancer Network® (NCCN) announced today that the organization is postponing the NCCN 2020 Annual Conference and preconference programs that were scheduled for March 19–22 in Orlando. The gathering for more than 1,500 oncology professionals was going to feature more than 30 ...

Kidney Cancer
Immunotherapy

Pembrolizumab Plus Bevacizumab for Metastatic Renal Cell Carcinoma

In a phase Ib/II trial (BTRC-GU14-003) reported in the Journal of Clinical Oncology, Dudek et al found that the combination of pembrolizumab and bevacizumab showed activity in patients with metastatic clear cell renal cell carcinoma.

As stated by the investigators, “Anti-angiogenic treatment has...

Breast Cancer

Anthracycline-Based Chemotherapy vs Docetaxel/Capecitabine: What’s the Better Adjuvant Therapy for Early Breast Cancer?

As reported in the Journal of Clinical Oncology by Delaloge et al, a second randomized component of the phase III EORTC 10041/BIG 3-04 MINDACT trial, though underpowered, suggested no benefit of docetaxel/capecitabine vs standard anthracycline-based adjuvant therapy for patients with early breast...

Solid Tumors

Pooled Analysis of Phase I/II Trials of Larotrectinib in TRK Fusion–Positive Solid Tumors

In a pooled analysis of phase I/II trials reported in The Lancet Oncology, Hong et al found that the tropomyosin receptor kinase (TRK) inhibitor larotrectinib produced a high response rate in pediatric and adult patients with advanced TRK fusion–positive solid tumors.

Larotrectinib received...

Prostate Cancer

Phenelzine for Biochemical Recurrent Castration-Sensitive Prostate Cancer

A monoamine oxidase A (MAOA) inhibitor in use for decades as an antidepressant demonstrated activity in patients with recurrent prostate cancer, with most toxicities seen with the treatment being reported as mild. These findings were published by Gross et al in Prostate Cancer and Prostatic...

Gynecologic Cancers

Olaparib vs Nonplatinum Chemotherapy in Platinum-Sensitive Relapsed BRCA1/2-Mutated Ovarian Cancer

In the phase III SOLO3 trial reported in the Journal of Clinical Oncology, Richard T. Penson, MD, and colleagues found that olaparib was associated with an improved objective response rate and progression-free survival vs nonplatinum chemotherapy in women with platinum-sensitive relapsed ovarian...

Lung Cancer
Immunotherapy

Concurrent Pembrolizumab and Chemoradiotherapy in Locally Advanced NSCLC

In a phase I trial reported in JAMA Oncology, Jabbour et al found that the use of pembrolizumab concurrently with chemoradiotherapy in advanced non–small cell lung cancer (NSCLC) was tolerable, and that progression-free survival with the combination therapy was 69.7% at 12 months.

As stated by the...

Genomics/Genetics
Pancreatic Cancer
Issues in Oncology

Geographic and Racial Variability in Germline BRCA Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer

In a study reported in the Journal of Clinical Oncology, Talia Golan, MD, and colleagues identified geographic and ethnic heterogeneity of germline BRCA1/2 mutation prevalence among patients screened for entry into the phase III POLO trial, which examined the efficacy of olaparib maintenance...

Breast Cancer

AI Algorithms Plus Radiologist Assessment May Help Improve Accuracy in Reading Mammography Results

An ensemble of machine-learning algorithms could help improve the accuracy of breast cancer screenings when used in combination with assessments from radiologists, according to a study published by Schaffter et al in JAMA Network Open.

The study was based on results from the Digital Mammography...

Skin Cancer
Issues in Oncology

Are Those Who Have Lost a Partner at a Higher Risk of Dying of Melanoma?

Individuals who experience the loss of a partner are less likely to be diagnosed with melanoma—but face an increased risk of dying from the disease, according to research published by Wong et al in the British Journal of Dermatology.

While previous studies have suggested a link between various...

Breast Cancer
Immunotherapy

Neoadjuvant and Adjuvant Pembrolizumab in Early Triple-Negative Breast Cancer

As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, and colleagues, interim analyses of the phase III KEYNOTE-522 trial have shown that the addition of pembrolizumab to neoadjuvant chemotherapy and use of adjuvant pembrolizumab vs placebo resulted in improvements in...

Gynecologic Cancers
Symptom Management

Gastrointestinal Patient-Reported Outcomes With Postoperative Intensity-Modulated Radiotherapy vs Standard Radiotherapy

In an analysis from the NRG Oncology RTOG 1203 study reported in the Journal of Clinical Oncology, Yeung et al found improved patient-reported gastrointestinal toxicity with intensity-modulated radiotherapy vs standard radiotherapy among patients with cervical or endometrial cancer requiring...

Issues in Oncology

Initiative to Reduce PET/CT Radiotracer Infiltrations

In a single-institution study reported in JCO Oncology Practice, Kiser et al found that implementation of a quality improvement plan significantly reduced the frequency of positron-emission tomography (PET)/computed tomography (CT) radiotracer infiltration among a team of technologists....

Issues in Oncology

Malnutrition Evaluation Before Oncologic Surgery

The best approach for surgeons to identify malnourished patients with cancer before they have major oncologic surgery may be specifically related to the type of cancer the patient has, according to researchers who found that common definitions of malnutrition do not apply equally to all cancers in...

Lung Cancer
Immunotherapy

Long-Term Outcomes and Retreatment Outcomes With Immunotherapy in PD-L1–Positive Advanced NSCLC

As reported in the Journal of Clinical Oncology by Roy S. Herbst, MD, PhD, and colleagues, long-term follow-up of patients with previously treated advanced programmed cell death ligand 1 (PD-L1)-positive non–small cell lung cancer (NSCLC) in the KEYNOTE-010 trial has shown a continued survival...

Sarcoma

Cabozantinib for Advanced Ewing Sarcoma or Osteosarcoma

In the French phase II CABONE trial reported in The Lancet Oncology, Italiano et al found that the MET and VEGFR2 inhibitor cabozantinib was active in patients with advanced Ewing sarcoma or osteosarcoma.

Study Details

In the multicenter trial, 81 evaluable patients aged ≥ 12 years with progressive ...

Issues in Oncology

Two Recent Studies Show Low-Nicotine Cigarettes Are Unlikely to Increase Compensatory Smoking

A pair of studies by Smith et al published in Cancer Epidemiology, Biomarkers & Prevention evaluating whether a mandated reduction in the nicotine content of cigarettes may cause smokers to compensate by engaging in compensatory smoking to obtain more nicotine has found that a reduction in...

Breast Cancer
Issues in Oncology

Weight Gain After Breast Cancer Diagnosis in Australia: Survey Results

New study findings suggest that weight gain after breast cancer is a greater problem than previously thought. The first national survey on weight after breast cancer in Australia, published by Ee et al in BMC Cancer, found close to two-thirds (63.7%) of women reported weight gain at an average of...

Lung Cancer
Immunotherapy

Plasma-Based Tumor Mutational Burden May Predict Response to Immunotherapy in Patients With Metastatic NSCLC

Patients with non–small cell lung cancer (NSCLC) with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to certain immunotherapy treatments than patients with a lower measure of mutations. A clinical trial showed that in cases where liquid...

Head and Neck Cancer

2020 Head and Neck Cancers Symposium: Adjuvant Everolimus for Advanced Head and Neck Cancer

The mTOR inhibitor everolimus may extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment. Patients enrolled in a randomized phase II trial who received the agent were more likely to be cancer-free 1 year after...

Head and Neck Cancer
Immunotherapy

2020 Head and Neck Cancers Symposium: Immune Restorative Agent May Boost Immunotherapy Response in Advanced Head and Neck Cancer

Immune modulation with checkpoint inhibitors has shown benefit in advanced head and neck squamous cell carcinoma, but responses have been limited to a small number of patients. According to data presented by Gregory T. Wolf, MD, FACS, Professor Emeritus in the Department of Otolaryngology-Head and...

Colorectal Cancer

Three vs Six Months of Adjuvant Chemotherapy for High-Risk Stage II Colorectal Cancer

As reported in JAMA Oncology by Petrelli et al, noninferiority in relapse-free survival for 3 vs 6 months of adjuvant chemotherapy was not established among patients with resected high-risk stage II colorectal cancer in the Italian phase III TOSCA trial. A potential regimen effect was observed,...

Breast Cancer

Abbreviated Breast MRI vs Digital Breast Tomosynthesis Screening in Women With Dense Breasts

As reported in JAMA by Christiane K. Kuhl, MD, PhD, and colleagues, the ECOG-ACRIN EA1141 trial has shown that abbreviated breast magnetic resonance imaging (MRI) was associated with a significantly higher invasive breast cancer detection rate vs digital breast tomosynthesis among women with dense...

Lung Cancer
Head and Neck Cancer
Gynecologic Cancers
Breast Cancer

FDA Pipeline: Priority Review in Lung Cancer, Breakthrough Therapy Designation in Head and Neck Cancer, and More

This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to brigatinib for the treatment of ALK-positive lung cancer and Breakthrough Therapy designation to a potential first-in-class oral antagonist of inhibitors of apoptosis proteins for the treatment of head and neck...

Immunotherapy
Head and Neck Cancer

2020 Head and Neck Cancers Symposium: Pembrolizumab Plus Radiotherapy for Platinum-Ineligible Patients With Locally Advanced HNSCC

A new phase II trial has found that the combination of radiation therapy and pembrolizumab led to improved survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination therapy may offer a new treatment option for...

Immunotherapy
Head and Neck Cancer

2020 Head and Neck Cancers Symposium: Nivolumab With or Without Ipilimumab for the Neoadjuvant Treatment of Patients With Oral Cavity Cancer

Results from a new clinical trial suggest that neoadjuvant immunotherapy for oral cavity cancers may elicit tumor regression, which could provide long-term benefit for patients. Findings were presented by Jonathan D. Schoenfeld, MD, MPH, of Dana-Farber/Brigham and Women's Cancer Center, and...

Lung Cancer
Global Cancer Care

Trends in Lung Cancer Incidence in Young Women vs Young Men Across 40 Countries

In a systematic analysis of data from 40 countries reported in the International Journal of Cancer, Fidler-Benaoudia et al identified a widespread emergence of higher lung cancer incidence rates in young women vs young men. The trend does not appear to be explained by differences in smoking...

Breast Cancer
Issues in Oncology

Are There Differences in Treatment and Outcomes for African American and White Women With Triple-Negative Breast Cancer?

In a study using Henry Ford Health System data reported in a research letter in JAMA Surgery, Chen et al found little difference in treatment and outcomes between African American and white women with nonmetastatic triple-negative breast cancer. Screen detection of disease was associated with...

Issues in Oncology

Depression and Suicidal Ideation in Patients With Cancer

As reported in JCO Oncology Practice by Omar Abdel-Rahman, MD, of the Cross Cancer Institute, University of Alberta, a study using U.S. National Health and Nutrition Examination Survey (NHANES) data indicated that patients with cancer were not more likely to have depressive disorders—but were more...

Breast Cancer
Immunotherapy

Trastuzumab Deruxtecan in HER2–Low-Expressing, Previously Treated Advanced Breast Cancer

In a phase Ib study reported in the Journal of Clinical Oncology, Shanu Modi, MD, and colleagues found that the antibody-drug conjugate trastuzumab deruxtecan was active in HER2–low-expressing, previously treated advanced breast cancer.

The drug component is a topoisomerase I inhibitor. The agent...

Solid Tumors

Treating Typical Solitary Fibrous Tumor With a Tyrosine Kinase Inhibitor

In a European phase II trial reported in The Lancet Oncology, Martin-Broto et al found that pazopanib showed activity in patients with typical solitary fibrous tumors.

The investigators previously reported findings with pazopanib treatment in a cohort of patients in the trial with advanced...

Issues in Oncology
Survivorship

Models for Predicting Acute Ovarian Failure in Survivors of Childhood Cancer

As reported in The Lancet Oncology, Clark et al have developed radiation dosimetric models that can be used to predict the risk of acute ovarian failure in female survivors of childhood cancer.

Study Details

The cohort study involved 5,886 eligible 5-year survivors in the Childhood Cancer Survivor ...

Issues in Oncology
Survivorship

Physical Activity and Quality of Life in African American Cancer Survivors

New research suggests that regular exercise may improve the well-being of African American cancer survivors, but most survivors do not meet current recommendations for physical activity. The findings were published by Jennifer Beebe-Dimmer, MPH, PhD, and colleagues in the journal Cancer.

Because...

Issues in Oncology
Survivorship

Late Mortality and Chronic Health Conditions in Long-Term Survivors of AYA Cancers

A retrospective analysis from the Childhood Cancer Survivor Study, reported in The Lancet Oncology by Eugene Suh, MD, and colleagues, showed that as with survivors of childhood cancers, survivors of adolescent and young adult (AYA) cancers are at increased risk of earlier mortality and chronic...

Breast Cancer

Addition of Capivasertib to Fulvestrant in Advanced ER-Positive Breast Cancer After Relapse or Disease Progression With Aromatase Inhibitor Treatment

In the phase II FAKTION trial reported in The Lancet Oncology, Jones et al found that the addition of the AKT inhibitor capivasertib to endocrine therapy with fulvestrant prolonged progression-free survival in postmenopausal women with aromatase inhibitor–resistant, estrogen receptor (ER)-positive, ...

Issues in Oncology

Hippocampal Avoidance During Whole-Brain Radiotherapy: Effects on Cognitive Function

As reported in the Journal of Clinical Oncology by Brown et al, the phase III NRG Oncology CC001 trial has shown superior cognitive function outcomes with hippocampal avoidance using intensity-modulated radiotherapy during whole-brain radiotherapy (WBRT) for the treatment of adult patients with...

Prostate Cancer

PSA-Stratified Screening for Prostate Cancer

Previous studies have shown that men with low prostate-specific antigen (PSA) levels (< 1.0 ng/mL) between ages 44 to 60 have a very low risk of developing prostate cancer in the future. A study published by Heijnsdijk et al in JNCI: Journal of the National Cancer Institute investigated benefits ...

Sarcoma

Immunogenomic Profiling of Osteosarcoma

Comprehensive profiling of tumor samples taken from patients with osteosarcoma showed that multiple factors contribute to the traditionally poor responses observed with immune checkpoint inhibitor treatment in patients with this malignancy, according to new research published by Wu et al in Nature...

Skin Cancer
Immunotherapy

Long-Term Outcomes With PD-1 Inhibitor Treatment and Response to Retreatment in Advanced Melanoma

In a single-center study reported in the Journal of Clinical Oncology, Allison Betof Warner, MD, PhD, and colleagues found that approximately three-quarters of patients with advanced melanoma achieving a complete response on programmed cell death protein 1 (PD-1) inhibitor therapy were alive...

Lung Cancer
Immunotherapy

Patient-Reported Outcomes With Addition of Pembrolizumab vs Placebo to Pemetrexed/Platinum for Nonsquamous NSCLC

As reported in The Lancet Oncology by Marina C. Garassino, MD, and colleagues, global health status/quality of life was maintained or improved with the addition of pembrolizumab vs placebo to pemetrexed/platinum therapy for previously untreated metastatic nonsquamous non–small cell lung cancer...

Lymphoma
Immunotherapy

Quality of Life With Tisagenlecleucel Therapy for Relapsed or Refractory DLBCL

Adult patients with diffuse large B-cell lymphoma (DLBCL) whose disease was effectively treated with the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel showed sustained and clinically meaningful improvement in a variety of self-reported quality-of-life measures, according to...

Lung Cancer
Lymphoma
Bladder Cancer
Head and Neck Cancer
Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

FDA Pipeline: Priority Reviews in Lung Cancers, Lymphoma

This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for non–small cell and small cell lung cancers, as well as for diffuse large-B cell lymphoma (DLBCL); Breakthrough Therapy designation to an antibody-drug conjugate for bladder cancer; and a double Fast...

Lung Cancer

Osimertinib Plus Savolitinib for EGFR-Mutated, MET-Amplified NSCLC After Disease Progression on EGFR Tyrosine Kinase Inhibitors

As reported in The Lancet Oncology, Lecia V. Sequist, MD, and colleagues have found activity and an acceptable risk-benefit profile with the combination of the third-generation EGFR tyrosine kinase inhibitor osimertinib and the MET tyrosine kinase inhibitor savolitinib in patients with EGFR...

Lymphoma

Haploidentical Related Donor vs Unrelated Cord Blood Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphomas

In a retrospective analysis reported in the Journal of Clinical Oncology, Fatobene et al found that nonmyeloablative haploidentical related donor cell transplantation was associated with better outcomes compared to unrelated cord blood hematopoietic transplantation in patients with Hodgkin and...

Prostate Cancer

HSD3B1 Genotype and Its Effect on Castration Resistance and Overall Survival in Prostate Cancer

As reported in JAMA Oncology, Nima Sharifi, MD, and colleagues have found that the adrenal-permissive HSD3B1 genotype is associated with earlier onset of castration resistance and poorer overall survival in men with low-volume metastatic prostate cancer.

As noted by the investigators, the...

Colorectal Cancer
Issues in Oncology

Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer

In a study published by Frankenfeld et al in Cancer Epidemiology, researchers found racial disparities in how the presence of cancer-related diagnostic and treatment technology is related to colorectal cancer patient outcomes in Georgia. The findings suggest that the hospital capacity and...

Gynecologic Cancers

Proteomic Analysis of Endometrial Cancer

A comprehensive molecular study of endometrial cancer published by Dou et al in Cell has further defined the contributions of key genes and proteins to the disease. The overview suggests new treatment approaches that could be tailored for each patient, as well as potential biologic targets for...

Gynecologic Cancers

Cervical Cancer Recurrence: Open vs Minimally Invasive Radical Hysterectomy

A multi-institutional retrospective study reported in the Journal of Clinical Oncology by Shitanshu Uppal, MBBS, and colleagues showed that minimally invasive radical hysterectomy was associated with a higher risk of disease recurrence vs open abdominal hysterectomy in women undergoing surgery for...

Skin Cancer

States With Highest Rates of Cutaneous Melanoma Due to Ultraviolet Exposure

A new study found a wide state-by-state variation in rates of melanoma caused by ultraviolet (UV) exposure, with highest rates in several states on the east and west coasts (including Hawaii), but also a few landlocked states (including Utah, Vermont, and Minnesota). The report, published by Islami ...

Hepatobiliary Cancer

PRH/HHEX Transcription Factor as a Treatment Target in Patients With Cholangiocarcinoma

Treatment of patients with cholangiocarcinoma could be improved by tailoring medication to the levels of a key protein in people with the disease, according to new research published by Kitchen et al in Cancer Research. Researchers have discovered that the proline-rich homeodomain...

Bladder Cancer
Immunotherapy

2020 GU Cancers Symposium: Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

In patients with metastatic urothelial carcinoma, platinum chemotherapy is the standard of care in the first-line setting; however, for patients who are ineligible for platinum treatment, the alternative standard—gemcitabine plus carboplatin—can be poorly tolerated and have limited durability and...

Lymphoma
Lung Cancer
Gastrointestinal Cancer
Breast Cancer
Head and Neck Cancer
Immunotherapy

FDA Pipeline: Priority Reviews in Lymphoma, Lung Cancer, GIST, and Breast Cancer

This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents in lymphoma, lung cancer, gastrointestinal stromal tumors, and breast cancer, and granted Fast Track designation to a first-in-class radioenhancer hafnium oxide nanoparticle in head and neck cancer.

Priority...

Prostate Cancer

2020 GU Cancers Symposium: Talazoparib for Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer

According to results from a phase II trial presented by Johann S. de Bono, MD, PhD, and colleagues at the 2020 Genitourinary (GU) Cancers Symposium (Abstract 119), treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib showed antitumor activity in patients with metastatic...

Immunotherapy
Symptom Management

Immune-Related Adverse Events in Patients With Cancer Receiving Influenza Vaccination During Treatment With Pembrolizumab

In a study reported in JCO Oncology Practice, Failing et al found that influenza vaccination did not increase the incidence of immune-related adverse events among patients receiving pembrolizumab for various cancers. On multivariate analysis, influenza vaccination was associated with a...

Kidney Cancer

2020 GU Cancers Symposium: Oral HIF2A Inhibitor for Advanced Clear Cell Renal Cell Carcinoma

A novel, first-in-class, small molecule, hypoxia-inducible factor 2 alpha (HIF2A) inhibitor showed single-agent activity in heavily pretreated patients with metastatic clear cell renal cell carcinoma. These results from a phase I/II study will be presented by Toni Choueiri, MD, and colleagues at...

Bladder Cancer
Kidney Cancer
Prostate Cancer
Issues in Oncology

2020 GU Cancers Symposium: Fear of Recurrence, Patients’ Prognostic Understanding Examined in Genitourinary Cancers

In studies to be presented at the 2020 Genitourinary Cancers Symposium (Abstracts 649 and 665), researchers examined the prevalence of fear of cancer recurrence in patients with renal cell carcinoma and evaluated the prognostic understanding patients with genitourinary cancer possess of their...

Head and Neck Cancer

Plasma Circulating Tumor HPV DNA for the Detection of Recurrent HPV-Associated Oropharyngeal Cancer

In a study reported in the Journal of Clinical Oncology, Bhishamjit S. Chera, MD, and colleagues found that surveillance for circulating tumor human papillomavirus (HPV) DNA was accurate in identifying disease recurrence in patients with curatively treated HPV-associated oropharyngeal squamous cell ...

Breast Cancer

Low-Fat Diets With Increased Vegetable, Fruit, and Grain Intake Linked to Reduced Risk of Breast Cancer Mortality in Postmenopausal Women

As reported in the Journal of Clinical Oncology by Rowan T. Chlebowski, MD, PhD, and colleagues, 20-year follow-up of the Women’s Health Initiative Dietary Modification trial has shown a maintained reduction in non–breast cancer-related mortality after breast cancer diagnosis and the emergence of a ...

Survivorship

Therapy-Associated Polyposis in Survivors of Childhood Cancer

A report published by Biller et al in Cancer Prevention Research provides new details about a recently discovered condition in which childhood cancer survivors develop numerous colorectal polyps, despite not having a hereditary susceptibility to the condition.

The condition—known as...

Lung Cancer

IASLC Early Lung Imaging Confederation Initiative for Analysis of Low-Dose CT Images

As reported by James L. Mulshine, MD, and colleagues in JCO Clinical Cancer Informatics, the International Association for the Study of Lung Cancer (IASLC) is developing the Early Lung Imaging Confederation (ELIC) “to serve as an open-source, international, universally accessible environment to...

Leukemia

Dengue Virus Infection May Increase Risk of Developing Leukemia

Compared to individuals without a history of dengue virus infection, those previously infected with the virus had over twice the risk of developing leukemia, with the highest risk occurring between 3 and 6 years after infection. The results of a study conducted in Taiwan were published by Chien et...

Bladder Cancer

Enfortumab Vedotin in Metastatic Urothelial Carcinoma

In the phase I EV-101 trial reported in the Journal of Clinical Oncology, Rosenberg et al found that the antibody-drug conjugate enfortumab vedotin had no maximum tolerated dose and was active in patients with metastatic urothelial carcinoma at the dose selected for phase II evaluation. The agent...

Skin Cancer
Issues in Oncology

Do Gay and Bisexual Men Have an Increased Risk of Developing Skin Cancer?

In the largest study to date of skin cancer rates among individuals who identify as gay, lesbian, or bisexual, investigators from Brigham and Women's Hospital reported important differences in skin cancer prevalence among sexual minorities. Rates of skin cancer were higher among gay and bisexual...

Skin Cancer

Biomarker Analysis in the COMBI-AD Trial of Adjuvant Dabrafenib Plus Trametinib in BRAF V600–Mutant Stage III Melanoma

In an exploratory biomarker analysis from the COMBI-AD trial, reported in The Lancet Oncology, Dummer et al found that tumor mutational burden (TMB) and interferon-gamma gene-signature profiles might be associated with an augmented benefit of adjuvant dabrafenib plus trametinib in resected BRAF...

Gynecologic Cancers

Modeling the Impact of HPV Vaccination and Cervical Screening on Cervical Cancer Elimination in Low-Income and Lower-Middle—Income Countries

In a modeling study reported in The Lancet, Brisson et al in the World Health Organization (WHO)-sponsored Cervical Cancer Elimination Modelling Consortium (CCEMC) found that high human papillomavirus (HPV) vaccine uptake in girls could lead to cervical cancer elimination in most low-income and...

Genomics/Genetics
Hematologic Malignancies

Genetic Mutations in Donor Stem Cells May Affect Hematopoietic Transplant Recipients

A new study on hematopoietic stem cell transplantation from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors’ stem cells—though not causing health problems in the donors—may be passed on to patients with cancer...

Prostate Cancer

Five-Year Patient-Reported Outcomes for Various Prostate Cancer Treatments

A 5-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment—radiation, surgery, or active surveillance—in patients of all ages and ethnicities is creating a road map for the future regarding long-term bowel, bladder, and sexual function in order to clarify...

Kidney Cancer
Immunotherapy

ASCO-SITC 2020: Ilixadencel/Sunitinib vs Sunitinib Alone in Synchronous Metastatic Kidney Cancer

In a study presented by Lindskog et al at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Abstract 11), researchers found ilixadencel, a cell-based allogeneic off-the-shelf product, in combination with sunitinib produced a higher objective response rate than sunitinib alone in patients with...

Lung Cancer
Immunotherapy
Symptom Management

ASCO-SITC 2020: Low Incidence of Nivolumab-Induced Radiation Recall Pneumonitis Among Patients With NSCLC

A multicenter retrospective study investigating the incidence of pneumonitis and the incidence, risk factors, and clinical characteristics of radiation recall pneumonitis in patients with non–small cell lung cancer (NSCLC) who had received nivolumab found the incidence of radiation recall...

Lung Cancer
Immunotherapy

ASCO-SITC 2020: Preliminary Results Show Antitumor Activity With Pepinemab/Avelumab in Patients With Advanced NSCLC

Interim results from the CLASSICAL-Lung phase Ib/II clinical trial of pepinemab, an IgG4 humanized monoclonal antibody targeting semaphorin 4D, in combination with the anti–programmed cell death ligand 1 antibody avelumab for patients with advanced NSCLC showed that the treatment is well tolerated...

Immunotherapy
Symptom Management

ASCO-SITC 2020: Vitamin D May Reduce Risk for Immune Checkpoint Inhibitor–Associated Colitis

In a study to be presented by Tyan et al at the upcoming 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Abstract 89), researchers found that vitamin D intake may be associated with reduced risk of colitis among patients being treated with immune checkpoint inhibitors.

Retrospective Analysis

In ...

Head and Neck Cancer
Issues in Oncology

Do Socioeconomic Factors Play a Role in Outcomes for HPV-Positive Head and Neck Cancer?

Survival outcomes for patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the head and neck have made significant gains in recent years, but new research published by Pike et al in JNCCN—Journal of the National Comprehensive Cancer Network has found some groups have not...

Breast Cancer
Genomics/Genetics
Issues in Oncology

Study Finds Women With Variants in Breast Cancer–Associated Genes May Not Always Be Receiving Guideline-Concordant Care

Women with early-stage breast cancer who test positive for an inherited genetic variant are not always receiving cancer treatment that follows current treatment guidelines, according to findings from a new study published by Allison W. Kurian, MD, MSc, and colleagues in JAMA Oncology.

An inherited ...

Skin Cancer

Circulating Tumor Cell Assessment to Predict Melanoma Relapse

A study published by Anthony Lucci, MD, and colleagues in Clinical Cancer Research showed that the presence of circulating tumor cells was independently associated with relapse of melanoma, suggesting circulating tumor cell assessment may be a useful tool for identifying patients at risk for...

Colorectal Cancer

Incidence Increases in New Colorectal Cancer Diagnoses Among Patients Between 49 and 50 Years Old

A year-by-year age analysis of colorectal cancer rates among adults in the United States has found a 46% increase in new diagnoses from ages 49 to 50, indicating that many latent cases of the disease are likely going undiagnosed until routine screenings begin at 50, according to a new study by...

Breast Cancer
Issues in Oncology

Is Distance to Treatment a Burden for Rural Patients With Breast Cancer?

A study published by Longacre et al in The Journal of Rural Health found that patients with breast cancer in the rural United States typically travel three times farther than those who live in urban areas for radiation therapy.

Researchers examined data from the Surveillance, Epidemiology, and End ...

Global Cancer Care

World Cancer Day 2020: 20th Anniversary of the Global Initiative

Today’s World Cancer Day, led by the Union for International Cancer Control (UICC), aims to mobilize urgent action from individuals, governments, and the global cancer community to close gaps in cancer risk awareness between higher and lower socioeconomic groups and the subsequent impact on their...

Global Cancer Care

WHO, IARC Release Reports in Response to Government’s Role in Cancer Control

The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) released two coordinated reports in light of World Cancer Day in response to government calls for more research into the scope and potential policies and programs to improve cancer control.

WHO Report

...

Gynecologic Cancers

Diffusion-Weighted MRI May Help Predict Treatment Response in Patients With Advanced Ovarian Cancer

A simple test using a magnetic resonance imaging (MRI) scan may be used to predict how well people with advanced epithelial ovarian cancer will respond to treatment, according to the results of a new study published by Winfield et al in Radiology. In a large clinical trial, scientists have shown a...

Solid Tumors
Immunotherapy

Peripheral Blood Lymphocytes and T Cells Targeting TP53 Mutations in Patients With Metastatic Solid Tumors

Although TP53 is the most frequently mutated gene across all cancers and encodes the tumor suppressor p53 protein, TP53-targeted therapies have not demonstrated efficacy beyond in vitro models and immunotherapies targeting mutant TP53 are not currently available. A study by Malekzadeh et al...

Lung Cancer

Patient Aid Improved Lung Cancer Screening Informed Decision-Making

In the first comparative clinical trial of lung cancer screening decision aid vs standard educational information, researchers from The University of Texas MD Anderson Cancer Center showed that a decision aid delivered through tobacco quitlines effectively reaches a screening-eligible population...

Leukemia

Dasatinib vs Imatinib in Pediatric Philadelphia Chromosome–Positive ALL

In a Chinese phase III trial reported in JAMA Oncology, Shen et al found that dasatinib was associated was superior event-free survival vs imatinib when combined with intensive chemotherapy in pediatric patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) not receiving...

Sarcoma
Immunotherapy

Immunotherapy Combination in Previously Treated Advanced Sarcoma

In a single-institution phase II study reported in JAMA Oncology, Kelly et al found that the combination of talimogene laherparepvec (T-VEC) and pembrolizumab produced durable responses in patients with previously treated advanced sarcoma.

As noted by the investigators, T-VEC has been found to...

Skin Cancer

Risk of CNS Metastasis in Patients With AJCC 8th Edition Stage III Melanoma

A study using data from two major melanoma centers in the United States and Australia, reported in the Journal of Clinical Oncology by Haydu et al, has shown a 5-year cumulative incidence of central nervous system (CNS) metastasis of 15.8% among patients with American Joint Committee on Cancer...

Lung Cancer
Thyroid Cancer
Myelodysplastic Syndromes

FDA Pipeline: Priority Review Granted for Treatment in Lung and Thyroid Cancers

This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for lung and thyroid cancers with a RET fusion or mutation; gave Breakthrough Therapy designation to a doublet therapy for TP53-mutated myelodysplastic syndromes; and issued an update to their...

Supportive Care
Integrative Oncology

Psilocybin-Assisted Psychotherapy and Cancer-Related Psychiatric Distress

In a study published by Agin-Liebes et al in the Journal of Psychopharmacology, researchers found that psychotherapy involving psilocybin—the active ingredient in “magic” or “psychedelic” mushrooms—may aid in long-term relief from cancer-related psychiatric distress.

Study Background and Design

An ...

Multiple Myeloma
Immunotherapy

Activity of Anti-BCMA BiTE Molecule AMG 420 in Relapsed or Refractory Multiple Myeloma

In a phase I study reported in the Journal of Clinical Oncology, Max S. Topp, MD, and colleagues found the maximum tolerated dose of the investigational anti–B cell maturation antigen (BCMA) bispecific T-cell engager (BiTE) molecule AMG 420 elicited a high response rate in patients with relapsed or ...

Head and Neck Cancer
Pain Management

Gabapentin and Methadone for Patients Undergoing Treatment of Head and Neck Cancer

With nearly all patients who undergo treatment for cancer of the head and neck experiencing oral mucositis, effective pain control is one of the main goals of physicians and care teams. Looking to provide more effective relief for patients—while also reducing the need for opioid painkillers—a team...

Issues in Oncology

Are Patient-Reported Outcomes Predictive of Survival and Likelihood of Hospitalization?

In a study reported in JCO Oncology Practice, Kerrigan et al found that patient-reported outcomes (PROs), obtained by using the National Cancer Institute (NCI) Patient-Reported Outcomes Measurement Information System–Cancer (PROMIS-Ca) Bank, may be prognostic for outcomes in patients with advanced...

Prostate Cancer
Issues in Oncology

Equal-Access Health-Care System for African American and White Men With Prostate Cancer

Among men with prostate cancer who received care from the U.S. Department of Veterans Affairs (VA) Health System, an equal-access health-care system, African American men did not have more advanced disease at the time of diagnosis or die earlier than white men, unlike trends seen in the greater...

Solid Tumors
Immunotherapy

Dual VEGF and PD-1 Inhibition in Advanced Solid Tumors

In a phase Ib/II trial reported in the Journal of Clinical Oncology, Taylor et al found the combination of the VEGF inhibitor lenvatinib and the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab showed activity across a range of advanced solid tumors. As stated by the authors, there is ...

Lung Cancer

STS 2020: Intraoperative Molecular Imaging Technology Helps Surgeons to Detect NSCLC

A tumor-highlighting technology—OTL38—enhances the visualization of lung cancer tissue, providing surgeons with a significantly better chance of finding and removing more cancer than previously possible, according to a scientific presentation by Gangadharan et al at the Plenary Session of the 56th...

Issues in Oncology

Ringing a Bell on the Last Day of Radiation Therapy: Helpful or Harmful?

Some patients with cancer celebrate the end of a course of radiation or chemotherapy by ringing a bell. Indeed, many patients say they love the graduation-like ceremony and the sense of closure it gives them. However, a study published by Williams et al in the International Journal of Radiation...

Breast Cancer
Colorectal Cancer
Legislation
Health-Care Policy

Late-Stage Cancer Diagnoses After Massachusetts Health Insurance Reform Law

Advanced-stage cancer diagnoses declined following health insurance expansion in Massachusetts, likely due to increased access to screening and diagnostic services that identified cancers earlier, according to new research published by Sabik et al in the journal Medical Care.

The analysis...

Survivorship

AYA Cancer Survivors at Greater Risk of Inpatient Hospitalization

A population-based study investigating the risk of inpatient hospitalizations among adolescent and young adult (AYA) cancer survivors compared with their siblings and those in the general population found that the AYA survivors had nearly double the risk of being hospitalized than the matched...

Issues in Oncology

Few Patients Enroll in Clinical Trials of First-Line Therapies

Patient enrollment in clinical trials as the first course of treatment after cancer diagnosis is low, despite the fact that enrollment may increase life expectancy, according to research published by Zaorsky et al in JNCCN–Journal of the National Comprehensive Cancer Network. Researchers also found ...

Issues in Oncology
Skin Cancer

Obstacles to Early Detection of Skin Cancer in Patients Living in Rural Western States

Residents of rural, sparsely populated “frontier counties” in the western United States have a higher incidence of skin cancer and related mortality rates. New research published by Jensen et al in Psychology, Health & Medicine indicated that the biggest obstacle to early detection and...

Colorectal Cancer
Genomics/Genetics

2020 GI Cancers Symposium: Data From Colorectal Cancer Cohorts of TAPUR Study Presented

Positive findings from three Targeted Agent and Profiling Utilization Registry (TAPUR) study cohorts on the potential benefit of various molecularly targeted drugs in patients with advanced colorectal cancer were presented at the 2020 Gastrointestinal Cancers Symposium.

The TAPUR study is the first ...

Pancreatic Cancer
Cost of Care

2020 GI Cancers Symposium: Cost of Pancreatic Cancer Care Over Time

In a study presented by Picozzi et al at the 2020 Gastrointestinal Cancers Symposium, researchers found that even as drug costs increased over the past decade, total inflation-adjusted pancreatic cancer care expenses declined, as did costs related to quality of life (Abstract 773).

Health...

Multiple Myeloma
Prostate Cancer
Lung Cancer
Hepatobiliary Cancer
Immunotherapy

FDA Pipeline: Priority Reviews in Multiple Myeloma, Prostate Cancer

Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for multiple myeloma and prostate cancer; gave Fast Track designation to a targeted gene therapy for lung cancer; granted Orphan Drug designation to a combination therapy for hepatocellular...

Hepatobiliary Cancer

2020 GI Cancers Symposium: Addition of Ramucirumab or Merestinib to Gemcitabine/Cisplatin for Biliary Tract Cancer

According to study results to be presented by Valle et al at the 2020 Gastrointestinal Cancers Symposium (Abstract 477), the addition of either ramucirumab or merestinib to the standard first-line therapy for biliary tract cancer—gemcitabine plus cisplatin—did not improve progression-free survival, ...

Colorectal Cancer

2020 GI Cancers Symposium: Higher Concentration of Fusobacterium nucleatum Found in Colorectal Tumors in Patients Younger Than 45

A bacterium typically linked to periodontal disease, Fusobacterium nucleatum, could play an important role in the rising incidence of colorectal cancer in people younger than age 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly fourfold...

Sarcoma

Pathologic Fracture and Prognosis in Adult and Pediatric Patients With High-Grade Osteosarcoma

In a study reported in the Journal of Clinical Oncology, Kelley et al found that pathologic fracture was associated with poorer overall survival among adult—but not pediatric—patients with primary central high-grade osteosarcoma of the extremities.

Study Details

The study involved retrospective...

CNS Cancers

Everolimus/Octreotide Shows Antitumor Activity in Recurrent Meningioma

According to the results from the small phase II CEVOREM trial, a targeted combination of the mTOR inhibitor everolimus and the somatostatin agonist octreotide showed antitumor activity in patients with recurrent meningioma not amenable to any type of surgery or radiotherapy. These findings were...

Gastrointestinal Cancer
Palliative Care

2020 GI Cancers Symposium: Does Receipt of Palliative Care Increase Survival in Patients With Metastatic Esophageal Cancer Declining Chemotherapy?

Patients with metastatic esophageal cancer who declined chemotherapy but received palliative care had a numerically higher, but not statistically significant, difference in overall survival. These findings will be presented by Manguso et al at the 2020 Gastrointestinal Cancers Symposium (Abstract...

Gastrointestinal Cancer

2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test

A blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal (GI) cancers could potentially help detect disease at earlier stages. This research will be presented by Brian M. Wolpin, MD, MPH, and colleagues at the 2020 Gastrointestinal Cancers...

Hepatobiliary Cancer
Colorectal Cancer

2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC

Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard-of-care treatments in patients with unresectable hepatocellular carcinoma and BRAF V600E­–mutant metastatic colorectal cancer. The results, from...

Colorectal Cancer
Issues in Oncology

2020 GI Cancers Symposium: Young Adults With Colorectal Cancer Living in Areas of Low Income, Education Likely to Have Worse Survival Outcomes

A retrospective analysis of 26,768 young adults with colorectal cancer aged 40 and under found that those who live in areas with lower income (a median income of less than $38,000) and less education (under 79% high school graduation rate), as well as those who live in urban areas, had worse...

Prostate Cancer
Health-Care Policy
Cost of Care

Price Transparency and Variation for Prostate Cancer Radiation Therapy

In a study reported in JAMA Oncology, Trevor Royce, MS, MD, MPH, and colleagues found that publicly available information on pricing for radiation treatment for prostate cancer was complex and inconsistent, and that pricing varied widely among National Cancer Institute (NCI)-designated cancer...

Skin Cancer
Immunotherapy

Immune-Related Adverse Events and Recurrence-Free Survival With Adjuvant Immunotherapy vs Placebo in Stage III Melanoma

In an analysis of the EORTC 1325/KEYNOTE-054 trial of adjuvant pembrolizumab vs placebo in stage III melanoma reported in JAMA Oncology, Alexander M.M. Eggermont, MD, PhD, and colleagues found that patients treated with pembrolizumab who experienced immune-related adverse events had improved...

Breast Cancer
Survivorship

Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?

Proton pump inhibitors, which are sometimes recommended to ease stomach problems during cancer treatment, may have an unintended side effect: impairment of breast cancer survivors' memory and concentration. These findings were published by Madison et al in the Journal of Cancer Survivorship.

...

Skin Cancer

Using T-Cell Fraction to Predict Melanoma Recurrence

In a paper published by Pruessmann et al in Nature Cancer, investigators presented a new, quantitative technique that leverages DNA sequencing to make more sophisticated and accurate predictions about which primary melanomas are likely to recur and spread.

"As recently as 10 years ago, the outlook...

Lung Cancer

Entrectinib in Advanced ROS1 Fusion–Positive NSCLC

As reported in The Lancet Oncology by Alexander Drilon, MD, and colleagues, an integrated analysis of three phase I/II trials has shown high activity of the TRK and ROS1 inhibitor entrectinib in ROS1 fusion-positive non–small cell lung cancer (NSCLC). This analysis supported the August 2019 U.S....

Solid Tumors

Relapse and Outcomes in Men Receiving Adjuvant Bleomycin/Etoposide/Cisplatin for Clinical Stage I Nonseminoma

In a study reported in the Journal of Clinical Oncology, Fischer et al found different patterns of relapse and associated outcomes among men with relapse after treatment with adjuvant bleomycin/etoposide/cisplatin for clinical stage I nonseminoma.

The study included data on 51 patients from 18...

Immunotherapy
Skin Cancer
Sarcoma
Kidney Cancer

Three Studies Examine Relationship Between B-Cell Enrichment and Response to Immunotherapy

The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures, according to three studies all recently published in Nature. The studies showed that enrichment of B cells...

Issues in Oncology
Prostate Cancer
Thyroid Cancer
Leukemia

Cancer Incidence in World Trade Center Responders to the September 11 Attacks

A study published by Shapiro et al in JNCI Cancer Spectrum showed that responders to the World Trade Center site after the attacks on September 11, 2001, have statistically significant elevations in cancer incidence for all cancer sites combined, and for prostate and thyroid cancer and leukemia....

Leukemia

Conditioning Intensity for Allogeneic Transplantation in Patients With AML

In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic...

Breast Cancer

External-Beam Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation After Breast-Conserving Surgery in DCIS or Node-Negative Breast Cancer

As reported in The Lancet by Timothy J. Whelan, BM, BCh, and colleagues, the phase III noninferiority RAPID trial has shown that external-beam accelerated partial-breast irradiation is noninferior to whole-breast irradiation in reducing risk of local recurrence after breast-conserving surgery in...

Hepatobiliary Cancer

Treatment Resistance and Novel Therapies in FGFR-Mutated Cholangiocarcinoma

A new study has shown how resistance to fibroblast growth factor receptor (FGFR) inhibitor treatment develops in patients with cholangiocarcinoma and suggests that adding another therapy at the time of disease progression might resensitize tumor cells to initial therapy. These findings were...

Breast Cancer

Are Women in Europe or Asia More Likely to Have Breast-Conserving Therapy Than Those in the United States?

Neoadjuvant systemic therapy can shrink tumors in patients with breast cancer and, in some cases, allow patients to receive breast-conserving therapy who would otherwise require mastectomy. However, in the United States, about 55% of patients who become eligible for breast-conserving therapy after...

Gynecologic Cancers
Prostate Cancer
Lung Cancer
Supportive Care
Multiple Myeloma
Colorectal Cancer
Immunotherapy

FDA Pipeline: Priority Reviews in Ovarian Cancer, Prostate Cancer, and NSCLC

This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for ovarian, prostate, and lung cancer; granted Orphan Drug designation to therapies for chemotherapy-induced thrombocytopenia and multiple myeloma; and granted Breakthrough Device designation to platforms...

Lung Cancer
Immunotherapy

Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous NSCLC

In a Japanese phase III trial reported in the Journal of Clinical Oncology, Seto et al found that the addition of maintenance pemetrexed to bevacizumab did not significantly improve overall survival in patients with previously untreated, advanced nonsquamous non–small cell lung cancer (NSCLC)...

Pancreatic Cancer
Genomics/Genetics

Genomic Aberrations and Pancreatic Cancer Subtypes

Researchers have discovered detailed new genetic information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment options and improved clinical outcomes for this lethal disease, Chan-Seng-Yue et al reported in Nature Genetics.

The study...

Skin Cancer
Immunotherapy

Different Doses of Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma

As reported in the Journal of Clinical Oncology by Tarhini et al, the phase III Intergroup E1609 trial has shown an overall survival advantage with adjuvant ipilimumab at 3 mg/kg—but not at 10 mg/kg—vs high-dose interferon alfa-2b in patients with resected high-risk cutaneous melanoma. The...

Breast Cancer

Higher 21-Gene Recurrence Score May Be Associated With Increased Risk of Locoregional Recurrence in Patients With Breast Cancer

A new study shows that a test physicians commonly use to guide chemotherapy for patients with breast cancer after surgery may also help them decide whether radiation therapy may be of benefit. Results published by Wendy A. Woodward, MD, PhD, and colleagues in JAMA Oncology suggest patients with an...

Issues in Oncology
Cost of Care
Survivorship

Cancer Survivors Face Substantial Medical Financial Hardship

Although advances in cancer treatments have led to huge increases in the number of survivors in the United States—more than 16.9 million in 2019—many of those survivors, particularly those aged 18 to 64, face substantial medical financial hardship due to their diagnosis and treatment, necessitating ...

Prostate Cancer

Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer

Researchers have developed a method based on artificial intelligence (AI) for the histopathologic diagnosis and grading of prostate cancer. The study, published by Ström et al in The Lancet Oncology, showed that the AI system can be trained to detect and grade prostate cancer from needle biopsy...

Prostate Cancer

Patient-Reported Functional Outcomes With Hypofractionated vs Conventionally Fractionated Radiotherapy for Nonmetastatic Prostate Cancer

In a national cohort study conducted in the United Kingdom and reported in the Journal of Clinical Oncology, Nossiter et al found no clinically important differences in patient-reported functional outcomes among men receiving hypofractionated vs conventionally fractionated radiotherapy for...

Breast Cancer
Issues in Oncology

Are Racial/Ethnic Disparities in Breast Cancer Diagnosis Caused by Health Insurance Coverage?

Lack of insurance coverage is a major cause of delayed breast cancer screening and treatment among minority women, which could lead to a decrease in a patient’s chance of survival. Nearly half of the disparity in later-stage diagnosis between non-Hispanic white women and black, Hispanic, and...

Head and Neck Cancer

Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer May Have Different Rates of Mortality

New research indicates that there is a higher risk of early death among patients with oropharyngeal cancer not associated with human papillomavirus (HPV) vs those whose tumors are HPV-positive. The findings are published by Fullerton et al in Cancer. 

The incidence of oropharyngeal cancer is...

Solid Tumors
Genomics/Genetics

Entrectinib in Advanced or Metastatic NTRK Fusion–Positive Solid Tumors

As reported in The Lancet Oncology by George D. Demetri, MD, and colleagues, integrated analysis of three phase I/II trials has shown high levels of activity of the tropomyosin receptor kinase (TRK) inhibitor entrectinib in advanced NTRK fusion–positive solid tumors. This analysis supported the...

Leukemia

Activity of Ruxolitinib in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

In a phase II study reported in the Journal of Clinical Oncology, Dao et al found that the JAK1/2 inhibitor ruxolitinib was active in patients with chronic neutrophilic leukemia (CNL), with less activity observed in those with atypical chronic myeloid leukemia (CML) and greater activity observed...

Colorectal Cancer

Association Between Colorectal Cancer and Ulcerative Colitis

Patients with the inflammatory bowel disease ulcerative colitis have a higher risk of dying from colorectal cancer, despite modern therapy, even though the risk has declined in recent years. Olén et al published these findings in The Lancet.

Previous research has shown that patients with ulcerative ...

Skin Cancer

Molecular Characteristics of Leptomeningeal Melanoma Metastases

Patients with advanced melanoma who develop metastases in the leptomeninges usually have a poor prognosis—most patients only survive for 8 to 10 weeks after diagnosis. One reason for this poor prognosis is that very little is known about the molecular development of leptomeningeal melanoma...

Breast Cancer

Does Adding Trastuzumab to Adjuvant Chemotherapy Improve Invasive Disease–Free Survival for Patients With HER2-Negative Breast Cancer?

As reported in the Journal of Clinical Oncology by Louis Fehrenbacher, MD, and colleagues, the phase III NSABP B-47/NRG Oncology trial has shown no invasive disease–free survival benefit with the addition of trastuzumab to adjuvant chemotherapy therapy in patients with HER2-negative breast cancer...

Colorectal Cancer

Does Statin Use Increase Overall Survival in Patients With Colorectal Cancer?

About 40 million adults in the United States take a statin to lower their cholesterol and reduce the risk for heart disease—but they may also be getting an added anticancer benefit, a growing body of evidence suggests. According to research presented at the American Heart Association’s Scientific...

Bladder Cancer
Hepatobiliary Cancer

FDA Pipeline: Fast Track/Orphan Drug Designation for Cholangiocarcinoma Treatment, Breakthrough Device Designation for Bladder Cancer Test

This week, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to infigratinib for patients with advanced or metastatic cholangiocarcinoma with a certain genetic mutation, and Orphan Drug designation to the treatment for patients with cholangiocarcinoma. The FDA also granted...

Lymphoma
Immunotherapy

Noninferiority of Four vs Six Cycles of CHOP for Patients With Favorable Prognosis B-Cell Lymphoma: FLYER Trial

As reported in The Lancet by Viola Poeschel, MD, and colleagues, the phase III FLYER trial has shown noninferiority of progression-free survival with four vs six cycles of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) in combination with six doses of rituximab in patients with...

Breast Cancer

Dietary Supplement Use During Adjuvant Chemotherapy and Treatment Outcomes in Patients With Early Breast Cancer

As reported in the Journal of Clinical Oncology by Ambrosone et al, an analysis of the SWOG S0221 trial population suggests that use of antioxidant and nonantioxidant dietary supplements, but not multivitamins, before and during adjuvant chemotherapy may be associated with poorer treatment outcomes ...

Issues in Oncology

Prevalence of Alcohol Use Among Patients With Cancer and Survivors

New research published by Nina N. Sanford, MD, and colleagues in JNCCN—Journal of the National Comprehensive Cancer Network has found most cancer survivors reported that they are current alcohol drinkers, with a subset of those survivors self-reporting excessive drinking behaviors.

“We recommend...

Lung Cancer

Step Counts May Help Predict Treatment Outcomes for Patients With NSCLC

A new study suggests step counters could play a role in predicting outcomes for people undergoing chemoradiation therapy for lung cancer. These findings were published by Ohri et al in the International Journal of Radiation Oncology • Biology • Physics.

“I consider step counts to be a new vital...

Prostate Cancer

Olaparib for Previously Treated, Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations

In the phase II TOPARP-B trial—reported by Mateo et al in The Lancet Oncology—investigators found that olaparib showed activity in men with metastatic castration-resistant prostate cancer and DNA damage response (DDR) gene aberrations who had received one or two prior taxane regimens.

Study...

Issues in Oncology

Largest Single-Year Drop in Cancer Mortality Reported in ‘Cancer Statistics, 2020’

The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017—the largest single-year drop in cancer mortality ever reported. These findings were reported in “Cancer Statistics, 2020,” the latest edition of the American Cancer Society’s annual report on cancer...

Breast Cancer

Recurrence Risk With Accelerated Partial- vs Whole-Breast Irradiation After Breast-Conserving Surgery for Early Breast Cancer: Long-Term Follow-up

As reported in The Lancet by Frank A. Vicini, MD, and colleagues, 10-year follow-up in the phase III NSABP B-39/RTOG 0413 equivalence trial has shown that accelerated partial-breast irradiation did not achieve equivalence to whole-breast irradiation in preventing local recurrence in women receiving ...

Skin Cancer

Does Weight-Loss Surgery Lower the Risk of Malignant Melanoma?

Bariatric surgery is associated with a distinct reduction in skin cancer risk, according to findings published by Taube et al in JAMA Dermatology. This finding further substantiates the connection between weight loss and malignant skin cancer.

“This [study] provides further evidence for a...

Gynecologic Cancers

Many Pelvic Examinations and Papanicolaou Tests Performed on Young Women May Be Unnecessary

Pelvic examinations and cervical cancer screenings are no longer recommended for most females under age 21 during routine health visits, but a new study has found that millions of young women are undergoing the tests, which can lead to false-positive testing, overtreatment, anxiety, and needless...

Lung Cancer

Long-Term Results of Standard- vs High-Dose Chemoradiotherapy With or Without Cetuximab in Patients With Stage III NSCLC

As reported in the Journal of Clinical Oncology by Jeffrey D. Bradley, MD, and colleagues, long-term results of the phase III NRG Oncology/RTOG 0617 trial indicate that standard-dose radiotherapy should remain the standard of care in chemoradiotherapy for nonresectable stage III non–small cell...

Breast Cancer

FDA Pooled Analysis of CDK4/6 Inhibitor Treatment for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer

In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Jennifer J. Gao, MD, and colleagues found that the magnitude of progression-free survival benefit with the addition of a cyclin-dependent kinase (CDK) 4/6 inhibitor to endocrine therapy in women with...

Solid Tumors
Lymphoma
Immunotherapy

Is Pembrolizumab Active in Pediatric Patients With PD-L1–Positive Advanced Solid Tumors or Lymphoma?

Interim analysis of the phase I/II KEYNOTE-051 trial, reported in The Lancet Oncology by Geoerger et al, indicated minimal activity of pembrolizumab in pediatric patients with programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed, or refractory solid tumors; however, activity was...

Head and Neck Cancer

T-DM1 Shows Activity in HER2-Amplified Salivary Gland Cancer in Small Patient Sample of NCI-MATCH

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) showed activity in HER2-amplified salivary gland tumors, according to data published by Jhaveri et al in Annals of Oncology.

The publication is for ‘Arm Q,’ which is one of nearly 40 single-arm phase II treatments in the NCI-Molecular...

Issues in Oncology

Physical Activity at Recommended Levels May Lower Risk of Multiple Cancers

A pooled analysis of nine prospective studies involving more than 750,000 adults has found that recommended amounts of leisure-time physical activity were linked to a lower risk for seven cancers, with several cancer types having a dose/response relationship. These findings were published by...

Breast Cancer

Overall Survival With the Addition of Ribociclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: MONALEESA-3

As reported in The New England Journal of Medicine by Dennis J. Slamon, MD, PhD, and colleagues, in the phase III MONALEESA-3 trial, the second interim analysis of overall survival has shown a significant benefit with the addition of ribociclib to fulvestrant in first- or second-line treatment of...

Prostate Cancer

Neoadjuvant vs Concurrent ADT With Dose-Escalated Radiotherapy for Localized Prostate Cancer

In a two-institute phase III trial reported in the Journal of Clinical Oncology, Malone et al found no difference in biochemical relapse–free survival with androgen-deprivation therapy (ADT) initiated prior to or concurrently with dose-escalated external-beam radiotherapy in patients with localized ...

Colorectal Cancer

Rates of Guideline-Aligned Genomic Profiling in Patients Diagnosed With Metastatic Colon Cancer

In a study reported in JCO Precision Oncology, Gutierrez et al found that most patients in a U.S. sample diagnosed with metastatic colon cancer between 2013 and 2017 did not receive guideline-aligned genomic testing for RAS, BRAF, and microsatellite instability/mismatch repair–deficiency (MSI/dMMR) ...

Solid Tumors

One Cycle of Bleomycin/Etoposide/Cisplatin May Be as Effective as Two for Patients With Testicular Cancer

Testicular cancer recurrence may be prevented by giving men one cycle of chemotherapy instead of the two cycles used as standard. Lowering the overall exposure to chemotherapy also reduced side effects. These findings were published by Cullen et al in European Urology.

Testicular cancer is the most ...

Multiple Myeloma
Immunotherapy

Overall Survival With the Addition of Daratumumab to VMP in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

As reported in The Lancet by Maria-Victoria Mateos, MD, and colleagues, interim analysis of overall survival in the phase III ALCYONE trial has shown a significant benefit of the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in patients with newly diagnosed multiple...

Breast Cancer

Long-Term Results of IBIS-II: Anastrozole for Breast Cancer Prevention

As reported by Jack Cuzick, PhD, and colleagues in The Lancet, blinded follow-up of the IBIS-II trial has shown the continued benefit of anastrozole vs placebo in preventing breast cancer in high-risk postmenopausal women during the 5-year posttreatment period.

For the international double-blind...

Solid Tumors
Issues in Oncology

Cardiovascular Risks After Bleomycin/Etoposide/Cisplatin Treatment for Germ Cell Cancer

In a Danish study reported in the Journal of Clinical Oncology, Lauritsen et al found that patients treated for germ cell cancer exhibited an increase of cardiovascular risk factors and cardiovascular disease at short- and long-term follow-up.

Study Details

The study involved 5,185 patients with...

Head and Neck Cancer

Saliva Test May Play A Role in the Early Detection of HPV-Related Oropharyngeal Cancer

A report by Wang et al in The Journal of Molecular Diagnostics described the use of acoustofluidics, a noninvasive method that analyzes saliva for the presence of human papillomavirus type 16 (HPV-16), the pathogenic strain of the disease associated with oropharyngeal cancers. This novel technique...

Issues in Oncology

FDA Finalizes Enforcement Policy on Unauthorized Flavored Cartridge-Based E-Cigarettes

Amid the epidemic levels of youth use of e-cigarettes and the popularity of certain products among children, the U.S. Food and Drug Administration (FDA) has issued a policy prioritizing enforcement against certain unauthorized flavored e-cigarette products that appeal to children, including fruit...

Lung Cancer

Osimertinib in Patients With NSCLC Harboring Uncommon EGFR Mutations

In a Korean phase II study reported in the Journal of Clinical Oncology, Myung-Ju Ahn, MD, PhD, and colleagues found that osimertinib was active in patients with metastatic or recurrent non–small cell lung cancer (NSCLC) with uncommon EGFR mutations.

Study Details

In the multicenter study, 36...

Breast Cancer

D-CARE Trial: Adjuvant Denosumab for Patients With Early Breast Cancer

As reported in The Lancet Oncology by Robert Coleman, MD, FRCP, and colleagues, the phase III D-CARE trial has shown no benefit of adjuvant therapy with the RANKL inhibitor denosumab vs placebo in improving bone metastasis–free survival in women with moderate- to high-risk early breast cancer.

...

Leukemia

Asciminib for Patients With CML After Failure of ABL Kinase Inhibitor Treatment

In a phase I trial reported in The New England Journal of Medicine, Hughes et al found that asciminib, an oral BCR-ABL1 inhibitor with a mechanism of action different from available ABL1 tyrosine kinase inhibitors, was active in patients with chronic myeloid leukemia (CML) after failure of ABL...

Colorectal Cancer

Screening Rates Rose Among People Aged 45–49 After Release of Updated Colorectal Cancer Guidelines

Colorectal cancer screening rates more than doubled among people aged 45 to 49 in the months after the release of updated American Cancer Society guidelines in 2018 recommending screening in that age group, according to a new study. According to the findings from Fedewa et al—published in

Leukemia
Immunotherapy

Fractionated Tisagenlecleucel Infusion for Adults With B-Cell Acute Lymphoblastic Leukemia May Improve Safety Without Reducing Efficacy

As reported by Noelle V. Frey, MD, and colleagues in the Journal of Clinical Oncology, single-center experience with the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel has shown that high-dose fractionated infusion with the ability to modify dosing in case of early signs...

Gastroesophageal Cancer
Genomics/Genetics

Treatment of Advanced Esophagogastric Cancer According to ERCC1 Expression

As reported in the Journal of Clinical Oncology by Iqbal and colleagues, the phase II SWOG S1201 trial showed a progression-free survival benefit with platinum-containing vs nonplatinum treatment among all patients with previously untreated HER2-negative advanced esophagogastric cancer and in a...

Breast Cancer

How Effective Is Supplemental MRI Screening for Women With Extremely Dense Breasts?

In the Dutch DENSE study reported in The New England Journal of Medicine, Bakker et al found that supplemental magnetic resonance imaging (MRI) in women with extremely dense breast tissue and normal results on screening mammography was associated with the diagnosis of significantly fewer interval...

Lung Cancer
Bladder Cancer
Colorectal Cancer
Hematologic Malignancies
Myelodysplastic Syndromes
Breast Cancer
Head and Neck Cancer
Immunotherapy

FDA Pipeline: Priority Reviews in SCLC, Bladder Cancer, Colorectal Cancer

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for treatments in extensive-stage small cell lung cancer (SCLC), non–muscle invasive bladder cancer, and BRAF V600E–mutant colorectal cancer. The Agency also recently issued multiple Breakthrough Therapy designations and ...

Solid Tumors
Immunotherapy

Nivolumab for Mismatch Repair–Deficient Noncolorectal Cancers

In a study (NCI-MATCH trial subprotocol, arm Z1D) reported in the Journal of Clinical Oncology, Azad et al found that nivolumab was active in mismatch repair–deficient noncolorectal cancers.

As stated by the investigators, “The National Cancer Institute Molecular Analysis for Therapy Choice...

Head and Neck Cancer
Integrative Oncology
Symptom Management

Acupuncture May Reduce Radiation-Induced Dry Mouth for Patients With Head and Neck Cancer

After receiving acupuncture treatment 3 days a week during the course of radiation treatment, patients with head and neck cancer experienced less dry mouth, according to study results published by Garcia et al in JAMA Network Open.

The results are from the first randomized, placebo-controlled,...

Gynecologic Cancers

First-Line Weekly Dose-Dense Chemotherapy in Epithelial Ovarian Cancer: ICON8 Trial

In the phase III Gynecologic Cancer Intergroup ICON8 trial reported in The Lancet, Clamp et al found that first-line weekly dose-dense chemotherapy did not improve progression-free survival vs standard 3-weekly chemotherapy in a predominantly European population with epithelial ovarian cancer.

...

Bladder Cancer

FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer

On December 18, the U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev) for adult patients with locally advanced or metastatic urothelial cancer who have previously received neoadjuvant or adjuvant treatment with a programmed cell death protein 1 ...

Hepatobiliary Cancer
Immunotherapy

Does Second-Line Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Confer a Survival Benefit?

As reported in the Journal of Clinical Oncology by Richard S. Finn, MD, and colleagues, the phase III KEYNOTE-240 trial has shown no statistically significant progression-free or overall survival benefit with pembrolizumab vs placebo in patients with advanced hepatocellular carcinoma who were...

Prostate Cancer
Issues in Oncology

Commercial Gene-Expression Tests for Prostate Cancer May Not Accurately Predict Disease Progression in African American Men

A study examining the differences in gene expression between African American and European American men with prostate cancer for three commercially available prostate cancer prognostic biomarker panels—Oncotype DX Prostate Score, Prolaris, and Decipher—has found that these tests may not accurately...

Cost of Care
Health-Care Policy

Rising Cost and Use of Oral Anticancer Drugs and Increased Medicare Part D Spending

In a study reported in a research letter in JAMA Oncology, Emily Stamell Ruiz, MD, MPH, and colleagues found that rising drug costs and use accounted for 56% and 44%, respectively, of increased Medicare Part D spending on oral anticancer drugs between 2013 and 2017.

Study Details

The analysis...

Prostate Cancer
Immunotherapy

Pembrolizumab in Refractory Metastatic Castration-Resistant Prostate Cancer

In the phase II KEYNOTE-199 study, reported in the Journal of Clinical Oncology by Antonarakis et al, pembrolizumab showed activity and had an acceptable safety profile in patients with treatment-refractory metastatic castration-resistant prostate cancer.

Study Details

The trial was conducted at 85 ...

Issues in Oncology

Survey of Anticipation and Experience of Adverse Effects in Patients Receiving Radiotherapy

In a study reported in the Journal of Oncology Practice, Reshma Jagsi, MD, DPhil, and colleagues found that most patients undergoing radiation therapy for cancer reported that they did not experience anticipated radiotherapy adverse effects, or that the adverse effect was no worse than expected....

Breast Cancer

Recurrence Risk in Black and White Women With Borderline Estrogen Receptor–Positive Breast Cancer

In a study reported in the Journal of the National Cancer Institute, Benefield et al found that black women with borderline estrogen receptor (ER)-positive breast cancer had significantly poorer disease-free interval compared with those with ER-positive disease, irrespective of whether they...

Symptom Management

Single-Fraction vs Multifraction Radiotherapy for Patients With Spine Metastases

Spinal canal compression is a common complication in patients with cancer if disease metastasizes to the spine—about 3% to 5% of patients with cancer develop it. Radiotherapy is used to control pain and alleviate symptoms. According to results from the SCORAD randomized clinical trial, published by ...

Skin Cancer

ASTRO Issues Clinical Guideline on Radiation Therapy for Basal Cell and Cutaneous Squamous Cell Carcinomas

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with the most common types of skin cancers. The guideline details when radiation treatments are appropriate as stand-alone therapy...

CancerCare to Provide Support for Patients With Cancer Impacted by the California Wildfires

As many California residents continue to deal with the aftermath of past wildfires and the advent of new ones, CancerCare is now offering a patient assistance program for both emotional and financial support to patients with cancer affected by the California fires.

As a leading national nonprofit...

Everett E. Vokes, MD, FASCO, Elected ASCO President for 2021–2022 Term

ASCO membership has elected Everett E. Vokes, MD, FASCO, a long-time member and volunteer, to serve as its President for the 2021–2022 term. He will take office as President-Elect during the ASCO Annual Meeting in June 2020.

Six new members were also elected to the ASCO Board of Directors and...

Breast Cancer
Immunotherapy

First-Line Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer: Second Overall Survival Interim Analysis

As reported in The Lancet Oncology by Peter Schmid, MD, and colleagues, the prespecified second interim analysis of overall survival in the phase III IMpassion130 trial has shown no overall survival benefit with the addition of atezolizumab to nab-paclitaxel as first-line treatment of unresectable, ...

Leukemia
Symptom Management

Risk of Asparaginase-Associated Pancreatitis in Patients With Acute Lymphoblastic Leukemia

In a study reported in the Journal of Clinical Oncology, Rank et al found a similar risk of asparaginase-associated pancreatitis in older children, adolescents, and adults and greater associated morbidity in adolescents with acute lymphoblastic leukemia treated according to the Nordic Society of...

Issues in Oncology

People With Mental Illness Receive Less Cancer Screening vs General Population

Results from a systematic review and comparative meta-analysis show that despite increased mortality from cancer in people with mental illness, this population receives less cancer screening compared to the general population. These findings were published by Solmi et al in The Lancet Psychiatry.

...

Kidney Cancer

TIVO-3: Third- or Fourth-Line Tivozanib vs Sorafenib in Metastatic Renal Cell Carcinoma

As reported in The Lancet Oncology by Brian I. Rini, MD, and colleagues, the phase III TIVO-3 trial has shown a statistically significant increase in progression-free survival with tivozanib vs sorafenib as a third- or fourth-line treatment for advanced renal cell carcinoma.

Study Details

The...

Multiple Myeloma

Evaluation of Residual Disease in Patients With Multiple Myeloma Using IMWG Flow Cytometry Criteria

In a study reported in the Journal of Clinical Oncology, Paiva et al examined the applicability of International Myeloma Working Group (IMWG) criteria for next-generation flow cytometry assessment of minimal residual disease (MRD) in multiple myeloma. They found that the IMWG flow MRD-negative...

Breast Cancer

SABCS 2019: Oral vs Intravenous Paclitaxel for Patients With Metastatic Breast Cancer

Patients with metastatic breast cancer who received an oral formulation of paclitaxel had better response and survival and less neuropathy than patients who received intravenous paclitaxel, according to results of a phase III trial presented at by Umanzor et al at the San Antonio Breast Cancer...

Breast Cancer

SABCS 2019: ctDNA May Be an Independent Predictor of Disease Recurrence in Patients With Early-Stage Triple-Negative Breast Cancer

The detection of circulating tumor DNA (ctDNA) in patients with early-stage triple-negative breast cancer treated with surgery following neoadjuvant chemotherapy is an independent predictor of disease recurrence, according to a phase II study investigating the potential of using ctDNA to detect...

Breast Cancer

SABCS 2019: Breast Cancer Incidence With Estrogen/Progestin vs Estrogen Alone in Postmenopausal Women

A study investigating the long-term influence of estrogen plus progestin compared with estrogen alone on breast cancer incidence in postmenopausal women has found that the menopausal hormone therapies had opposite effects on breast cancer incidence. While estrogen alone decreased breast cancer...

Breast Cancer

SABCS 2019: Residual Cancer Burden After Neoadjuvant Chemotherapy as a Predictive Tool

A large meta-analysis of patients with breast cancer showed that residual cancer burden after neoadjuvant chemotherapy is an accurate long-term predictor of recurrence and survival across all breast cancer subtypes, according to data presented by Yau et al at the 2019 San Antonio Breast Cancer...

Breast Cancer

SABCS 2019: IBIS-II Study Finds Long-Term Preventive Benefit With Anastrozole Among Postmenopausal Women at High Risk for Breast Cancer

A 10-year median follow-up analysis of the IBIS-II trial on the efficacy and safety of the aromatase inhibitor anastrozole for healthy postmenopausal women at increased risk of developing breast cancer has found that the therapy reduced the likelihood of breast cancer incidence by 50% and had few...

Breast Cancer

SABCS 2019: Ribociclib/Letrozole vs Multiagent Chemotherapy in Patients With High-Risk Luminal B Breast Cancer

A phase II study by Gavilá et al evaluating the efficacy of the combination of the CDK4/6 inhibitor ribociclib and the aromatase inhibitor letrozole in combination as a neoadjuvant treatment in patients with high-risk luminal B breast cancer has found that the therapy produced response rates...

Breast Cancer

SABCS 2019: 10-Year Follow-up of Adjuvant Accelerated Partial-Breast Irradiation vs Adjuvant Whole-Breast Irradiation

A 10-year follow-up study of patients with breast cancer who had been treated with accelerated partial-breast irradiation (APBI) after surgery showed that their rates of disease recurrence were similar to those of patients who had received whole-breast irradiation (WBI), according to data presented ...

Breast Cancer

SABCS 2019: 6-Year Analysis of the Addition of Pertuzumab to Trastuzumab Plus Chemotherapy as Adjuvant Therapy

Data from the 6-year analysis of the APHINITY trial showed that adding pertuzumab to the previous standard treatment of trastuzumab plus chemotherapy after surgery continued to reduce the risk of recurrence and death in patients with HER2-positive early breast cancer, according to findings...

Breast Cancer
Immunotherapy

SABCS 2019: Does Treatment With Pembrolizumab Improve Pathologic Complete Response in Patients With Triple-Negative Breast Cancer and Lymph Node Involvement?

The addition of the checkpoint inhibitor pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased the rates of pathologic complete response in patients with triple-negative breast cancer who had lymph node involvement, according to results from the KEYNOTE-522 trial, which were...

Breast Cancer

SABCS 2019: Adding Tucatinib to Capecitabine/Trastuzumab Improved Survival for Patients With Advanced HER2-Positive Breast Cancer

The addition of tucatinib to capecitabine and trastuzumab significantly improved progression-free survival and overall survival in patients with advanced HER2-positive breast cancer, with or without brain metastasis. These findings—from the HER2CLIMB study—were presented by Murthy et al at the 2019 ...

Breast Cancer

SABCS 2019: [Fam-] Trastuzumab Deruxtecan in Patients With Pretreated HER2-Positive Metastatic Breast Cancer

A phase II clinical study investigating [fam-] trastuzumab deruxtecan (T-DXd) in patients with metastatic HER2-positive breast cancer previously treated with trastuzumab emtansine (T-DM1) showed patients had an overall response rate of 60.9% with the treatment. The study by Krop et al was presented ...

Breast Cancer

SABCS 2019: Postoperative S-1 Plus Endocrine Therapy for HR-Positive, HER2-Negative Breast Cancer

The postoperative combination of S-1, an oral fluoropyrimidine-based drug, with endocrine therapy improved invasive disease–free survival and 5-year invasive disease–free survival estimates in patients with hormone receptor (HR)-positive, HER2-negative breast cancer, according to results from the...

Leukemia
Immunotherapy

ASH 2019: Blinatumomab vs Standard Chemotherapy for Pediatric Patients With Relapsed B-ALL

Blinatumomab improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy, accordings to findings from a study presented by Brown et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract LBA-1)....

Leukemia

ASH 2019: Oral Azacitidine Improves Survival in Older Patients With AML in First Remission

Treatment with an investigational oral form of azacitidine, CC-486, improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy with or without consolidation therapy, according to a phase III study...

Leukemia
Myelodysplastic Syndromes

ASH 2019: New Genomic Mutational and Expressional Data in AML, MDS

Researchers have completed the first comprehensive analysis combining full genomic sequencing and gene-expression profiles of more than 1,300 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The research was presented by Iacobucci et al during the 2019 American Society...

Lymphoma

ASH 2019: PET-Directed Therapy for Early-Stage DLBCL

Most people diagnosed with early-stage, or limited, diffuse large B-cell lymphoma (DLBCL) may be able to safely skip radiation treatment after a clear positron-emission tomography (PET) scan, according to new clinical trial results from SWOG presented by Persky et al at the 2019 American Society of ...

Leukemia
Genomics/Genetics

ASH 2019: Genomic Features of AML in Patients Aged 60 or Older May Predict Stem Cell Transplant Outcome

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of leukemic genetic characteristics, according to results presented by Murdock et al at the 2019 American Society of Hematology (ASH) Annual...

Lymphoma

ASH 2019: Pilot Study of Next-Generation Sequencing for Undetectable Minimal Residual Disease in Patients With Follicular Lymphoma

Patients with follicular lymphoma who have been treated and are in remission for at least 2 years may no longer be incurable based on highly sensitive testing. This may mean they no longer need therapy or active follow-up, according to findings presented by Sarraf Yazdy et al at the 2019 American...

Leukemia
Issues in Oncology

ASH 2019: Should African American Patients With AML and Evidence of Abnormal Kidney Function Be Enrolled Into Clinical Trials?

A study of more than 1,000 patients with acute myeloid leukemia (AML) revealed that African Americans were more likely to have evidence of abnormal kidney functioning than whites, but this was not associated with any difference in overall survival. The findings, presented by Statler et al at the...

Multiple Myeloma
Geriatric Oncology

ASH 2019: Is Autologous Hematopoietic Stem Cell Transplant Safe and Effective for Patients Aged 70 or Older With Multiple Myeloma?

Even though autologous hematopoietic stem cell transplantation (AHCT) is an effective treatment for multiple myeloma, only 4 out of 10 patients receive this therapy. A new study presented by Munshi et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 782) ...

Leukemia
Issues in Oncology

ASH 2019: Lower Area-Based Income and Educational Attainment Associated With Poorer Survival Among Pediatric Patients With AML

Children from lower-income neighborhoods were 2.4 times more likely to die during treatment for acute myeloid leukemia (AML) than children from middle- and high-income neighborhoods, according to findings from a study that analyzed nearly 1,500 clinical trial participants. While previous research...

Immunotherapy
Lymphoma
Geriatric Oncology

ASH 2019: CAR T-Cell Therapy Shows Activity, Reduces Health-Care Utilization in Older Patients With DLBCL

A new analysis of Medicare claims data presented by  Kilgore et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 793) has provided the first real-world evidence using claims data available after the approval of autologous anti-CD19 chimeric antigen...

Hematologic Malignancies

ASH 2019: Early-Phase Study of Venetoclax in Reduced-Intensity Transplant Conditioning Regimen for Patients With High-Risk Myeloid Malignancies

For patients with high-risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplant, adding the BCL-2 inhibitor venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to engraft. The phase I study was...

Multiple Myeloma
Immunotherapy

ASH 2019: Phase Ib/II Study of BCMA-Directed CAR T-Cell Therapy for Pretreated Multiple Myeloma

Patients with multiple myeloma who had received a median of five prior therapies with refractory disease had a high response rate when treated with the investigational chimeric antigen receptor (CAR) T-cell therapy JNJ-4528, which targets B-cell maturation antigen (BCMA), a protein commonly found...

Multiple Myeloma
Immunotherapy

ASH 2019: Dose-Climbing Trial of Dual-Target CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma

More than three out of four patients with relapsed multiple myeloma, or myeloma that was refractory to at least two therapies, remained in remission 7 months after treatment with a novel chimeric antigen receptor (CAR) T-cell therapy targeting two proteins that are frequently found on myeloma...

Hematologic Malignancies
Immunotherapy

ASH 2019: CAR-NK Therapy for B-Cell Malignancies Shows Activity in Preclinical Studies

Preclinical studies have provided the first evidence that cellular immunotherapy for B-cell cancers could ultimately become an off-the-shelf product, capable of being uniformly manufactured in large quantities. The product—FT596—is among the first cellular immunotherapies to be based on...

Breast Cancer

Breast-Conserving Surgery and Partial-Breast Reirradiation in Patients With Ipsilateral Disease Recurrence

Findings from the phase II NRG Oncology/RTOG 1014 trial, reported in JAMA Oncology by Arthur et al, showed that partial-breast reirradiation after second lumpectomy for recurrence of ipsilateral breast cancer following previous whole-breast irradiation was an effective treatment approach and could...

Issues in Oncology

Factors Associated With Prolonged Grief Symptom Levels in Parents of Children Who Have Died of Cancer

In a Swedish study reported in the Journal of Clinical Oncology, Pohlkamp et al identified factors associated with levels of prolonged grief symptoms in parents of children who have died of cancer, with factors being found to differ between mothers and fathers.

As stated by the investigators,...

Solid Tumors
Lymphoma
Immunotherapy

Atezolizumab for Pediatric and Young Adult Patients With Previously Treated Solid Tumors or Lymphomas

In a phase I/II study reported in The Lancet Oncology, Geoerger et al found little activity of atezolizumab alone in pediatric and young adult patients with relapsed or refractory malignancies (including solid tumors, non-Hodgkin lymphoma, and Hodgkin lymphoma) with known or expected programmed...

Lung Cancer
Immunotherapy

FDA Approves Atezolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC

On December 4, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with chemotherapy (nab-paclitaxel and carboplatin) for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor...

Breast Cancer

FDA Approves FoundationOne CDx as a Companion Diagnostic for Alpelisib/Fulvestrant Treatment in Breast Cancer

On December 4, the U.S. Food and Drug Administration (FDA) approved FoundationOne CDx to be used as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of postmenopausal female patients as well as male patients with hormone receptor (HR)-positive, HER2-negative,...

Cardiovascular Disease Risk May Be Associated With Cancer Risk

People with risk factors for cardiovascular diseases (determined by traditional risk, 10-year artherosclerotic cardiovascular disease risk score, and biomarkers) were also at higher risk for developing cancer compared to people with lower cardiovascular disease risk, according to research presented ...

Lung Cancer
Immunotherapy

Does Adding Pembrolizumab or Placebo to Chemotherapy for Patients With Metastatic Squamous NSCLC Improve Quality of Life?

In a health-related quality of life analysis from the phase III KEYNOTE-407 trial reported in the Journal of Clinical Oncology, Mazières et al found that the patients with metastatic squamous non–small cell lung cancer (NSCLC) who received pembrolizumab in addition to chemotherapy had better...

Skin Cancer

RSNA 2019: High-Dose Brachytherapy for Older Patients With Nonmelanoma Skin Cancer

High-dose brachytherapy for elderly patients with nonmelanoma skin cancer produces excellent cure rates and cosmetic outcomes, according to a new study presented at the 2019 annual meeting of the Radiological Society of North America (RSNA) (Abstract SSM24-02).

“For elderly patients [with...

Bladder Cancer

Does the Addition of Ramucirumab to Docetaxel Improve Overall Survival in Previously Treated Urothelial Carcinoma?

As reported in The Lancet Oncology by Daniel P. Petrylak, MD, and colleagues, the phase III RANGE trial has shown no significant improvement in overall survival with the addition of ramucirumab to docetaxel in patients with locally advanced or metastatic urothelial carcinoma previously treated with ...

Colorectal Cancer

Meta-Analysis of Overall Survival With Laparoscopic vs Open Resection for Colorectal Liver Metastases

In an individual patient-level meta-analysis reported in the Annals of Surgery, Syn et al found that laparoscopic resection vs open surgery was associated with significantly improved overall survival as treatment for colorectal liver metastases.

Study Details

The meta-analysis included data from...

Multiple Myeloma
Geriatric Oncology

Use of an On-Site Touchscreen-Based Geriatric Assessment for Older Patients With Multiple Myeloma

In a study reported in the Journal of Oncology Practice, Nathwani et al found that the use of a tablet-based modified geriatric assessment during physician visits by older patients with multiple myeloma was feasible and provided physicians with information that influenced treatment decisions.

Study ...

Colorectal Cancer
Immunotherapy

Pembrolizumab in Previously Treated Metastatic MSI-H/dMMR Colorectal Cancer

As reported in the Journal of Clinical Oncology by Dung T. Le, MD, and colleagues, the phase II KEYNOTE-164 trial demonstrated activity of pembrolizumab in previously treated metastatic microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) colorectal cancer.

Findings from the...

Breast Cancer

Swedish Population Study of Risk-Adapted Screening Starting Ages for Relatives of Patients With Breast Cancer

In a study reported in JAMA Oncology, Mukama et al identified risk-adapted screening starting ages for relatives of patients with breast cancer according to the number of affected first-degree and second-degree relatives and the age at diagnosis of affected relatives.

Study Details

The nationwide...

Breast Cancer

Associations of Oncotype DX Breast Recurrence Score With Mortality Prediction and Difference Between Sexes

A study comparing the prognostic value of the Oncotype DX Breast Recurrence Score in male and female patients with early-stage estrogen receptor (ER)-positive breast cancer has found that the score is associated with mortality in male patients at a much lower threshold than female patients. The...

CNS Cancers

Quality of Life and Neurocognitive Function in Patients With Gliomas Treated With Temozolomide-Based Chemoradiotherapy

A secondary analysis of the phase II NRG-RTOG 0424 trial—which initially reported a 73.1% 3-year overall survival rate—has shown a decline in neurocognitive function for half of the trial participants with high-risk, low-grade gliomas up to a year after receiving concurrent chemoradiotherapy with...

Prostate Cancer

Sequencing of Enzalutamide and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer

In a Canadian phase II crossover trial reported in The Lancet Oncology, Kim N. Chi, MD, and colleagues found that time to second prostate-specific antigen (PSA) progression from start of treatment was longer with crossover from abiraterone acetate/prednisone to enzalutamide vs the reverse sequence...

Solid Tumors
Immunotherapy

Activity of Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or With Nivolumab in Advanced Solid Tumors

In a phase I/IIa study reported in JAMA Oncology, Lillian L. Siu, MD, FRCPC, FASCO, and colleagues found no evidence of activity of the glucocorticoid-induced tumor necrosis factor (TNF) receptor–related protein (GITR) agonist antibody BMS-986156 alone or in combination with nivolumab in patients...

Head and Neck Cancer

PIK3CA Mutation Status and Disease-Free Survival in Patients With HPV-Associated Head and Neck Cancer Treated With Deintensified Chemoradiotherapy

In a study reported in the Journal of the National Cancer Institute, Beaty et al found that the presence of a PIK3CA mutation was associated with poorer disease-free survival among patients receiving deintensified definitive chemoradiotherapy for human papillomavirus (HPV)-associated oropharyngeal...

Thyroid Cancer

DUOX2 Mutation in Familial Thyroid Cancers

Researchers have identified a new genetic mutation that may cause a type of familial thyroid cancer. According to the researchers, DUOX2 is the first and only mutation associated with familial thyroid cancer to be identified in a gene that is primarily expressed in the thyroid gland. These findings ...

Hematologic Malignancies
Geriatric Oncology

Geriatric Assessment–Guided Multidisciplinary Care May Benefit Older Patients Undergoing Stem Cell Transplantation

Older adults with blood cancers may benefit from a team-based, holistic evaluation before undergoing transplantation, according to a study published by Derman et al in Blood Advances. The study, which reported on a multidisciplinary clinic at the University of Chicago Medical Center, found that...

Gynecologic Cancers

Secondary Surgical Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer

In the phase III trial Gynecologic Oncology Group (GOG)-0213 trial, reported in The New England Journal of Medicine by Robert L. Coleman, MD, and colleagues, no overall survival benefit was found for secondary surgical cytoreduction followed by chemotherapy vs chemotherapy alone in women with...

CNS Cancers

Molecular Changes in Progression of IDH Wild-Type Glioblastoma

In a study reported in the Journal of Clinical Oncology, Draaisma et al identified molecular changes at tumor recurrence vs the primary tumor profiles in patients receiving standard chemoradiotherapy with temozolomide for IDH wild-type glioblastoma multiforme. The findings may help inform precision ...

Hepatobiliary Cancer
Lymphoma
Neuroendocrine Tumors
Gastrointestinal Cancer
Genomics/Genetics

FDA Pipeline: Recent Designations in Hepatocellular Carcinoma, Cholangiocarcioma, Lymphoma, and More

Over the past few weeks, the U.S. Food and Drug Administration (FDA) granted reviews or designations to treatments for gastrointestinal cancers and lymphoma, and also provided authorizations for products designed to screen for malignancies and tumor mutational burden.

Priority Review for Nivolumab...

Multiple Myeloma
Immunotherapy

ICARIA-MM: Addition of Isatuximab to Pomalidomide/Dexamethasone in Relapsed and Refractory Multiple Myeloma

As reported in The Lancet by Michel Attal, MD, and colleagues, the phase III ICARIA-MM trial has shown that the addition of the CD38-targeted antibody isatuximab to pomalidomide and low-dose dexamethasone significantly improved progression-free survival in patients with relapsed and refractory...

Hepatobiliary Cancer
Immunotherapy

ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Combination therapy with the programmed cell death ligand 1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improved overall and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to sorafenib, according to findings from the phase ...

Breast Cancer

ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer

The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported by Xu et al at the European...

FDA Approves Voxelotor for Sickle Cell Disease

On November 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to voxelotor (Oxbryta) for adults and pediatric patients 12 years of age and older with sickle cell disease.

“[Voxelotor] is an inhibitor of deoxygenated sickle hemoglobin polymerization, which is the central...

Gynecologic Cancers
Global Cancer Care

Thermal Ablation vs Cryotherapy or Loop Excision in Zambian Women Positive for Cervical Precancer

In the pilot phase of an ongoing randomized trial reported in The Lancet Oncology, Pinder et al found that thermal ablation and cryotherapy produced similar treatment success rates in Zambian women positive for cervical precancer on visual inspection with acetic acid.

The investigators noted that...

Prostate Cancer

Activity of Anti-STEAP1 Antibody-Drug Conjugate in Patients With Metastatic Castration-Resistant Prostate Cancer

In a phase I trial reported in the Journal of Clinical Oncology, Danila et al found that the antibody-drug conjugate DSTP3086S, which targets the six-transmembrane epithelial antigen of the prostate 1 (STEAP1), had acceptable safety and evidence of activity in patients with metastatic...

Immunotherapy

Characteristics of Metastatic Lesion Responses to PD-1 Inhibition

In a study reported in the Journal of Clinical Oncology, Osorio et al found that responses to programmed cell death protein 1 (PD-1) inhibitor therapy tended to be consistent across metastases and occur simultaneously in metastatic lesions of non–small cell lung cancer (NSCLC) and mismatch...

Solid Tumors

Machine Learning Algorithm for Genome-Derived Prediction of Tumor Type

In a study reported in JAMA Oncology, Penson et al developed a machine learning algorithmic classifier that may be successful in identifying tumor type and origin based on DNA-sequence data obtained at point of care.

The study used machine learning to construct and train an algorithmic classifier...

Issues in Oncology

Mental Health Outcomes in Mothers and Siblings of Children With Cancer

In a Canadian study reported in the Journal of Clinical Oncology, van Warmerdam et al found that mothers and siblings of children with cancer were significantly more likely to have mental health–related outpatient health-care contacts than their general population counterparts.

The study involved...

Skin Cancer

MicroRNA Panel Could Aid in the Detection of Uveal Melanoma

A blood test could soon become a monitoring tool for the early detection of uveal melanoma. Stark et al discovered markers in the blood that can differentiate between a benign mole and a melanoma, while also determining whether the cancer has metastasized, according to findings they published in...

Lung Cancer

2019 State of Lung Cancer Report Released

More Americans than ever are surviving lung cancer. While the disease remains the leading cause of cancer deaths among both women and men, over the past decade, the survival rate has increased. A new report from the American Lung Association—the 2019 State of Lung Cancer—examines this promising...

Leukemia
Lymphoma

FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis

On November 21, as part of Project Orbis—a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada—the U.S. Food and Drug Administration (FDA) granted supplemental approval to acalabrutinib (Calquence) for the treatment of adults with chronic lymphocytic leukemia...

Head and Neck Cancer
Immunotherapy

Pembrolizumab With or Without Chemotherapy vs Cetuximab Plus Chemotherapy in Recurrent or Metastatic HNSCC

As reported in The Lancet by Barbara Burtness, MD, and colleagues, the phase III KEYNOTE-048 trial has shown improved overall survival with first-line pembrolizumab plus chemotherapy vs cetuximab plus chemotherapy among patients with recurrent or metastatic squamous cell carcinoma of the head and...

Skin Cancer

Long-Term Analysis of Vemurafenib/Cobimetinib in Patients With BRAF-Mutated Melanoma

A phase Ib study evaluating the safety and long-term benefit of combination treatment with the BRAF inhibitor vemurafenib plus the MEK1 inhibitor cobimetinib in patients with advanced BRAF V600E–mutated melanoma has found that nearly 40% of the patients experienced extended survival of 4 to 5 years ...

Issues in Oncology
Pain Management

Opioid Prescriptions in Patients With Cancer in Southwest Virginia

In a study in residents of rural southwest Virginia reported in the Journal of Oncology Practice, Virginia T. LeBaron, PhD, and colleagues found that most patients with cancer never received a prescription opioid medication, that few patients were admitted to hospital for opioid use disorders, and...

Kidney Cancer
Immunotherapy

Atezolizumab/Bevacizumab in Metastatic Renal Cell Carcinoma With Variant Histology or Sarcomatoid Features

In a phase II trial reported in the Journal of Clinical Oncology, Toni K. Choueiri, MD, and colleagues found that the combination of atezolizumab and bevacizumab was active in metastatic renal cell carcinoma with variant histology and clear cell renal cell carcinoma with ≥ 20% sarcomatoid...

Issues in Oncology
Pain Management

Prescribed Opioid Use and Infection Risk in Patients With Cancer and Treatment-Associated Neutropenia

In a German study reported in a research letter in JAMA Internal Medicine, Jakob et al found that prescribed opioid use did not appear to increase risk of infection in hospitalized patients with cancer who developed treatment-associated neutropenia. According to the investigators, recent data have...

Leukemia

Late Bone Marrow Relapse Risk Stratification in Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia

In an analysis of the German ALL-REZ BFM 2002 trial, reported in the Journal of Clinical Oncology, Eckert et al found that postinduction minimal residual disease (MRD)-based treatment stratification resulted in “excellent survival” in pediatric patients with late relapse of B-cell precursor acute...

Issues in Oncology

Does Testosterone Replacement Therapy Benefit Young Male Cancer Survivors?

Young male cancer survivors may significantly benefit from testosterone replacement therapy—especially after testicular cancer. Research published by Walsh et al in PLOS Medicine looked at one of the most common late-onset side effects experienced by young male survivors—reduced levels of the male...

Lung Cancer

Gefitinib Alone vs Gefitinib Plus Chemotherapy in EGFR-Mutated Metastatic NSCLC

In the Japanese phase III NEJ009 trial reported in the Journal of Clinical Oncology, Hosomi et al found that the addition of first-line gefitinib to carboplatin/pemetrexed improved progression-free survival vs gefitinib alone in patients with EGFR-mutated metastatic non–small cell lung cancer...

Solid Tumors
Immunotherapy

Pembrolizumab in Noncolorectal MSI-H/dMMR Solid Tumors

As reported in the Journal of Clinical Oncology by Marabelle et al, the phase II KEYNOTE-158 trial has shown robust activity of pembrolizumab in patients with noncolorectal microsatellite instability­–high (MSI-H)/mismatch repair–deficient (dMMR) solid tumors.

Findings in the study supported the...

Hematologic Malignancies

Outcomes With Haploidentical Stem Cell Transplantation Plus Cyclophosphamide in Adults With Hematologic Cancers

In a meta-analysis reported in JAMA Oncology, Gagelmann et al found that overall survival with haploidentical stem cell transplantation with post-transplantation cyclophosphamide was poorer vs matched related donor transplantation and similar vs matched unrelated donor transplantation in adult...

Issues in Oncology

Disparities in Culturally Competent Cancer Care

Many nonwhite minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study. The study, which is one of the first nationally-representative studies to...

Skin Cancer

Role of Voriconazole in Cutaneous Squamous Cell Carcinoma Development

For the last decade, medical experts have known that voriconazole—an antifungal medication used to prevent infections in patients with compromised immune systems—is linked to the development of particularly aggressive squamous cell carcinoma in skin exposed to ultraviolet (UV) rays. However, the...

Lymphoma
Immunotherapy

Polatuzumab Vedotin Plus Bendamustine/Rituximab for Transplantation-Ineligible Relapsed or Refractory DLBCL

In a phase Ib/II trial reported in the Journal of Clinical Oncology, Laurie H. Sehn, MD, MPH, and colleagues found that the addition of polatuzumab vedotin to bendamustine/rituximab improved response rate and progression-free and overall survival among transplantation-ineligible patients with...

Gastrointestinal Cancer

Maximizing Benefit in the Treatment of Immune-Mediated Colitis

Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...

Geriatric Oncology

Improving Communication With Older Patients Using Geriatric Assessment During Oncology Visits

In the COACH study, reported in JAMA Oncology, Supriya G. Mohile, MD, MS, and colleagues found that including geriatric assessment in oncology visits for older adults with advanced cancer improved patient and caregiver satisfaction with communication regarding aging-related concerns.

Study Details

...

Gynecologic Cancers
Immunotherapy

Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer

In a phase II trial reported in JAMA Oncology, Liu et al found evidence of the activity of combined nivolumab and bevacizumab in relapsed ovarian cancer, with activity appearing to be greater in platinum-sensitive disease.

Study Details

In the trial, 38 women with relapsed epithelial ovarian cancer ...

Solid Tumors

Long-Term Effects of Denosumab in Patients With Giant Cell Tumor of Bone

As reported by Chawla et al in The Lancet Oncology, long-term data from the final analysis of an international phase II study suggest that a favorable risk-benefit ratio is maintained over time with denosumab treatment of patients with giant cell tumor of bone. Benefit of denosumab was indicated in ...

Issues in Oncology

Presenting Symptoms and Cancer Stage at Diagnosis

In a population-based study reported in The Lancet Oncology, Koo et al found that presenting symptoms of cancer were mostly associated with stage earlier than stage IV, suggesting a benefit of symptom awareness campaigns based on common symptoms.

As stated by the investigators, “Early diagnosis...

Multiple Myeloma

Lenalidomide vs Observation in Asymptomatic Smoldering Multiple Myeloma

In a phase III trial reported in the Journal of Clinical Oncology, Sagar Lonial, MD, and colleagues found that lenalidomide significantly improved progression-free survival vs observation in patients with intermediate- or high-risk smoldering multiple myeloma. As noted by the investigators,...

Hepatobiliary Cancer

Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine/Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma

In a single-center phase II trial reported in JAMA Oncology, Andrea Cercek, MD, and colleagues found that hepatic arterial infusion of floxuridine in combination with systemic gemcitabine/oxaliplatin produced high response and disease control rates and was associated with promising overall survival ...

Issues in Oncology
Survivorship

Exercise Intolerance in Adult Survivors of Childhood Cancer

In a study reported in the Journal of Clinical Oncology, Ness et al found a high rate of exercise intolerance among adult survivors of childhood cancer, irrespective of exposure to cardiotoxic treatment. Exercise intolerance was associated with poorer overall survival.

The study involved 1,041...

Hepatobiliary Cancer

Oral Direct-Acting Antiviral Therapy May Improve Survival in Patients With Hepatitis C Virus–Related HCC

Data from a new study presented by Dang et al at The Liver Meeting (Abstract 40) found that patients with hepatitis C virus–related hepatocellular carcinoma (HCC) who achieved sustained virologic response (denoting an undetectable level of the virus) with any oral direct-acting antiviral therapy...

Lung Cancer
Issues in Oncology

Rates of Non–Guideline-Concordant Lung Cancer Treatment in the United States

Only about 6 in 10 patients with lung cancer in the United States receive the minimal lung cancer treatments recommended by National Comprehensive Cancer Network® (NCCN) Guidelines, according to new research published by Blom et al in the Annals of the American Thoracic Society.

Erik F. Blom, MD,...

Breast Cancer

Prognostic Biomarkers in Triple-Negative Breast Cancer Treated With Adjuvant Doxorubicin/Cyclophosphamide

As reported in the Journal of Clinical Oncology by Priyanka Sharma, MD, and colleagues, biomarker analysis among women with triple-negative breast cancer treated with adjuvant doxorubicin/cyclophosphamide in the SWOG 9313c trial has confirmed a 44-gene DNA damage immune response signature and...

Colorectal Cancer

2019 NCRI: Use of Mendelian Randomization to Determine Role of Human Gut Microbiome in Colorectal Cancer Development

A study using a technique called Mendelian randomization to investigate the causal role played by bacteria in the development of colorectal cancer was presented at the 2019 National Cancer Research Institute (NCRI) Cancer Conference.

First study author Kaitlin Wade, PhD, of the University of...

Lymphoma
Immunotherapy

Bendamustine/Rituximab Followed by Yttrium Y-90 Ibritumomab Tiuxetan in Previously Untreated Follicular Lymphoma

In the phase II Fol-BRITe study reported in Clinical Cancer Research, Lansigan et al found that a short course of bendamustine/rituximab followed by consolidation with yttrium Y-90 ibritumomab tiuxetan (Y-90 ibritumomab tiuxetan) was associated with a high response rate and a high rate of...

Survivorship

Risk of Subsequent Malignant Neoplasms in Childhood Cancer Survivors After Treatment With Chemotherapy Alone

As reported in the Journal of Clinical Oncology by Turcotte et al, analysis of the Childhood Cancer Survivor Study Cohort showed that childhood cancer survivors treated with chemotherapy alone—particularly higher cumulative doses of platinum and alkylating agents—are at an increased risk of...

Head and Neck Cancer
Skin Cancer

Head and Neck Melanoma in Adolescents and Young Adults: 1995 to 2014

Head and neck melanoma appears to be on the rise in young people in the United States and Canada, according to a study by Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES, of the Saint Louis University (SLU) School of Medicine, and colleagues. Because the prognosis of head and neck melanoma is...

Colorectal Cancer
Geriatric Oncology

Short-Term Survival in Patients Aged 85 Years and Older After Colorectal Cancer Surgery

Results from a preliminary research study showed the majority of patients aged 85 years and older were still alive in the short-term after undergoing segmental colectomy for stage II and III colon cancer. Kaur et al presented these findings at the American College of Surgeons Clinical Congress...

Issues in Oncology
Hepatobiliary Cancer

Financial Burdens of Patients With Cirrhosis and Impact on Screening for HCC

Data from a new study presented by Singal et al at The Liver Meeting found that patients with cirrhosis in the United States have substantial financial burden and this is associated with underuse of surveillance for hepatocellular carcinoma (HCC) (Abstract 201). Improved intervention strategies are ...

Lung Cancer

Dietary Fiber, Yogurt Consumption, and Lung Cancer Risk

In a pooled analysis reported in JAMA Oncology, Yang et al found that higher fiber and higher yogurt consumption were associated with significantly reduced risk of lung cancer.

Study Details

The analysis included 627,988 men (mean age = 57.9 years) and 817, 862 women (mean age = 54.8 years) from...

Hepatobiliary Cancer

2019 NCRI: Hepatocellular Carcinoma Incidence and Mortality Rates in England Have Tripled Over the Past 20 Years

From 1997 to 2016, incidence and deaths from hepatocellular carcinoma have tripled in England, according to research presented by Burton et al at the 2019 National Cancer Research Institute (NCRI) Cancer Conference.

Anya Burton, PhD, a cancer epidemiologist at Public Health England, said in a press ...

Gynecologic Cancers

2019 NCRI: CA125 Testing May Help General Practitioners to Detect Ovarian Cancer

Testing for levels of the serum biomarker cancer antigen 125 (CA125) in the blood may be a useful tool for the detection of ovarian cancer, and could help detect other types of cancer among patients in primary care, according to research presented by Funston et al at the 2019 National Cancer...

Prostate Cancer

2019 NCRI: Higher IGF-1 and Free Testosterone Levels May be Risk Factors for Prostate Cancer

Men with higher levels of free (biologically active) testosterone and insulin-like growth factor-1 (IGF-1) in their blood are more likely to be diagnosed with prostate cancer, according to research presented by Travis et al at the 2019 National Cancer Research Institute (NCRI) Cancer Conference....

Solid Tumors
Immunotherapy

High-Dose Bevacizumab for Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

In a phase II trial reported in the Journal of Clinical Oncology, Plotkin et al found that high-dose bevacizumab induction therapy did not appear to produce better outcomes compared with lower-dose treatment in patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas. As...

Breast Cancer

Regional Disparities in Metastatic Breast Cancer Survival Between 1990 and 2011

In a study reported in Cancer, Judith A. Malmgren, PhD, and colleagues found marked regional differences in improvements in breast cancer–specific survival among women diagnosed with metastatic breast cancer between 1990 and 2011, with the best rates found in an institutional cohort.

Study ...

Hepatobiliary Cancer

Studies Report Efficacy of Proton Radiotherapy for Hepatocellular Carcinoma

Two new studies published in the International Journal of Radiation Oncology • Biology • Physics focused on the use of proton radiation therapy to treat patients with hepatocellular carcinoma. The first study, by Sanford et al, found that proton radiation may extend overall survival compared to...

Lung Cancer

Nearly One-Quarter of Completed Lung Cancer Clinical Trials Remain Unpublished

A new analysis has found that the results of up to one-fourth of completed lung cancer clinical trials are not published. This finding was published in a research letter by Al-Shbool et al in JAMA Network Open. 

“It is surprising to see that a quarter of trials that have been completed end up not...

Leukemia

ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML

As reported in The New England Journal of Medicine by Perl et al, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage chemotherapy in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia...

Colorectal Cancer

American College of Physicians Issues Guidance on Colorectal Cancer Screening for Average-Risk, Asymptomatic Adults Aged 50 to 75 Years

The American College of Physicians has issued a new guidance statement on colorectal cancer screening, which recommends screening for average-risk adults who do not have symptoms and are between the ages of 50 and 75 years. The guidelines were published by Qaseem et al in Annals of Internal...

Prostate Cancer

DNA Vaccine for Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

In a phase II study reported in the Journal of Clinical Oncology, McNeel et al found that a DNA vaccine (pTVG-HP) encoding prostatic acid phosphatase did not improve 2-year metastasis-free survival vs control treatment in patients with progressive, nonmetastatic, castration-sensitive prostate...

Breast Cancer

Is There a Difference in Breast Cancer Recurrence Rates After Surgery With Regional vs General Anesthesia?

In a trial reported in The Lancet, Sessler et al found no difference in breast cancer recurrence after surgery with regional anesthesia-analgesia using paravertebral block and propofol vs general anesthesia with the volatile anesthetic sevoflurane and opioid analgesia. They also found no difference ...

FDA Office of Hematology Oncology Products Reorganizes, Renamed Office of Oncologic Diseases

As part of modernization plans approved in September 2019, the U.S. Food and Drug Administration (FDA) office responsible for reviewing applications for new and existing cancer therapies has reorganized and been renamed. The Center for Drug Evaluation and Research (CDER) Office of Hematology and...

Breast Cancer

Outcomes in Patients With Early Breast Cancer and High 21-Gene Recurrence Score Treated With Adjuvant Chemotherapy Plus Endocrine Therapy: Secondary Analysis of TAILORx

In a secondary analysis of the phase III TAILORx trial reported in JAMA Oncology, Joseph Sparano, MD, and colleagues found that adjuvant chemotherapy plus endocrine therapy produced good 5-year outcomes among women with hormone receptor–positive, HER2-negative, axillary node–negative breast cancer...

Colorectal Cancer

ctDNA and Recurrence Risk After Surgery and Adjuvant Chemotherapy for Stage III Colon Cancer

In a cohort biomarker study reported in JAMA Oncology, Tie et al showed that the circulating tumor DNA (ctDNA)-positive status after surgery and chemotherapy was associated with an increased risk of disease recurrence in patients with stage III colon cancer.

Study Details

The Australian multicenter ...

Lymphoma

Long-Term Follow-up of Patients With Nodular Lymphocyte–Predominant Hodgkin Lymphoma Treated in GHSG Trials

In an analysis reported in the Journal of Clinical Oncology, Eichenauer et al found that patients with newly diagnosed nodular lymphocyte–predominant Hodgkin lymphoma treated in German Hodgkin Study Group (GHSG) trials had good long-term outcomes overall.

Study Details

The analysis identified the...

Issues in Oncology
Cost of Care

Study Finds Nearly One in Four Oncologists Rarely or Never Mention Cost When Discussing Genomic Testing

Nearly one in four oncologists report rarely or never discussing the costs of genomic testing with their patients, according to a new study led by American Cancer Society investigators. The study, published by Yabroff et al in the Journal of the National Cancer Institute, found that oncologists...

Multiple Myeloma

Levofloxacin Prophylaxis During Treatment of Newly Diagnosed Multiple Myeloma

In the phase III TEAMM trial reported in The Lancet Oncology, Drayson et al found that prophylactic treatment with levofloxacin during the first 12 weeks of multiple myeloma treatment in newly diagnosed patients was associated with a significant reduction in first febrile episodes or death from any ...

Lung Cancer
Immunotherapy

Patient-Reported Outcomes Observed With Durvalumab Treatment After Chemoradiotherapy for Stage III Unresectable NSCLC

As reported in The Lancet Oncology by Hui et al, no clinically important differences in patient-reported outcomes were observed among patients receiving durvalumab vs placebo after chemoradiation for stage III unresectable non–small cell lung cancer (NSCLC) in the phase III PACIFIC trial.

The...

Breast Cancer

Factors Influencing Freedom From Distant Recurrence in Premenopausal Women With Hormone Receptor–Positive, HER2-Negative Breast Cancer

In a long-term analysis of the TEXT/SOFT trials reported in the Journal of Clinical Oncology, Pagani et al found that potential benefits of escalating adjuvant endocrine therapy beyond tamoxifen alone in preventing distant recurrence may be minimal in premenopausal women with hormone...

Colorectal Cancer

Do Poorly Differentiated Clusters in Liver Metastases From Colorectal Cancer Offer Prognostic Value?

A study published by Yonemura et al in The American Journal of Surgical Pathology has shown a correlation between the poorly differentiated cluster grade in primary colorectal cancer tumors and metastatic lesions in the liver. The researchers wrote, “[Grade of] poorly differentiated clusters in...

Thyroid Cancer

2019 Annual Meeting of the American Thyroid Association Briefs

The American Thyroid Association held its 2019 Annual Meeting from October 30 to November 3 in Chicago. Below are brief summaries of important oral presentations on thyroid cancer from the meeting.

Incidence and Incidence-Based Mortality in a State

Results of a retrospective analysis of thyroid...

Head and Neck Cancer

AACR-NCI-EORTC: Activity of Tipifarnib in Patients With HRAS-Mutant Head and Neck Squamous Cell Carcinoma

A small phase II study investigating the efficacy and safety of the investigational farnesyl transferase inhibitor tipifarnib in patients with recurrent and metastatic HRAS-mutant head and neck squamous cell carcinoma found the agent produced objective responses in the patient population. Based on...

Solid Tumors

AACR-NCI-EORTC: Investigational KRAS G12C Inhibitor for KRAS-Mutant Solid Tumors

The investigational KRAS G12C inhibitor MRTX849 yielded clinical responses in patients with non–small cell lung cancer (NSCLC) and colorectal cancer harboring KRAS G12C mutations, according to data from a phase I clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular...

Solid Tumors

AACR-NCI-EORTC: Selumetinib for Adult Patients With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

The investigational MEK inhibitor selumetinib showed clinical activity in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, according to preliminary results from an ongoing phase II study presented at the AACR-NCI-EORTC International Conference on Molecular...

Immunotherapy

Association Between Prior Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy Outcomes

In a study presented in a brief report in JAMA Oncology, David J. Pinato, MD, PhD, and colleagues found that past but not concurrent use of broad-spectrum antibiotic therapy was associated with poorer treatment outcomes in patients receiving immune checkpoint inhibitors for various cancers in...

Hepatobiliary Cancer

Postdiagnosis Use of Aspirin in Patients With Biliary Tract Cancer

In a study reported in a research letter in JAMA Oncology, Jackson et al found that postdiagnosis aspirin use was associated with significantly improved overall survival across biliary tract cancer types.

Study Details

The study involved 2,934 adult patients diagnosed with biliary tract cancer...

Lymphoma

Pretreatment Vitamin D Deficiency and Outcomes in Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, Borchmann et al found that pretreatment vitamin D deficiency was associated with poorer progression-free and overall survival rates in patients receiving first-line treatment for Hodgkin lymphoma.

Study Details

The analysis involved 351...

Prostate Cancer

Long-Term Follow-up of Salvage Short-Term ADT Plus Radiotherapy After Radical Prostatectomy

As reported in The Lancet Oncology by Carrie et al, the 112-month follow-up of the French phase III GETUG-AFU 16 trial has confirmed the initial 5-year report of the trial, which reported improved progression-free survival with the addition of short-term androgen-deprivation therapy (ADT) to...

Breast Cancer

Long-Term Recurrence-Free Survival With the Addition of Adjuvant Trastuzumab to Chemotherapy in HER2-Positive Breast Cancer

Long-term follow-up analysis of the NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31 trials, reported in the Journal of Clinical Oncology by Chumsri et al, showed poorer recurrence-free survival in hormone receptor (HR)-negative vs HR-positive HER2-positive breast cancer, with the addition of...

Survivorship
Pain Management
Symptom Management

First Survivor Views Survey Highlights Barriers to Addressing Side Effects of Cancer Treatment

Barriers to accessing appropriate therapies to address the physical and psychological side effects of cancer treatment continue to persist for patients and survivors, according to results of the Survivor Views survey conducted by the American Cancer Society Cancer Action Network (ACS CAN).

...

Issues in Oncology

ASCO National Cancer Opinion Survey: Cancer Prevention, E-Cigarette, and End-of-Life Knowledge Gaps Reported

One in four Americans say they incorporate cancer prevention into their daily lives, according to ASCO’s third annual National Cancer Opinion Survey, despite research showing that as many as half of all cancer cases are preventable. The survey found low levels of awareness of known cancer risk...

Breast Cancer

MONARCH 2: Interim Analysis of Overall Survival With Abemaciclib/Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer

As reported in JAMA Oncology by George W. Sledge, Jr, MD, and colleagues, an interim analysis of overall survival in the phase III MONARCH 2 trial has shown a significant advantage for abemaciclib plus fulvestrant vs fulvestrant alone in women with advanced hormone receptor–positive, HER2-negative...

Colorectal Cancer

Panitumumab Plus Modified FOLFOXIRI for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer

In the German phase II VOLFI trial reported in the Journal of Clinical Oncology, Modest et al found that panitumumab plus modified FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) used as first-line therapy improved the objective response rate in patients with RAS wild-type...

Issues in Oncology
Survivorship

Leydig Cell Failure and Dysfunction and Associated Adverse Health Outcomes in Male Survivors of Childhood Cancer

In a retrospective analysis from the St. Jude Lifetime Cohort Study reported in the Journal of Clinical Oncology, Chemaitilly et al identified the prevalence of and risk factors for failure and dysfunction of Leydig cells, which are responsible for testosterone secretion, and associated adverse...

Hepatobiliary Cancer

Contrast-Enhanced Ultrasound May Help to Predict Cirrhotic Nodule Transformation to Hepatocellular Carcinoma

An article published by Lin et al in the American Journal of Roentgenology has identified sonographic biomarkers that may predict eventual malignant transformation of pathologically confirmed cirrhotic nodules for patients at risk for hepatocellular carcinoma.

Lead investigator Manxia Lin, MD, of...

Health-Care Policy
Palliative Care

Palliative Care Bill Unanimously Approved by U.S. House of Representatives

On October 28, the U.S. House of Representatives unanimously approved the Palliative Care and Hospice Education and Training Act (PCHETA). The bipartisan bill would increase federal research funding for palliative care—including pain and symptom management—and would establish palliative care...

Lung Cancer
Immunotherapy

CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLC

As reported in The Lancet by Luis Paz-Ares, MD, and colleagues, an interim analysis of the phase III CASPIAN trial has shown an overall survival benefit with the addition of durvalumab to platinum (either cisplatin or carboplatin)/etoposide chemotherapy in the first-line treatment of...

Immunotherapy
Solid Tumors

Pembrolizumab for Patients With Advanced Adrenocortical Carcinoma

In a single-center phase II study reported in the Journal of Clinical Oncology, Raj et al found that pembrolizumab showed activity in advanced adrenocortical carcinoma.

Study Details

Thirty-nine patients with advanced adrenocortical carcinoma were enrolled in the study between February 2016 and...

Head and Neck Cancer
Symptom Management

Superoxide Dismutase Mimetic for Reducing Severe Oral Mucositis From Concurrent Radiotherapy and Cisplatin in Head and Neck Cancer

In a phase IIb trial reported in the Journal of Clinical Oncology, Anderson et al found that the superoxide dismutase mimetic GC4419 was effective in reducing the duration, incidence, and severity of severe oral mucositis in patients with head and neck cancer receiving concurrent radiotherapy and...

Skin Cancer

Relapse-Free Survival After Vismodegib Discontinuation in Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma

In a French retrospective study reported in the Journal of Clinical Oncology, Herms et al found that long-term response is frequently maintained in patients discontinuing vismodegib after complete remission of locally advanced basal cell carcinoma, and that responses can be achieved with vismodegib ...

Pancreatic Cancer
Global Cancer Care

Global Burden of Pancreatic Cancer From 1990–2017

The incidence and mortality rates of pancreatic cancer have increased in 195 countries and territories over a 27-year period, according to a systematic analysis performed within the Global Burden of Disease Study 2017 and published in The Lancet Gastroenterology & Hepatology. The study is the...

Gastroesophageal Cancer
Gastrointestinal Cancer

Trifluridine/Tipiracil Survival Benefit for Patients With Metastatic Gastric Cancer Who Had or Had Not Undergone Prior Gastrectomy

In a subgroup analysis of the phase III TAGS trial (TAS-102 Gastric Study) reported in JAMA Oncology, David H. Ilson, MD, PhD, and colleagues found positive trends in survival benefit with trifluridine/tipiracil treatment vs placebo for patients with pretreated metastatic gastric cancer or...

Breast Cancer

Addition of Trilaciclib to Chemotherapy in Metastatic Triple-Negative Breast Cancer

In a phase II trial reported in The Lancet Oncology, Tan et al found that the addition of the cell-cycle inhibitor trilaciclib to gemcitabine/carboplatin chemotherapy did not reduce the duration or incidence of severe neutropenia during chemotherapy in women with triple-negative breast cancer. A...

Pancreatic Cancer

Nab-paclitaxel/Gemcitabine/Cisplatin for Previously Untreated, Advanced Pancreatic Cancer

In a phase Ib/II pilot study reported in JAMA Oncology, Jameson et al found that treatment with nab-paclitaxel, gemcitabine, and cisplatin was active in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Study Details

In the study, 25 patients were enrolled between...

Breast Cancer
Genomics/Genetics

Factors in Genetic Testing Decisions Among Women With a Personal and Family History of Breast Cancer

In a study reported in the Journal of Oncology Practice, Scott et al identified several factors that motivated breast cancer survivors with high genetic risk to undergo genetic testing and found that clinicians often failed to discuss all relevant factors in decision-making.

Study Details

The...

Issues in Oncology
Cost of Care

Health Insurance Literacy and Financial Hardship in Cancer Survivors

A new study published by Zhao et al in JNCI Cancer Spectrum has linked health insurance literacy with medical financial hardship as well as nonmedical financial sacrifices among adult cancer survivors in the United States. The study’s authors say the study indicated that health insurance literacy...

Breast Cancer
Leukemia
Prostate Cancer
Lymphoma

FDA Pipeline: Treatments for HER2-Positive Breast Cancer, AML; Breakthrough Device for Prostate Cancer; Statement on Safety Information for Breast Implants

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to trastuzumab deruxtecan for the treatment of HER2-positive metastatic breast cancer; granted Fast Track designation for bemcentinib for elderly patients with relapsed acute myeloid leukemia (AML); granted Breakthrough...

Immunotherapy
Head and Neck Cancer

Addition of Bevacizumab to Chemotherapy in Recurrent or Metastatic Head and Neck Cancer

As reported in the Journal of Clinical Oncology by Argiris et al, the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network Cancer Research Group–coordinated phase III E1305 trial has shown no overall survival benefit with the addition of bevacizumab to...

Immunotherapy
Lymphoma

Immunotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Findings from the phase Ib KEYNOTE-013 and phase II KEYNOTE-170 trials reported in the Journal of Clinical Oncology by Armand et al indicated that pembrolizumab is highly active in relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL). The KEYNOTE-170 trial supported the 2018...

Leukemia
Genomics/Genetics
Immunotherapy

Gene Signature to Identify Benefit of Front-Line Fludarabine, Cyclophosphamide, and Rituximab in IGHV-Unmutated CLL

In a retrospective cohort study reported in The Lancet Oncology, Herling et al identified a 17-gene signature that distinguished patients with IGHV-unmutated chronic lymphocytic leukemia (CLL) more likely to achieve long-term remission after front-line chemoimmunotherapy with fludarabine,...

Issues in Oncology
Multiple Myeloma

Study Finds Disparities in Treatment of African American and Hispanic Patients With Multiple Myeloma

African American and Hispanic patients with multiple myeloma generally start treatment with novel therapy significantly later than white patients, according to a study published by Ailawadhi et al in Blood Advances. The study found that, on average, it took about 3 months for white patients to...

Pancreatic Cancer
Supportive Care

2019 Supportive Care: Racial Disparities in Use of Hospice Care Near Death Among Patients With Pancreatic Cancer

A study investigating the utilization of hospice care among racial/ethnic minority patients following treatment for pancreatic cancer has found that African American and Hispanic patients who underwent surgical removal of the pancreas were less likely than white patients to use hospice services at...

Supportive Care
Pain Management

2019 Supportive Care: Anxiety, Depression, and Low Social Support Are Significant Factors in Cancer Pain Intensity

Pain is one of the most common symptoms associated with cancer and its treatment, and feelings of anxiety and depression can intensify the level of pain patients experience, according to the results from a study by Galloway et al that will be presented at the 2019 Supportive Care in Oncology...

Supportive Care

2019 Supportive Care: Oncology Massage May Relieve Symptoms of Chemotherapy-Induced Peripheral Neuropathy

A new study has found that oncology massage therapy can provide symptomatic relief for a common and difficult-to-treat side effect of cancer treatment. Patients with chemotherapy-induced peripheral neuropathy experienced a sustained reduction in lower-extremity pain up to 6 weeks after completion...

Immunotherapy

Algorithm for Identifying Genetic Mutations Likely to Respond to Immunotherapy

A new model works to determine which genetic mutations may respond best to treatment with immunotherapy. Richman et al published the data on the model’s development in Cell Systems, and the algorithm, antigen.garnish, is already available online as an open source technology to serve as a resource.

...

Skin Cancer

No Survival Benefit With Complete Lymph Node Dissection vs Observation in Sentinel Node–Positive Melanoma

As reported by Leiter et al in the Journal of Clinical Oncology, the final analysis of the German phase III DeCOG-SLT trial have shown no distant metastasis-free survival, recurrence-free survival, or overall survival benefit with complete lymph node dissection vs observation in patients with...

Solid Tumors
Immunotherapy

Pegilodecakin Plus Pembrolizumab or Nivolumab in Advanced Solid Tumors

In a phase Ib trial reported in The Lancet Oncology, Naing et al found that the combination of pegilodecakin (pegylated interleukin [IL]-10) with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab or nivolumab was active in previously treated advanced solid tumors. 

In the study,...

Prostate Cancer

Apalutamide Treatment for Metastatic Castration-Sensitive Prostate Cancer and Health-Related Quality of Life

In an analysis of the phase III TITAN trial reported in The Lancet Oncology, Neeraj Agarwal, MD, and colleagues found that that treatment with apalatuamide was associated with preserved health-related quality of life, including pain and fatigue outcomes, in patients with metastatic...

Issues in Oncology

Exercise for Patients With Cancer to Minimize Treatment Cardiotoxicity

Tailored exercise may help to minimize cardiotoxicity in patients with cancer, according to a report published by D’Ascenzi et al in the European Journal of Preventive Cardiology.

Cardiovascular diseases are common side effects in patients with cancer. This is the result of cardiotoxicity, whereby...

Lymphoma
Symptom Management

FDA Pipeline: Designations for Acute Graft-vs-Host Disease, Peripheral T-Cell Lymphoma

Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a therapy for steroid-refractory acute graft-vs-host disease and granted Orphan Drug designation to a therapy for peripheral T-cell lymphoma.

Fast Track Designation for T-Guard in Steroid-Refractory Acute...

Head and Neck Cancer
Issues in Oncology

Effect of Patient General Preference for More vs Less Medical Care on Intensity of Posttreatment Thyroid Cancer Surveillance

In an analysis reported in the Journal of Clinical Oncology, Evron et al found that patients with thyroid cancer who were declared disease-free after initial treatment were more likely to have increased numbers of physician visits and imaging tests if they reported a generalized preference for...

Breast Cancer
Geriatric Oncology

Pooled Analysis of Outcomes in Older Women With Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Plus Aromatase Inhibitor Therapy

In a U.S. Food and Drug Administration (FDA) pooled analysis reported in the Journal of Clinical Oncology, Howie et al found that progression-free survival and benefit were similar for older vs younger postmenopausal women treated with combined cyclin-dependent kinase 4/6 (CDK4/6) plus aromatase...

Issues in Oncology

Virtual Molecular Tumor Boards May Help to Efficiently Deliver Precision Medicine to Patients

Using virtual, cloud-based, interconnected computing techniques applied to 51,000 variables, researchers reduced the time needed to assess a patient’s tumor profile and suitability for clinical trials from 14 to 4 days. This method also increased the number of cases that could be assessed compared...

Lung Cancer

IASLC North America: Lung Cancer Screening Among First Responders

National lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders, according to a study reported by Vershalee Shukla, MD, at the International Association for the Study of Lung Cancer’s (IASLC) North America ...

Symptom Management

Romiplostim for Patients With Chemotherapy-Induced Thrombocytopenia

In a single-center phase II study reported in the Journal of Clinical Oncology, Soff et al found that treatment with romiplostim was effective in rapidly correcting chemotherapy-induced thrombocytopenia, with maintenance treatment being effective in reducing risk of recurrent chemotherapy-induced...

Lung Cancer

RELAY Trial: Addition of Ramucirumab to Erlotinib in Previously Untreated, EGFR-Mutated Advanced NSCLC

As reported in The Lancet Oncology by Nakagawa et al, the phase III RELAY trial has shown that the addition of the VEGFR2 inhibitor ramucirumab to the EGFR inhibitor erlotinib improved progression-free survival in treatment-naive, advanced EGFR-mutated non–small cell lung cancer (NSCLC).

Study...

Gastroesophageal Cancer
Immunotherapy

Nivolumab vs Chemotherapy in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

As reported in The Lancet Oncology by Kato et al, the phase III ATTRACTION-3 trial conducted in predominantly Asian patients has shown a survival benefit with nivolumab vs paclitaxel or docetaxel in patients with advanced esophageal squamous cell carcinoma who were refractory to or intolerant of...

Breast Cancer
Cost of Care

Deviation From NCCN Guidelines May Result in Greater Costs for Patients With Metastatic Breast Cancer

A study published by Williams et al in JNCCN—Journal of the National Comprehensive Cancer Network found that direct costs for patients with metastatic breast cancer increased when their treatment differed from recommendations found in the NCCN Clinical Practice Guidelines in Oncology® (NCCN...

Solid Tumors

Anti-GD2 Monoclonal Antibody Plus Induction Chemotherapy in High-Risk Neuroblastoma

A phase II study evaluating whether combining an investigational anti-GD2 monoclonal antibody with induction chemotherapy improved outcomes in children with newly diagnosed high-risk neuroblastoma found that the therapy significantly improved 2-year event-free survival. Furman et al published the...

Skin Cancer
Genomics/Genetics

BRAF and MEK Inhibition in Advanced Melanoma With Rare BRAF Mutations

In a study reported in the Journal of Clinical Oncology, Menzer et al found that combined BRAF/MEK inhibitor therapy appeared to be more active than single-inhibitor therapy in advanced melanoma with rare BRAF mutations.

Study Details

The study involved data from 103 patients with advanced melanoma ...

Sarcoma

Maintenance Chemotherapy Improves Survival in High-Risk Rhabdomyosarcoma

In the phase III RMS 2005 trial reported by Gianni Bisogno, MD, and colleagues in The Lancet Oncology, maintenance vinorelbine and low-dose continuous cyclophosphamide was associated with nonsignificant improvement in disease-free survival and significantly improved overall survival vs no further...

Colorectal Cancer

Colorectal Cancer Screening With Fecal Immunochemical Testing, Sigmoidoscopy, or Colonoscopy for Patients Aged 50 to 79 Years Old

As reported in The British Medical Journal (BMJ) by Helsingen et al, a clinical practice guideline on colorectal cancer screening published as a BMJ Rapid Recommendations guideline indicates that previously unscreened individuals aged 50 to 79 years old with 15-year colorectal cancer risk of ≥ 3%...

Issues in Oncology
Lymphoma

Effect of Race and Ethnicity on Survival in Pediatric and Adolescent Hodgkin Lymphoma

In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Kahn et al found that event-free survival in pediatric and adolescent patients with Hodgkin lymphoma was similar by race and ethnicity in COG trials, but that adjusted overall survival was better in white...

Hematologic Malignancies
Issues in Oncology

High Blood Pressure and Cardiac Adverse Events in Patients Treated With Ibrutinib

Over half of patients treated with the Bruton’s tyrosine kinase inhibitor ibrutinib developed new or worsened high blood pressure within 6 months of starting the medication, according to a study published by Dickerson et al in Blood. The analysis is also the first to tie ibrutinib-related...

Prostate Cancer

Acute Toxicity With Intensity-Modulated Fractionated Radiotherapy vs Stereotactic Body Radiotherapy for Prostate Cancer

In an analysis from the phase III PACE-B trial reported in The Lancet Oncology, Brand et al found that shortened treatment courses with stereotactic body radiotherapy did not increase gastrointestinal or genitourinary acute toxicity vs intensity-modulated fractionated radiotherapy in low-risk to...

Lung Cancer

ASCO Breakthrough: Computer-Aided Diagnosis System for Detecting Lung Nodule Locations and Characteristics

A computer-aided diagnosis system using deep-learning analysis to detect lung lesion locations and quantitatively characterize the lesions on computed tomography (CT) images offered a fast and convenient approach for assisting radiologists in the diagnosis of lung nodule pathologies. These findings ...

Solid Tumors

Plasma miR371 Expression as a Biomarker for Active Germ Cell Malignancy

In a study reported in the Journal of Clinical Oncology, Nappi et al showed that plasma microRNA miR371 expression was associated with high specificity and positive predictive values in predicting active germ cell malignancy.

Study Details

The study included 111 patients with a history of or newly ...

Solid Tumors

ASCO Breakthrough: Blood-Based Screening Assay With a Novel Multivariate Cancer Risk Score Model

A novel multivariate cancer risk score model demonstrated 60% sensitivity at 98.5% specificity. These findings demonstrate that a blood-based cancer screening assay with a novel risk score model may be a viable method for detecting cancer in asymptomatic individuals, especially in populations at...

Solid Tumors

ASCO Breakthrough: Targeted Methylation Sequencing Assay May Provide New Tool for Cancer Detection Across Stages and Tissues of Origin

A study by Oxnard et al using bisulfite sequencing of plasma cell-free DNA to identify methylomic signatures for multicancer detection and tissue of origin found the assay achieved accurate detection of multiple cancers across stages and tissue of origin localization. The targeted methylation assay ...

Colorectal Cancer

Effect of Tumor Sidedness and Molecular Alterations on Outcomes in Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Morano et al assessed prognostic/predictive role of tumor sidedness and presence of uncommon molecular alterations in anti-EGFR treatment primary resistance in patients with RAS/BRAF wild-type metastatic colorectal cancer.

Study Details

The...

Gynecologic Cancers

Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer

In a single-center retrospective study reported in the Journal of Oncology Practice, Lee et al found that implementation of an interprofessional malignant bowel obstruction program changed care patterns and improved outcomes for women with advanced gynecologic cancers and malignant bowel...

Colorectal Cancer

Parenchymal-Sparing Hepatectomy for Colorectal Cancer Liver Metastases

In a meta-analysis published by Deng et al in Cancer Medicine, researchers found parenchymal-sparing hepatectomy was associated with better perioperative outcomes vs extended hepatectomy for the treatment of colorectal cancer liver metastases, without compromising long-term oncologic outcomes.

The...

Skin Cancer

Whole-Brain Radiation Therapy vs Observation After Local Treatment of Melanoma Brain Metastases

In a phase III trial reported in the Journal of Clinical Oncology, Hong et al found that adjuvant whole-brain radiotherapy (WBRT) was not associated with a significant benefit in distant intracranial control vs observation after local treatment of patients with one to three melanoma brain...

Lung Cancer

Addition of Metformin to Tyrosine Kinase Inhibitor Therapy in EGFR-Mutant NSCLC

In a single-center phase II trial reported in JAMA Oncology, Arrieta et al found that the addition of metformin to EGFR tyrosine kinase inhibitor therapy resulted in improved progression-free and overall survival in patients with non–small cell lung cancer (NSCLC) with an activating EGFR mutation.

...

Sarcoma

High-Dose Chemotherapy vs Standard Chemotherapy and Whole-Lung Irradiation in Ewing Sarcoma With Pulmonary Metastases

As reported in the Journal of Clinical Oncology by Dirksen et al, the R2Pulm trial showed no significant event-free or overall survival benefit with busulfan/melphalan high-dose chemotherapy with autologous stem cell rescue (BuMel) vs standard chemotherapy with whole-lung irradiation in patients...

Multiple Myeloma
Issues in Oncology

Impact of Treating Facility, Provider Volume, and Patient-Sharing in the Treatment of Patients With Multiple Myeloma

A study published by Freeman et al in JNCCN—Journal of the National Comprehensive Cancer Network found that generally, providers with more experience treating multiple myeloma have better outcomes than those with more limited experience. Providers who saw the most cases were more likely to be...

Breast Cancer

Recent Trends in the Treatment and Prognosis of Male Breast Cancer

A recent analysis published by Yadav et al in Cancer reviewed how the treatment of male breast cancer has evolved over the years 2004 to 2014. In addition, certain patient-, tumor-, and treatment-related factors were found to be linked with better survival.

Male breast cancer comprises 1% of all...

Lung Cancer
Immunotherapy

ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLC

As reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA4) and simultaneously in The New England Journal of Medicine by Matthew D. Hellmann, MD, and colleagues, the phase III CheckMate 227 trial has shown that nivolumab plus ipilimumab improved overall survival vs ...

Colorectal Cancer
Immunotherapy

ESMO 2019: Interim Analysis of the BEACON CRC Trial

In an interim analysis of the phase III BEACON CRC trial reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA32) and in The New England Journal of Medicine, Scott Kopetz, MD, PhD, and colleagues found improved overall survival and overall response rate in...

Hepatobiliary Cancer

Addition of Doxorubicin to Sorafenib in Advanced Hepatocellular Carcinoma

As reported in JAMA Oncology by Ghassan K. Abou-Alfa, MD, and colleagues, the phase III Alliance/CALGB 80802 trial has shown no progression-free or overall survival benefit with the addition of doxorubicin to sorafenib in patients with advanced hepatocellular carcinoma. The study was stopped early...

Solid Tumors

Use of Adjuvant Chemotherapy for Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features

In a Children’s Oncology Group study (COG ARET0332) reported in the Journal of Clinical Oncology, Chévez-Barrios et al found discrepancies between central and institutional identification of high-risk features of enucleated unilateral retinoblastoma, and that use of adjuvant chemotherapy based on...

Issues in Oncology
Lung Cancer

Preclinical Study Finds Exposure to E-Cigarette Smoke Increased Risk of Cancer in Mice

Exposure to e-cigarette smoke caused mice to develop lung cancer, according to findings from a preclinical study published by Tang et al in the Proceedings of National Academy of Sciences of the United States of America (PNAS).

The study found that 9 of 40 mice (22.5%) exposed to e-cigarette smoke...

Skin Cancer

Association Between Cutaneous Squamous Cell Carcinoma Risk and Indoor Tanning Use in Women

In a Norwegian study published by Lergenmuller et al in JAMA Dermatology, researchers found evidence of a dose-response association between lifetime indoor tanning and risk of development of cutaneous squamous cell carcinoma in women. The association was the same regardless of duration of use and...

Prostate Cancer

ESMO 2019: Cabazitaxel vs Abiraterone or Enzalutamide in Previously Treated Metastatic Castration-Resistant Prostate Cancer

As reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA13) and simultaneously published in The New England Journal of Medicine by Ronald de Wit, MD, and colleagues, the phase III CARD trial has shown improved imaging-based progression-free survival and overall...

Gynecologic Cancers

ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Serous Ovarian Cancer

In the phase III VELIA/GOG-3005 trial—reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA3) and simultaneously published in The New England Journal of Medicine—Robert L. Coleman, MD, and colleagues found that the use of the poly (ADP-ribose) polymerase inhibitor ...

Skin Cancer
Lymphoma
Immunotherapy

Pembrolizumab for Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome

In a phase II study reported in the Journal of Clinical Oncology, Khodadoust et al found that pembrolizumab was active in patients with advanced relapsed or refractory mycosis fungoides or Sézary syndrome.

In the U.S.-based multicenter trial, 24 patients with advanced mycosis fungoides (n = 9) or...

Gastrointestinal Cancer

Individual Patient Meta-analysis of Microsatellite Instability as a Prognostic Marker in Resectable Gastric Cancer

In an individual patient data meta-analysis reported in the Journal of Clinical Oncology, Pietrantonio et al found that microsatellite instability (MSI) status was a strong prognostic marker in patients with resectable gastric cancer.

The study involved data from 1,556 patients with resectable...

Breast Cancer

Addition of Ovarian Function Suppression to Ongoing Tamoxifen in Premenopausal Breast Cancer

In a phase III trial reported in the Journal of Clinical Oncology,  Kim et al found that the addition of 2 years of ovarian function suppression during ongoing tamoxifen treatment improved disease-free survival vs 5 years of tamoxifen alone in patients with estrogen receptor–positive breast cancer...

Gynecologic Cancers

ESMO 2019: Molecular Classification for Adjuvant Treatment in Women With High-Risk Endometrial Cancer

A study by Creutzberg et al investigated the survival outcome of combined adjuvant chemotherapy and radiotherapy vs radiotherapy alone in women with endometrial cancer with high-risk features. The researchers found that 5-year recurrence-free survival varied according to a patient’s specific...

Lung Cancer

ESMO 2019: Liquid Biopsy to Determine Best Treatment for Patients With NSCLC

Patients with advanced lung cancer might soon be offered a blood test that could help decide the best treatment for them, instead of relying on tumor biopsy analysis. New data from the BFAST trial presented by Gadgeel et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract ...

Prostate Cancer
Bladder Cancer
Hematologic Malignancies
Breast Cancer
CNS Cancers
Leukemia
Skin Cancer

FDA Pipeline: Advances in Prostate Cancer, Urothelial Cancer, Myelofibrosis, and More

In the past few weeks, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions in prostate cancer, urothelial cancer, myelofibrosis, breast cancer, pediatric brain cancer, leukemia, and skin cancer.

Breakthrough Therapy Designation for Niraparib in Metastatic...

Pancreatic Cancer

ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer

Induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) followed by surgical exploration induced high conversion rates in patients with locally advanced pancreatic cancer, and conversion was associated with...

Skin Cancer
Immunotherapy

ESMO 2019: 3-Year Results From CheckMate 238: Adjuvant Nivolumab vs Ipilimumab in Advanced Melanoma

Superior recurrence-free survival benefit was observed with nivolumab vs ipilimumab—and was consistent across disease stage, programmed cell death ligand 1 (PD-L1) expression levels, and BRAF mutation status—in patients with resected stage III/IV melanoma and a high risk of recurrence, according to ...

Colorectal Cancer

Reduced Risk of Recurrence and Improved Long-Term Outcome With Complete Mesocolic Excision in Right-Sided Colon Cancer

In a Danish population-based cohort study reported in The Lancet Oncology, Bertelesen et al found that complete mesocolic lymph node excision was associated with reduced risk of recurrence vs noncomplete excision approaches among patients with stage I to III right-sided colon adenocarcinomas. 

...

Gynecologic Cancers

Time Without Symptoms or Toxicity After Niraparib Maintenance Therapy in Recurrent Ovarian Cancer

In a study reported in the Journal of Clinical Oncology, Ursula A. Matulonis, MD, and colleagues found that niraparib maintenance therapy was associated with increased time without symptoms or toxicity (TWiST) vs routine surveillance among women with platinum-sensitive recurrent ovarian cancer in...

Immunotherapy

ESMO 2019: Study Suggests Difference in Response to Immunotherapy Regimens Between Sexes

A meta-analysis of 16 phase III randomized clinical trials evaluating programmed cell death protein 1/ligand 1 (PD-1/-L1) inhibitors either alone or in combination with chemotherapy for solid tumors has found that women derived significantly greater benefit from the addition of chemotherapy to...

Bladder Cancer
Immunotherapy

ESMO 2019: IMvigor130: Addition of Atezolizumab to Platinum-Based Chemotherapy in Advanced Urothelial Carcinoma

Patients with locally advanced or metastatic urothelial carcinoma demonstrated prolonged progression-free survival with the addition of atezolizumab to first-line platinum-based chemotherapy vs treatment with chemotherapy alone, according to phase III data from the IMvigor130 study presented by...

Solid Tumors

ESMO 2019: Lenvatinib for Advanced Thymic Carcinoma

Patients with thymic carcinoma that has progressed following treatment with platinum-based chemotherapy may benefit from treatment with lenvatinib, according to findings from a phase II study reported by Itoh et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract ...

Head and Neck Cancer
Geriatric Oncology

ESMO 2019: Personalized Treatment for Head and Neck Cancer Based on Geriatric Assessment

Fit elderly patients aged 70 years and older with head and neck squamous cell carcinoma were able to undergo rigorous treatment that provided benefit similar to that observed in younger patients. However, elderly patients with head and neck squamous cell carcinoma classified by geriatric assessment ...

Lung Cancer

ESMO 2019: ASCEND-7: Ceritinib for Patients With ALK-Positive NSCLC Metastatic to the Brain

Patients with ALK-positive non–small cell lung cancer (NSCLC) that was metastatic to the brain at baseline demonstrated whole-body, intracranial, and extracranial responses following treatment with ceritinib, according to findings from the phase II ASCEND-7 study presented by Chow et al at the...

Thyroid Cancer

ESMO 2019: LIBRETTO-001 Trial of Selpercatinib in RET Fusion–Positive Thyroid Cancer

Patients with advanced RET fusion–positive thyroid cancer and RET-mutant medullary thyroid cancer had high rates of response following treatment with selpercatinib, according to findings from the phase I/II LIBRETTO-001 trial presented by Wirth et al at the European Society for Medical Oncology...

Breast Cancer

ESMO 2019: BROCADE 3: Veliparib Plus Carboplatin/Paclitaxel in Patients With HER2-Negative, Germline BRCA-Mutated Advanced Breast Cancer

Patients with advanced or metastatic HER2-negative breast cancer with a germline BRCA mutation demonstrated significantly improved progression-free survival (PFS) with the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to chemotherapy (comprised of carboplatin/paclitaxel)...

Hepatobiliary Cancer

ESMO 2019: Ivosidenib in IDH1-Mutated Advanced Cholangiocarcinoma

Patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation showed clinical benefit and improved progression-free survival (PFS) when treated with ivosidenib vs placebo, according to results presented by Ghassan K. Abou-Alfa, MD, at the European Society for Medical...

Palliative Care
Issues in Oncology

Is Implicit Bias Contributing to Time Disparities in Goals-of-Care Conversations With Minority Patients?

GUEST EDITOR

Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development.

It has been well...

Colorectal Cancer

ESMO 2019: ctDNA as a Marker for Disease-Free Survival With Oxaliplatin Treatment in Stage III Colon Cancer

Patients with advanced colon cancer and plasma samples containing circulating tumor DNA (ctDNA) were less likely to achieve 2-year disease-free survival with oxaliplatin-based adjuvant treatment than patients with ctDNA-negative samples, according to findings presented at the European Society for...

Gynecologic Cancers

ESMO 2019: Studies Show PARP Inhibitors Improve Survival, Reduce Risk of Disease Recurrence or Death in Newly Diagnosed Ovarian Cancer

Two studies presented at the European Society for Medical Oncology (ESMO) 2019 Congress showed the efficacy of poly ADP ribose polymerase (PARP) inhibitors in patients with newly diagnosed ovarian cancer.

In the PRIMA/ENGOT-OV26/GOG-3012 study, presented by González Martín et al (Abstract LBA1;...

Solid Tumors

ESMO 2019: Tailored Treatment vs Empiric Chemotherapy for Cancer of an Unknown Primary

Treatment tailored by comprehensive molecular gene-expression analysis of tumors from patients with carcinomas of an unknown primary site did not improve progression-free survival vs empiric chemotherapy consisting of cisplatin/gemcitabine. Fizazi et al presented these findings at the European...

Skin Cancer
Immunotherapy

ESMO 2019: 5-Year Survival and Response With Nivolumab/Ipilimumab in Advanced Melanoma

An update of results of the phase III CheckMate 067 trial at 5 years presented by Larkin et al at the European Society for Medical Oncology (ESMO) 2019 Congress showed that both nivolumab in combination with ipilimumab and nivolumab alone provided significant improvements in overall survival,...

Prostate Cancer

ESMO 2019: Men With Prostate Cancer May Avoid Postoperative Radiotherapy, Study Finds

Men with prostate cancer may be spared radiotherapy after surgery, according to late-breaking results of the RADICALS-RT trial presented by Parker et al at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA49_PR). The study answers a long-standing question about whether...

Hepatobiliary Cancer
Immunotherapy

ESMO 2019: First-Line Immunotherapy Shows Clinical Benefit in Advanced Hepatocellular Carcinoma

New data have shown a trend toward clinically meaningful improvements in survival and response rates and a favorable safety profile with first-line immunotherapy compared to current standard treatment for advanced hepatocellular carcinoma (HCC).

The data, reported by Yau et al at the European...

Immunotherapy
Issues in Oncology

Prior Antibiotic Treatment and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

In a study presented in a brief report in JAMA Oncology, Pinato et al found that past—but not concurrent—use of broad-spectrum antibiotic therapy was associated with poorer treatment outcomes in patients receiving immune checkpoint inhibitors for various cancers in routine clinical practice.

As...

Issues in Oncology

FDA Announces Voluntary Recall of Certain Ranitidine Capsules

This week, the U.S. Food and Drug Administration (FDA) alerted health-care professionals and patients of a voluntary recall of 14 lots of prescription ranitidine capsules distributed by Sandoz Inc, used to decrease the amount of acid created by the stomach. This recall is due to a nitrosamine...

Skin Cancer
Immunotherapy

Treatment-Free Survival as an Outcome Measure of Nivolumab/Ipilimumab Therapy in Advanced Melanoma

In a pooled analysis reported in the Journal of Clinical Oncology, Regan et al evaluated treatment-free survival as an outcome measure among patients with advanced melanoma receiving nivolumab/ipilimumab or either agent alone in the CheckMate 067 and 069 trials.

Study Details

The study involved...

Head and Neck Cancer

Addition of Induction Gemcitabine/Cisplatin to Chemoradiotherapy in Nasopharyngeal Carcinoma

In a Chinese phase III trial reported in The New England Journal of Medicine, Zhang et al found that the addition of gemcitabine/cisplatin induction chemotherapy to standard platinum-based chemoradiotherapy improved recurrence-free survival vs chemoradiotherapy alone in locoregionally advanced...

Gynecologic Cancers
Immunotherapy

Immunotherapy for Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma

As reported in the Journal of Clinical Oncology by Naumann et al, the phase I/II CheckMate 358 trial found that nivolumab showed activity in a cohort of patients with recurrent or metastatic cervical, vaginal, or vulvar squamous cell carcinoma.  

Study Details

A total of 24 patients were enrolled...

CNS Cancers

Risk of Subsequent Neoplasms in Childhood Cancer Survivors With Neurofibromatosis Type 1

In a study reported in the Journal of Clinical Oncology, Smita Bhatia, MD, MPH, and colleagues found that childhood cancer survivors with pathogenic neurofibromatosis type 1 (NF1) variants had a greater risk of subsequent neoplasms than survivors without NFI variants and that radiotherapy was...

Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Issues in Oncology

AACR Disparities: Uninsured/Underinsured, Lower-Income, and/or Minority Patients More Likely to Receive Cancer Diagnosis After ED Visit

Medicare patients from lower socioeconomic groups and several ethnic minority groups were more likely to be diagnosed with cancer following an emergency department visit, according to results of a study presented at the 12th American Association for Cancer Research Conference on The Science of...

Gynecologic Cancers

Origin and Taxonomy of Mucinous Ovarian Cancer

An international study has revealed the origin of mucinous ovarian cancer, confirming that unlike other types of ovarian cancer, this cancer arises from benign and borderline precursors at the ovaries and are not extraovarian metastases. These findings were published by Cheasley et al in Nature...

Lymphoma

Effect of MYC Rearrangement and Translocation Partner in DLBCL

In a Lunenburg Lymphoma Biomarker Consortium study reported in the Journal of Clinical Oncology, Rosenwald et al found that MYC rearrangement was associated with poorer outcomes in diffuse large B-cell lymphoma (DLBCL) when accompanied by rearrangement of BCL2 and/or BCL6 and an immunoglobulin...

Colorectal Cancer

AACR Disparities: Mortality Rate for Colorectal Cancer Higher for Blacks Than for Whites in Major U.S. Cities

According to the American Cancer Society, excluding skin cancers, colorectal cancer is the third most common cancer in both men and women in the United States and the second most common cause of cancer deaths. This year, it is expected that more than 51,000 people will die of the malignancy....

Issues in Oncology

AACR Disparities: Survey Finds LGBTQI+ Latinx Community Members Are Not Receiving Tailored Cancer-Related Information and Care

According to the National LGBT Cancer Network, lesbian, gay, bisexual, transgender, queer/questioning, and intersex (LGBTQI+) individuals are at greater risk for several cancers, including cervical, oral, and breast cancers.

A survey to assess LGBTQI+ Latinx communities’ experience with cancer...

Hematologic Malignancies

Risk Model for Advanced Systemic Mastocytosis

As reported in the Journal of Clinical Oncology, Jawhar et al have developed a risk model for advanced systemic mastocytosis that differentiates low-, intermediate-, and high-risk disease.

Study Details

The study included 383 patients with advanced systemic mastocytosis from the German Registry on ...

Issues in Oncology
Prostate Cancer

Adoption of Conservative Management of Prostate Cancer Among Urology Practices

In a study reported in the Journal of Oncology Practice, Modi et al found that the difference in the rates of use of conservative management of prostate cancer widened between lower-use and higher-use urology practices between 2014 and 2018.

Study Details

Use of a sample of Medicare claims...

Breast Cancer
Issues in Oncology

Two Studies Show Variation in Effectiveness of Mammography Across Populations

Two recent studies showed varying degrees of the effectiveness of mammography in different populations. In a report published in Radiology, Gao et al showed that in men at high risk for breast cancer, screening mammography may be able to increase the rate of detection of early-stage disease....

Hepatobiliary Cancer

Sorafenib Plus Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma

During the past decade, scientists began to test whether the addition of transarterial chemoembolization (TACE) to treatment with sorafenib could increase survival in patients with advanced hepatocellular carcinoma. Scientists from Taiwan and Japan performed the first large, national-level,...

Lymphoma

Final Results of a Phase III Trial of PET-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma

As reported in the Journal of Clinical Oncology by Fuchs et al, final results of the German Hodgkin Study Group phase III HD16 trial in early-stage favorable Hodgkin lymphoma indicate that combined modality therapy (CMT) is associated with better progression-free survival vs chemotherapy alone...

Colorectal Cancer
Genomics/Genetics

Patients With Metastatic Colorectal Cancer Carrying Class 3 BRAF Mutations May Respond to Anti-EGFR Therapy

Although between 8% and 12% of patients with metastatic colorectal cancer harbor a BRAF gene mutation, not all non-V600 BRAF alterations respond to EGFR antibody treatment, according to findings from a study by Yaeger et al published in Clinical Cancer Research. The study investigated whether...

Global Cancer Care

Cancer Survival, Incidence, and Mortality in Seven High-Income Countries From 1995–2014

As reported by Arnold and colleagues in The Lancet Oncology, the International Cancer Benchmarking Partnership Cancer Survival in High-Income Countries (SURVMARK-2) project has found general improvement in cancer survival between 1995 and 2014 in Australia, Canada, Denmark, Ireland, New Zealand,...

Symptom Management

International Guidelines for Treatment and Prophylaxis of VTE in Patients With Cancer

The 2019 International Initiative on Thrombosis and Cancer (ITAC) has issued updated clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer. They were published by Farge et al in The Lancet Oncology.

The guidelines consist of...

Leukemia

SOHO 2019: Asciminib/Imatinib in Patients With Previously Treated CML

In a phase I trial, the combination of the BCR-ABL1 inhibitor asciminib and the small-molecule kinase inhibitor imatinib showed preliminary efficacy, safety, and tolerability in patients with chronic myeloid leukemia (CML) resistant to or intolerant of treatment with two or more prior tyrosine...

Genomics/Genetics
Immunotherapy

POLE/POLD1 Mutations Across Cancer Types and Association With Immune Checkpoint Inhibitor Therapy Outcomes

In a research letter published in JAMA Oncology, Wang et al identified the frequency of mutations in DNA polymerase epsilon (POLE) and delta 1 (POLD1) genes across cancer types and found that these mutations were associated with better survival outcomes among patients receiving immune checkpoint...

Colorectal Cancer

Addition of Selective Internal Radiotherapy to Chemotherapy May Improve Resectability of Colorectal Cancer Liver Metastases

In a report published by Garlipp et al in the British Journal of Surgery, the addition of selective internal radiotherapy (SIRT) to modified FOLFOX6-based chemotherapy (mFOLFOX6; oxaliplatin/leucovorin/fluorouracil) improved the resectability of initially unresectable colorectal cancer liver...

Prostate Cancer

ASTRO 2019: Long-Term Hormone Therapy May Increase Other-Cause Mortality in Men With Prostate Cancer Receiving Early Salvage Radiotherapy

Findings from the randomized phase III NRG Oncology/RTOG 9601 trial were initially reported in 2017, and showed that the addition of 2 years of antiandrogen therapy to postsurgical radiation treatment for men with recurrent prostate cancer increased their long-term overall survival rate. That study ...

Lung Cancer
Immunotherapy

ASTRO 2019: Patterns of Disease Progression in Patients With Unresectable Stage III NSCLC: Analysis of the PACIFIC Trial

Andreas Rimner, MD, of Memorial Sloan Kettering Cancer Center, presented an update of the landmark PACIFIC trial at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO) (Abstract LBA-6).

In earlier reports from the randomized phase III trial, Antonia et al had evaluated...

Gynecologic Cancers
Immunotherapy

Bevacizumab/Niraparib vs Niraparib Alone for Platinum-Sensitive Recurrent Ovarian Cancer

In the phase II NSGO-AVANOVA2/ENGOT-ov24 trial reported in The Lancet Oncology, Mansoor Raza Mirza, MD, and colleagues found that the combination of bevacizumab plus niraparib prolonged progression-free survival vs niraparib alone in women with platinum-sensitive recurrent ovarian cancer.

Study...

Head and Neck Cancer
Symptom Management

ASTRO 2019: Machine-Learning Model May Accurately Predict Radiation Side Effects in Patients With Head and Neck Cancers

A study by Reddy et al investigating the use of a machine-learning model to predict which patients with head and neck cancer being treated with radiation may experience significant weight loss, feeding tube placement, and unplanned hospitalization has found that the model accurately identified the...

Issues in Oncology
Pain Management

Access to Cannabis Products for Patients With Cancer in a State With Restrictive Medical Marijuana Laws

Results of a survey reported by Singh et al in the Journal of Oncology Practice found that a population of primarily patients with cancer enrolled in Georgia’s medical marijuana program reported concerns about the legality of marijuana-related products and their ability to obtain the products.

As...

Prostate Cancer

ASTRO 2019: ORIOLE Trial: Observation vs SABR for Oligometastatic Prostate Cancer

The randomized, phase II ORIOLE trial studying the efficacy of targeted high-dose radiation for men with oligometastatic prostate cancer has shown that stereotactic ablative radiation (SABR) is an effective and safe option for patients who wish to delay hormone-suppression therapy. Data from the...

Lung Cancer
Immunotherapy

ASTRO 2019: SBRT After Disease Progression on Immunotherapy Increases PFS in Patients With Metastatic NSCLC

Non–small cell lung cancer (NSCLC) accounts for the vast majority of all lung cancers—between 80% and 85% of those diagnosed in the United States—and is among the most deadly cancers for both men and women, exceeding the mortality rate of colon, breast, and pancreatic cancers combined.

The results...

Issues in Oncology
Gynecologic Cancers
Health-Care Policy

ASTRO 2019: Effect of Closure of Women’s Health Clinics From 2010 to 2013 on Cervical Cancer Screening and Detection

Following the closure of nearly 100 women’s health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer; more women were diagnosed with advanced stages of the disease; and disease mortality rates rose. Findings from a new analysis combining several...

Hematologic Malignancies
Issues in Oncology

Single-Center Study of Human Herpesvirus 6B Detection in Bronchoalveolar Lavage Fluid After Hematopoietic Cell Transplantation

In a single-institution study reported in the Journal of Clinical Oncology, Hill et al found that detection of human herpesvirus 6B (HHV-6B) in bronchoalveolar lavage fluid was associated with increased mortality in recipients of allogeneic hematopoietic cell transplantation (HCT) with lower...

Breast Cancer
Survivorship
Symptom Management

Home-Based Exercise and Weight Loss Programs for Lymphedema Management in Overweight Breast Cancer Survivors

As reported in JAMA Oncology by Schmitz et al, the WISER Survivor trial showed no benefit of home-based exercise and weight loss programs on lymphedema outcomes vs facility-based lymphedema care among overweight breast cancer survivors.

Study Details

In the trial, 351 overweight breast cancer...

Breast Cancer
Issues in Oncology

FDA Issues Drug Safety Communication on Lung Inflammation Due to Treatment With CDK4/6 Inhibitors

On September 13, the U.S. Food and Drug Administration (FDA) issued a drug safety communication warning that palbociclib, ribociclib, and abemaciclib—used to treat some patients with advanced breast cancer—may cause rare but severe inflammation of the lungs. The agency approved new warnings about...

Gynecologic Cancers

Neoadjuvant Cisplatin/Gemcitabine Followed by Standard Chemoradiation in Locally Advanced Cervical Cancer

In a Brazilian single-center phase II trial reported in the Journal of Clinical Oncology, da Costa et al found that neoadjuvant cisplatin/gemcitabine followed by standard chemoradiation therapy with cisplatin did not improve outcomes vs chemoradiation therapy alone in locally advanced cervical...

Lung Cancer
Immunotherapy

WCLC 2019: KEYNOTE-024 Survival Update Shows Benefit With Pembrolizumab vs Chemotherapy in Advanced NSCLC

First-line pembrolizumab monotherapy provides durable long-term overall survival benefit compared to chemotherapy in patients with advanced non–small cell lung cancer (NSCLC), according to data from the KEYNOTE-024 trial presented by Martin Reck, MD, PhD, at the International Association for the...

Lung Cancer

WCLC 2019: Selpercatinib in RET Fusion–Positive NSCLC

Patients with RET fusion–positive non–small cell lung cancer (NSCLC) comprise up to 2% of all NSCLC cases, but there are no targeted therapies currently approved for patients with this form of lung cancer. Selpercatinib (also known as LOXO-292) is an oral and highly selective investigational drug...

Lung Cancer

WCLC 2019: Video-Assisted Thoracic Surgery vs Open Surgery in Lung Cancer

Video-assisted thoracic surgery was associated with lower in-hospital complications and a shorter length of stay compared with open surgery among British patients who were diagnosed with early-stage lung cancer, according to research presented by Lim et al at the International Association for the...

Lung Cancer
Multiple Myeloma
Sarcoma

FDA Pipeline: Breakthrough Therapy Designation in Lung Cancer, Orphan Drug Designations in Myeloma and Soft-Tissue Sarcoma

Recently, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to tepotinib for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations, and Orphan Drug designations to novel chimeric antigen receptor T-cell therapies in both multiple myeloma ...

Lung Cancer
Immunotherapy

WCLC 2019: Final Overall Survival Results of IMpower131 Trial in Advanced Squamous NSCLC

Patients with stage IV squamous non–small cell lung cancer (NSCLC) with high programmed cell death ligand 1 (PD-L1) expression treated with atezolizumab and chemotherapy experienced longer overall survival rates than those treated with chemotherapy alone. The data from the IMpower131 trial were...

Lung Cancer

WCLC 2019: Autoantibody Diagnostic Test Followed by CT Imaging May Improve Diagnosis, Reduce Mortality in Lung Cancer

A combination of the EarlyCDT-Lung Test followed by computed tomography (CT) imaging in Scottish patients at risk for lung cancer resulted in a significant decrease in late-stage diagnosis of lung cancer and may decrease lung cancer–specific mortality, according to research presented at...

Lung Cancer

WCLC 2019: BioMILD Trial of Blood MicroRNA Plus Low-Dose CT to Reduce CT Repeats in Lung Cancer Screening

Researchers from Milan reported that using a blood microRNA assay accompanied by low-dose computed tomography (CT) screening is safe and effective in screening patients for lung cancer. The results were shared at the International Association for the Study of Lung Cancer (IASLC) 2019 World...

Issues in Oncology

WCLC 2019: Declaration From IASLC on Tobacco Cessation After Cancer Diagnosis

The International Association for the Study of Lung Cancer (IASLC) used the platform of the 2019 World Conference on Lung Cancer (WCLC) to call attention to the importance of tobacco cessation after cancer diagnosis and urged all physicians to screen patients with cancer for tobacco use and...

Lung Cancer
Immunotherapy

WCLC 2019: Pooled Analysis of CheckMate 017 and 057: 5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC

Pooled data on two clinical trials demonstrated patients with previously treated non–small cell lung cancer (NSCLC) treated with nivolumab had a greater than fivefold increase in 5-year overall survival rate compared to treatment with the chemotherapy docetaxel. Scott Gettinger, MD, of Yale...

Lung Cancer
Immunotherapy

WCLC 2019: CASPIAN Trial Finds Addition of Durvalumab to Chemotherapy Improves Overall Survival in Patients With Extensive-Stage SCLC

The addition of durvalumab to chemotherapy improved overall survival in patients with extensive-stage small cell lung cancer (SCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) (Abstract PL02.11)....

2019 Lasker Awards for Basic and Clinical Medical Research and Public Service Announced

On September 10, The Lasker Foundation announced the winners of its 2019 Lasker Awards: Max D. Cooper, MD, of Emory University, and Jacques Miller, AC, FRS, FAA, of the Walter and Eliza Hall Institute of Medical Research, will receive the Albert Lasker Basic Medical Research Award; H. Michael...

Breast Cancer
Immunotherapy

T-DM1 Plus Neratinib in Metastatic HER2-Positive Breast Cancer

In the phase Ib NSABP Foundation Trial FB-10 reported in the Journal of Clinical Oncology, Jame Abraham, MD, and colleagues found evidence of activity of the combination of ado-trastuzumab emtansine (T-DM1) plus neratinib in metastatic HER2-positive breast cancer and identified the dose of the...

Solid Tumors
Immunotherapy

Pamiparib Plus Tislelizumab in Advanced Solid Tumors

In an Australian phase Ia/b trial reported in The Lancet Oncology, Friedlander et al found evidence of activity of the combination of the poly (ADP-ribose) polymerase inhibitor pamiparib and the programmed cell death protein 1 inhibitor tislelizumab in patients with previously treated advanced...

Lung Cancer

WCLC 2019: Screening Efficacy of PLCOm2012 vs USPSTF Criteria

Researchers reported that a prospective trial comparing two screening methods for patients at risk of developing lung cancer found that a model used by Canadian, Australian, and European public health organizations detected more cancers than the screening model used by the United States Preventive...

Lung Cancer
Issues in Oncology

WCLC 2019: Survey Findings on Evidence-Based Guidelines for Molecular Testing in Lung Cancer

One-third of those who responded to a survey reported they are unaware of evidence-based guidelines that support the use of molecular testing in lung cancer, according to results from the International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung...

Lung Cancer
Immunotherapy

WCLC 2019: First-Line Nivolumab/Ipilimumab in Special Populations With NSCLC

First-line therapy consisting of nivolumab plus ipilimumab showed a consistent safety profile in special populations with advanced non–small cell lung cancer (NSCLC), according to research presented by Fabrice Barlesi, MD, PhD, of Aix-Marseille University, Assistance Publique Hôpitaux de Marseille...

Lung Cancer

WCLC 2019: Safety and Toxicity of AMG 510 for KRAS G12C–Mutated, Advanced NSCLC

In a clinical trial testing the toxicity of a KRAS inhibitor, the treatment demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. The research was presented by Govindan et al at the...

Lung Cancer
Immunotherapy

WCLC 2019: Two Studies Show Tumor Mutational Burden Not Associated With Pembrolizumab Efficacy in NSCLC

At the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC), two presentations showed that tumor mutational burden is not associated with the efficacy of pembrolizumab in combination with chemotherapy in patients with non–small cell lung cancer...

Gynecologic Cancers

2019 Quality Care: Improving Caregiver Identification and Support in a Gynecologic Oncology Practice

In a study reported at the ASCO Quality Care Symposium and simultaneously published in the Journal of Oncology Practice, Campbell et al found that an ASCO Quality Training Program Project—the Plan-Do-Study-Act (PDSA) initiative—resulted in improvement in primary caregiver identification and...

Symptom Management
Pain Management

2019 Quality Care: Improving Documentation of Pain and Constipation Assessment and Management

In a study reported at the ASCO Quality Care Symposium and simultaneously published in the Journal of Oncology Practice, Chineke et al found that a Quality Oncology Practice Initiative (QOPI) initiated in collaboration with ASCO at the Georgia Cancer Center for Excellence (GCCE) at Grady Health...

Issues in Oncology

2019 Quality Care: Intervention to Improve Rates of Resident Advanced Care Planning Documentation

In a single-center study reported at the ASCO Quality Care Symposium and simultaneously published in the Journal of Oncology Practice, Switzer et al found that an intervention consisting of a resident training module and use of a best practice alert (BPA) in electronic medical records (EMRs)...

Gynecologic Cancers
Immunotherapy

Avelumab for Mismatch Repair–Deficient and Mismatch Repair–Proficient Endometrial Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Panagiotis A. Konstantinopoulos, MD, PhD, and colleagues found evidence of promising activity of the programmed cell death ligand 1 (PD-L1) inhibitor avelumab in mismatch repair–deficient (MMRD) recurrent or persistent endometrial...

Hepatobiliary Cancer

Real-Time ctDNA Evaluation in Patients With Hepatocellular Carcinoma

In a study published in the Journal of Gastrointestinal Oncology, Mody et al described results from patients with hepatocellular carcinoma undergoing circulating tumor DNA (ctDNA) testing in a real-time clinical context. The authors wrote, “[ctDNA assessment] holds incredible promise for early...

Myelodysplastic Syndromes
Leukemia
Lung Cancer
Solid Tumors
Colorectal Cancer
Hepatobiliary Cancer

FDA Pipeline: Fast Track Designation in Myelodysplastic Syndrome and AML, Plus Multiple Breakthrough Designations

Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to magrolimab in myelodysplastic syndrome and acute myeloid leukemia (AML). The agency also granted Breakthrough Therapy designations in lung cancer and desmoid tumors, as well as Breakthrough Device designations...

Lymphoma

Tumor Immune Infiltration and Disease Progression in Follicular Lymphoma

In a study reported in the Journal of Clinical Oncology, Tobin et al found that low tumor immune infiltration—indicated by low programmed cell death ligand 2 (PD-L2) expression—was associated with earlier disease progression in follicular lymphoma.

As stated by the investigators, “Understanding the ...

Pancreatic Cancer

ASTRO Guideline on Use of Radiation Therapy for Patients With Pancreatic Cancer

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with pancreatic cancer, including when radiation treatments are appropriate, as well as the optimal dosing, timing, and...

Gynecologic Cancers

Does PTSD Increase the Risk of Developing Ovarian Cancer?

Women who experienced six or more symptoms of posttraumatic stress disorder (PTSD) at some point in life had a twofold greater risk of developing ovarian cancer compared with women who never experienced any PTSD symptoms. These findings were published by Roberts et al in Cancer Research.

The...

Lung Cancer
Immunotherapy

Does the Addition of Bevacizumab to Erlotinib in Advanced EGFR-Mutant NSCLC Improve PFS?

In a phase II trial reported in JAMA OncologyThomas E. Stinchcombe, MD, and colleagues found that the addition of bevacizumab to erlotinib did not significantly improve progression-free survival (PFS) in patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC).

Study Details

The...

Breast Cancer

Neoadjuvant Talazoparib for Operable BRCA-Mutated Breast Cancer

In a study reported in the Journal of Clinical Oncology, Jennifer K. Litton, MD, and colleagues found that 6 months of neoadjuvant talazoparib therapy resulted in a high rate of residual cancer burden (RCB) of 0 (pathologic complete response) in patients with stage I–III breast cancer with germline ...

Survivorship

Solid Organ Transplantation in Aging Survivors of Childhood Cancer

A retrospective analysis from the Childhood Cancer Survivor Study reported in The Lancet Oncology by Dietz et al found that the need for solid organ transplantation was infrequent in aging survivors of childhood cancer, with greater organ-specific risk being associated with particular therapeutic...

Issues in Oncology

Association Between Postdischarge Bleeding in Patients With Acute Coronary Syndrome and Subsequent Cancer Diagnosis

Bleeding during the first 6 months after discharge from the hospital for acute coronary syndrome may be linked to subsequent cancer diagnosis, according to research presented by Muñoz Pousa et al at the European Society of Cardiology Congress 2019 (Abstract P677).

“Our results suggest that patients ...

Issues in Oncology

New Report Finds Cancer Drugs Account for Over a Quarter of All New Drug Approvals in the United States

Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010—an increase from the 4% share they occupied in the 1980s, a newly completed analysis summarized in the most recent issue of the Tufts CSDD Impact Report.

From 1980 through 2018, the U.S. Food and Drug...

Issues in Oncology
Cost of Care

2019 Quality Care: Cost of Treatment, Prior Authorization of Treatment Plans May Cause Barriers to Care

Drug costs and requirements for prior authorization of treatment plans pose barriers to cancer treatment and can potentially affect outcomes for many patients, according to two studies that will be presented at the ASCO Quality Care Symposium.

The studies respectively examine how the high...

Issues in Oncology

2019 Quality Care: Socioeconomic Deprivation and Outcomes in Cancer Clinical Trials

In a study to be presented by Unger et al at the 2019 ASCO Quality Care Symposium, researchers found patients living in socioeconomically deprived areas were more likely to experience worse survival in cancer clinical trials, even after adjustments for race and insurance (Abstract 162).

Methods

...

Issues in Oncology

2019 Quality Care: End-of-Life Care in Western Washington State vs Alberta, Canada

In a study to be presented by Khaki et al at the 2019 ASCO Quality Care Symposium, researchers found more aggressive end-of-life measures—including use of chemotherapy and admissions to the intensive care unit (ICU)—were employed in the last 30 days of life in Western Washington state vs Alberta,...

Kidney Cancer
Immunotherapy

Individualized Axitinib Regimens After Immunotherapy for Advanced Renal Cell Carcinoma

In a phase II study reported in The Lancet Oncology, Ornstein et al found that individualized axitinib regimens showed activity in patients with locally recurrent or metastatic renal cell carcinoma who had previously received immune checkpoint inhibitor therapy, although the progression-free...

Leukemia
Survivorship

Risk of Infections in Survivors of Childhood Leukemia

In a study reported in the Journal of Clinical Oncology, Pelland-Marcotte et al found that survivors of childhood leukemia remained at significantly increased risk of infection compared with matched controls during an extended period following completion of treatment.  

Study Details

The...

Hematologic Malignancies
Issues in Oncology

Reducing Time to Chemotherapy Initiation in Patients Electively Admitted to a Hematologic Malignancy Service

In a single-institution study reported in the Journal of Oncology Practice, Galeas et al found that intervention in key drivers in the care process could reduce the time to initiation of chemotherapy in patients with elective admission to a hematologic malignancy service.

Study Details

The goal of...

Issues in Oncology

Analysis of HPV-Related Cancers Reported From 2012 to 2016

During 2012–2016, an average of approximately 34,800 human papillomavirus (HPV)-associated cancers were reported each year, according to a new study published by Senkomago et al in Morbidity and Mortality Weekly Report. Among the cancers probably caused by HPV, 92% are attributable to the HPV types ...

Issues in Oncology

FDA Recommendation on Duodenoscopes With Disposable Components

The U.S. Food and Drug Administration (FDA) has recommended that duodenoscope manufacturers and health-care facilities transition to different types of duodenoscopes that may pose less risk to patient safety. Specifically, because of challenges with cleaning these devices for reuse and persistent...

Breast Cancer

Pyrotinib or Lapatinib With Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer

In a Chinese phase II trial reported in the Journal of Clinical Oncology by Ma et al, the combination of the pan-ErbB inhibitor pyrotinib and capecitabine improved response rate vs lapatinib/capecitabine in women with HER2-positive relapsed or metastatic breast cancer previously treated with...

Genomics/Genetics
Leukemia

Chromosomal Abnormalities and Prognosis in NPM1-Mutant AML

In a study reported in the Journal of Clinical Oncology, Angenendt et al found that adverse-risk cytogenetics were associated with significantly poorer outcomes vs normal karyotype among patients with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation.

As stated by the...

Hepatobiliary Cancer
Pancreatic Cancer

Results From the TAPUR Study on Palbociclib for Pancreatic Cancer and Cholangiocarcinoma

New results from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study have demonstrated that single-agent palbociclib has no meaningful clinical activity in patients with CDKN2A-mutated or -deleted advanced pancreatic adenocarcinoma and cholangiocarcinoma. These findings were...

Issues in Oncology
Survivorship

What Role Do Physicians Play in Health Promotion Among Patients With Cancer?

A recent study published by Stump et al in Cancer indicated that certain physicians who care for patients with cancer do not often promote healthy lifestyle changes to cancer survivors, and they may fear that providing such advice would distress or overwhelm patients. The findings are noteworthy...

Kidney Cancer
Immunotherapy

Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCC

As reported in The Lancet Oncology by Robert J. Motzer, MD, and colleagues, extended follow-up of the phase III CheckMate 214 trial has shown a maintained survival benefit for first-line nivolumab/ipilimumab vs sunitinib in patients with previously untreated intermediate- or poor-risk advanced...

Issues in Oncology
Survivorship

High-Deductible Health Plans, Access to Care, and Emergency Department Use Among Cancer Survivors

In a study reported in the Journal of Oncology Practice, Zheng et al found that patients with cancer and high-deductible health plans had increases in delayed/forgone care, an effect that was attenuated for those with health savings accounts. Emergency department use was similar across insurance...

Issues in Oncology

Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students

A growing number of middle and high school students are being exposed to secondhand aerosols from electronic cigarettes (e-cigarettes) by living with or being around individuals who are vaping, according to data from a national survey. Such exposure increased rapidly in 2018 compared to the years...

Colorectal Cancer
Issues in Oncology

Text Instructions and Reminders May Improve Colonoscopy Adherence Rates

Having text message conversations with patients 1 week before they are scheduled for a colonoscopy decreased “no-show” rates, according to a recent study published by Mahmud et al in Health Education & Behavior. Through sending reminders and instruction, the team increased the rate of...

Neuroendocrine Tumors

Prognostic Tool for Advanced, Well-Differentiated Neuroendocrine Tumors Treated With a Somatostatin Analog

In the GETNE-TRASGU study (Spanish Group of Neuroendocrine and Endocrine Tumors Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) reported in the Journal of Clinical Oncology, Carmona-Bayonas et al developed a predictive model for progression-free survival in...

Breast Cancer
Issues in Oncology

FDA Issues Draft Guidance Encouraging Inclusion of Male Patients in Breast Cancer Clinical Trials

A draft guidance issued by the U.S. Food Drug Administration (FDA) on August 26 includes draft recommendations for the inclusion of male patients in breast cancer clinical trials.

Historically, males either have not been included in clinical trials for drugs to treat breast cancer, or inclusion of...

Pancreatic Cancer

Role of the YAP Regulatory Network in Pancreatic Ductal Adenocarcinoma

Researchers have decoded a chain of molecules that are critical for the growth and survival of pancreatic ductal adenocarcinoma. They say their findings, published by Murakami et al in Developmental Cell, suggest that inhibiting the YAP biologic network may effectively regress early-stage...

Hepatobiliary Cancer

Direct-Acting Antiviral Therapy and Reduced Mortality in Patients With Hepatitis C and a History of Liver Cancer

A study published by Singal et al in Gastroenterology demonstrated that treatment with antiviral therapy for hepatitis C reduced liver-related deaths by nearly 50% in patients with a history of liver cancer.

Previous Research

The finding builds on a December 2018 study by Singal et al also...

Immunotherapy
Skin Cancer

Phase Ib Trial of Toripalimab/Axitinib in Asian Patients With Advanced Mucosal Melanoma

In a Chinese phase Ib study reported in the Journal of Clinical Oncology, Sheng et al reported activity with the combination of the anti–programmed cell death protein 1 (PD-1) agent toripalimab plus axitinib in patients with metastatic mucosal melanoma.

As stated by the investigators, whereas...

lymphoma
prostate cancer

FDA Pipeline: Priority Reviews in Prostate Cancer, Mantle Cell Lymphoma

This week, the U.S. Food and Drug Administration (FDA) accepted new drug applications for enzalutamide in metastatic hormone-sensitive prostate cancer and zanubrutinib in relapsed or refractory mantle cell lymphoma, and granted both applications Priority Review. Priority Review for Enzalutamide in ...

skin cancer

Genomic Landscape of Merkel Cell Carcinoma

Researchers have developed the largest descriptive genomic analysis of patients with Merkel cell carcinoma to date. Their analysis, published by Knepper et al in Clinical Cancer Research, will provide important information to improve the care and treatment of patients with Merkel cell...

lung cancer

Addition of Pemetrexed/Carboplatin to Gefitinib in Advanced EGFR-Mutant NSCLC

In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Noronha et al found that the addition of pemetrexed/carboplatin to gefitinib improved progression-free and overall survival in first-line treatment of advanced EGFR-mutant non–small cell lung cancer...

head and neck cancer

Swallowing-Related Quality of Life After Radiotherapy vs Surgery for Oropharyngeal Squamous Cell Carcinoma

In the phase II ORATOR trial reported in The Lancet Oncology, Nichols et al found a statistical but not clinically meaningful improvement in swallowing-related quality of life outcomes 1 year after treatment with radiotherapy vs transoral robotic surgery and neck dissection in patients with...

bladder cancer

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

colorectal cancer

Oral Antibiotics and Risk of Colon or Rectal Cancer

In an extensive data mining analysis of British medical records, researchers found that taking even a single course of antibiotics might boost—albeit slightly—the risk of developing colon cancer, but not rectal cancer, a decade later. The findings, reported by Zhang et al in Gut,...

skin cancer

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

head and neck cancer

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

breast cancer
gynecologic cancer

USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer

As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended risk assessment and, if indicated, genetic counseling and testing for potentially harmful BRCA1/2 mutations in women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have...

head and neck cancer

Incidence of HPV-Associated Head and Neck Cancers in the United States

In a study by Mahal et al published in Cancer Epidemiology, Biomarkers & Prevention, researchers conducted a population-based assessment of the incidence and demographic burden of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma in the United States. The researchers...

issues in oncology

Racial Reporting and Representation in Oncology Trials

New research published by Loree et al in JAMA Oncology found that race and race subgroup analysis reporting does not occur frequently and that black and Hispanic populations are underrepresented in oncology trials that have led to U.S. Food and Drug Administration (FDA) approvals. The study raises...

breast cancer

Total Cumulative Chemotherapy Dose and Survival in Breast Cancer

Physicians should attempt to maintain full doses of chemotherapy, especially early in the course of treatment, for patients with intermediate- or high-risk breast cancer, according to research published by Veitch et al in JNCCN—Journal of the National Comprehensive Cancer Network. The...

pancreatic cancer

Adavosertib Plus Gemcitabine and Radiotherapy in Locally Advanced Pancreatic Cancer

In a phase I dose-escalation trial reported in the Journal of Clinical Oncology, Cuneo et al established the phase II dose of the Wee1 kinase inhibitor adavosertib in combination with gemcitabine and radiotherapy in locally advanced pancreatic cancer. Wee1 inhibition impedes DNA damage response and ...

skin cancer
symptom management

Risk of Cardiovascular Adverse Events in Patients With Melanoma Treated With Combined BRAF and MEK Inhibition vs BRAF Inhibition Alone

In a meta-analysis reported in JAMA Network Open, Mincu et al found that the risk of some types of cardiovascular adverse events was higher with combined BRAF and MEK inhibitor treatment vs BRAF inhibitor monotherapy in patients with melanoma. The meta-analysis included 2,317 patients in five...

lymphoma
immunotherapy

Nivolumab/Brentuximab Vedotin in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

As reported in the Journal of Clinical Oncology by Zinzani et al, findings in a phase II expansion cohort of the CheckMate 436 study indicated high levels of activity with the combination of nivolumab and brentuximab vedotin in relapsed or refractory primary mediastinal large B-cell lymphoma. As...

issues in oncology

Obesity-Associated Cancers and Age Demographics

A study published by Koroukian et al in JAMA Network Open found that from 2000 to 2016, incident obesity-associated cancers were increasingly found in younger age groups. The authors suggest that interventions are needed to reduce obesity and to implement individualized screening programs. The...

solid tumors
immunotherapy

T-Cell Receptor Gene Therapy in HPV-Associated Epithelial Cancers

In a first-in-human phase I/II study reported in the Journal of Clinical Oncology, Doran et al found that autologous genetically engineered T cells expressing a T-cell receptor directed against the human papillomavirus (HPV)16 E6 oncoprotein were capable of inducing tumor regression in metastatic,...

breast cancer

Neoadjuvant Letrozole Plus Taselisib or Placebo in Postmenopausal Women With ER-Positive, HER2-Negative Early Breast Cancer

In the phase II LORELEI trial reported in The Lancet Oncology, Saura et al found that the addition of the phosphatidylinositol-3 kinase (PI3K) inhibitor taselisib to neoadjuvant letrozole improved objective response rates but not pathologic complete response rates in women with estrogen receptor...

issues in oncology

Relationship Between Sleep Apnea and Cancer Risk in Women

Women with severe sleep apnea appear to also have an elevated risk of developing cancer, according to findings from a study by Pataka et al in the European Respiratory Journal. No causal relationship was demonstrated, but a link between nocturnal hypoxia in women and higher cancer risk was...

NCORP Expands to More Sites

The National Cancer Institute (NCI) has awarded 53 grants to researchers in the NCI Community Oncology Research Program (NCORP) to conduct multisite cancer clinical trials and cancer care delivery studies in their communities. In addition to seven research hubs, these NCI grants went to 32...

prostate cancer

Mortality Risk for Patients With Preexisting Cardiovascular Conditions Treated With Abiraterone Acetate or Enzalutamide

A new population-based study showed that novel oral androgen signaling–inhibitor therapies may be associated with an increased risk of death in patients with preexisting cardiovascular conditions. The research was published by Lu-Yao et al in European Urology. “Data from published ...

lung cancer
immunotherapy

Pooled Analysis of 4-Year Survival With Nivolumab Therapy in Patients With Previously Treated Advanced NSCLC

In an analysis reported in The Lancet Oncology, Antonia et al identified long-term survival rates with nivolumab therapy in patients with previously treated advanced non–small cell lung cancer (NSCLC). The pooled analysis included data from the CheckMate 017, 057, 063, and 003 trials, each...

pancreatic cancer

Surgical Resection Among Patients Receiving Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer

In an Italian prospective cohort study reported in JAMA Surgery, Maggino et al found that among patients receiving primary chemotherapy for newly diagnosed pancreatic ductal adenocarcinoma, conversion to surgical resection was achieved in 24% of those with borderline resectable disease and 9% of...

colorectal cancer

Does Exercise Improve Outcomes in Patients With Metastatic Colorectal Cancer?

Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study published by Guercio et al in the Journal of Clinical...

FDA OCE and Syapse Announce Research Collaboration Focused on Regulatory Use of Real-World Evidence

Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multiyear research collaboration agreement focused on the use of real-world evidence to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to...

leukemia
prostate cancer
gastrointestinal cancer

FDA Pipeline: Designation in CLL, New Drug Application in GIST, New Prostate Ablation System Receives 510(k) Clearance

Recently, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to acalabrutinib in chronic lymphocytic leukemia (CLL), accepted a new drug application for avapritinib in some types of gastrointestinal stromal tumors (GIST), and granted 501(k) clearance to market the...

hematologic malignancies

FDA Approves Fedratinib for Myelofibrosis

Today, the U.S. Food and Drug Administration (FDA) approved fedratinib (Inrebic) for adults with intermediate-2 or high-risk primary or secondary (postpolycythemia vera or postessential thrombocythemia) myelofibrosis. “Prior to today, there was one FDA-approved drug to treat patients with...

solid tumors

Relapse of Nonseminomatous Germ Cell Tumors During Active Surveillance

In a single-institution study reported in the Journal of Clinical Oncology, Hamilton et al found that relapses of clinical stage I nonseminomatous germ cell tumors (NSGCT) during postorchiectomy active surveillance most frequently occurred in the retroperitoneum and were cured by single-modality...

breast cancer

Circulating Tumor DNA and Relapse in Early-Stage Breast Cancer

In a study reported in JAMA Oncology, Garcia-Murillas et al found that detection of circulating tumor DNA (ctDNA) during follow-up after initial treatment for early breast cancer was associated with a high risk of relapse. Detection at diagnosis was also associated with poorer relapse-free...

issues in oncology

Single-Institution Study of Next-Generation Sequencing Outcomes in Patients With Cancer

In a single-institution retrospective study reported in the Journal of Oncology Practice, Davis and colleagues found that next-generation sequencing (NGS) tests resulted in changes in management in a small proportion of patients with cancer. Study Details The study involved retrospective review...

breast cancer
colorectal cancer
head and neck cancer
lung cancer

FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC

Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek) for adult and adolescent patients whose cancers have an NTRK (neurotrophic tyrosine receptor kinase) genetic fusion and for whom there are no effective treatments. Entrectinib was also...

hepatobiliary cancer

CD8-Positive, Ki67-Positive T Cells Producing Interferon Gamma as a Biomarker of Response to Sorafenib Therapy in Patients With Advanced HCC

Immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to sorafenib, a common chemotherapy used in the treatment of hepatocellular carcinoma (HCC). Their analysis of immune responses among patients receiving sorafenib, published by...

breast cancer
survivorship

Adiposity Distribution and Risk for Cardiovascular Disease Among Breast Cancer Survivors

In a study reported in the Journal of Clinical Oncology, Cespedes Feliciano et al found that increased visceral and intramuscular adiposity were associated with increased risk of cardiovascular disease among breast cancer survivors, independent of baseline risk factors and cancer treatment. Study...

lung cancer

Olaparib/Temozolomide Shows Activity in Patients With Relapsed Small Cell Lung Cancer

Small cell lung cancer accounts for approximately 15% of all lung cancers and has high metastatic potential and poor clinical outcomes. While untreated small cell lung cancers are usually highly sensitive to cytotoxic chemotherapy—with response rates of between 50% and 70%—patients...

prostate cancer

FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson's Disease Treatments Containing Entacapone

A U.S. Food and Drug Administration (FDA) review of additional data found no increased risk of prostate cancer with the use of entacapone to treat Parkinson’s disease. The FDA conducted this review after an earlier trial—the Stalevo Reduction in Dyskinesia Evaluation–Parkinson's...

issues in oncology

Age Disparities Among Patients in Cancer Clinical Trials and Patients With Cancer in the General Population

In a study reported in JAMA Oncology, Ludmir et al found that the median age of patients with common cancers enrolled in clinical trials was substantially lower than the median age of patients with the same cancers in the general population. Age disparity was greater in industry-funded trials....

prostate cancer

Are MRI-Assisted Biopsies More Effective Than Standard Ultrasound-Guided Biopsies Alone in the Detection of Prostate Cancer?

Using magnetic resonance imaging (MRI) to target biopsies is more effective at detecting prostate cancers that are likely to need treatment than standard ultrasound-guided biopsies alone, according to research published by Elwenspoek et al in JAMA Network Open. Prostate biopsies can cause side...

pancreatic cancer

Germline RABL3 Mutation May Increase Risk of Pancreatic Cancer Development

Scientists who studied a highly cancer-prone single family have identified a rare, inherited gene mutation that may raise the lifetime risk of pancreatic and other cancers. Their findings were published by Nissim et al in Nature Genetics. The discovery of the previously unknown mutation could lead ...

immunotherapy

Immune-Related Adverse Events Requiring Hospitalization in Patients Receiving Immune Checkpoint Inhibitors

In a single-center analysis reported in the Journal of Oncology Practice, Balaji et al found that immune-related adverse events associated with immune checkpoint inhibitor treatment often require hospitalization and multidisciplinary management. The study involved data from patients who had...

issues in oncology

Outcomes Among Older HIV-Positive Patients With Cancer in the United States

In a study reported in JAMA Oncology, Coghill et al found that outcomes are often worse among human immunodeficiency virus (HIV)-positive patients aged 65 years or older with cancer vs HIV-negative patients with cancer, after adjustment for the first courses of treatment. In the study,...

lung cancer

Addition of Cediranib to Cisplatin/Pemetrexed in Chemotherapy-Naive Unresectable Malignant Pleural Mesothelioma

In the phase II SWOG S0905 trial reported in the Journal of Clinical Oncology, Tsao et al found that the addition of the epidermal growth factor receptor and platelet-derived growth factor receptor inhibitor cediranib to cisplatin/pemetrexed was associated with limited benefit and greater toxicity...

hepatobiliary cancer

Outcomes in Nonalcoholic Fatty Liver Disease–Associated HCC

A recent study has found that nonalcoholic fatty liver disease–associated hepatocellular carcinoma (HCC) is associated with greater surgical morbidity and postresection liver failure, but long-term survival was better than in non–nonalcoholic fatty liver disease etiologies. These...

issues in oncology
survivorship

Access to Care and Quality of Life Among Sexual Minority Cancer Survivors

In a study published by Boehmer et al in Cancer, researchers found access to care among sexual minority cancer survivors was lacking. Moreover, sexual minority women with poor access to care, in particular, had a worse quality of life. Methods Researchers performed a secondary analysis of 4...

solid tumors

Pazopanib or Methotrexate/Vinblastine in Progressive Desmoid Tumors

In the French Sarcoma Group noncomparative phase II DESMOPAZ trial reported in The Lancet Oncology, Toulmonde et al found that the oral vascular endothelial growth factor (VEGF) receptor inhibitor pazopanib was active in adult patients with progressive desmoid tumors. As noted by the investigators, ...

cns cancers

Response- and Biology-Based Therapy for Pediatric Intermediate-Risk Neuroblastoma

As reported in the Journal of Clinical Oncology by Twist et al, use of reduced therapy for subsets of pediatric patients with intermediate-risk neuroblastoma in the Children’s Oncology Group (COG) study ANBL0531 did not affect the excellent overall survival rates observed in prior COG studies ...

pancreatic cancer

USPSTF Recommendation on Screening for Pancreatic Cancer in Asymptomatic Adults

As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF), in a reaffirmation of its 2004 recommendation, has recommended against screening for pancreatic cancer in asymptomatic adults (a grade D recommendation). In developing the current recommendation, the USPSTF reviewed...

breast cancer

Circulating Tumor DNA Analysis for Detection of Residual Disease in Breast Cancer

Researchers have developed a new method for tracking residual disease in patients with breast cancer that could one day help doctors better tailor treatments and prevent unnecessary surgeries for some people with the disease. Findings were published by McDonald et al in Science Translational...

hematologic malignancies

First-Degree Familial Risk in Blood Cancer Development

New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with a hematologic malignancy themselves. A study by Sud et al published in Blood offers the first...

skin cancer

Can Genetic Counseling and Test Reporting in Patients Susceptible to Melanoma Development Change Behavior?

A new study published by Stump et al in Genetics in Medicine investigated whether genetic testing would motivate people at risk of developing melanoma to alter their behavior in order to reduce their risk. “We are trying to understand whether a genetic test result adds value over and above...

prostate cancer

Comparison of Scans for Detection of Early Biochemical Recurrence of Prostate Cancer After Prostatectomy

In a single-center study reported in The Lancet Oncology, Calais et al found that the use of gallium Ga-68 prostate-specific membrane antigen-11 positron-emission tomography/computed tomography (PSMA PET/CT) resulted in higher detection rates of early biochemical recurrence of prostate cancer after ...

Advertisement

Advertisement



Advertisement